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1 Introduction 
1.1 Description of inflammatory bowel disease 
 
Inflammatory bowel disease (IBD) is a chronic, relapsing inflammatory disorder of the 
gastrointestinal tract. The exact origin of IBD is unknown, but identified factors that influence IBD 
pathogenesis involve the interaction of genetic background, environment, and immune 
mechanisms. Symptoms of IBD include abdominal pain, diarrhea, weight loss, and fever (Yang et 
al., 2001). The incidence of IBD is about 0.1% worldwide, with a higher rate in developed countries. 
Onset of IBD typically occurs in the late-teens/early twenties, and there are two main subtypes of 
IBD, Crohn's disease (CD) and ulcerative colitis (UC). 
 
Distinct clinical features separate the two subtypes, although mucosal inflammation, ulceration, and 
chronic mucosal damage are common to both CD and UC. In CD, any part of the gastrointestinal 
tract may be affected in a discontinuous fashion, resulting in 'skip lesions'. In contrast, the mucosal 
damage in UC is restricted to the colon and extends continuously from the rectum, resulting in 
proctitis (inflammation of the rectum), left-sided colitis (inflammation extending from rectum to left 
flexure), or pancolitis (inflammation of the entire colon). Histologically, CD is characterized by 
thickened intestinal walls, fissures or fistulae, fibrosis, the presence of granulomas in all tissue 
layers, and inflammation affecting all layers of the intestinal mucosa. In UC, affected areas are 
primarily restricted to the superficial layers (mucosa), goblet cells are depleted, and ulcers 
penetrate deeply into the submucosa (Hendrickson et al., 2002). 
 
Complications arising from IBD are diverse. It is considered that general defects in the immune 
response can lead to extraintestinal inflammation causing complications such as joint disorders 
(ankylosing spondylitis), skin disorders (erythema nodosum, epidermolysis bullosa acquisita), 
hepatobiliary diseases (primary sclerosing cholangitis), and eye diseases (uveitis). UC is often 
associated with ankylosing spondylitis, arthritis, primary sclerosing cholangitis, and an increased 
risk of colon carcinoma (1998), while CD is more often associated with psoriasis and thrombotic 
vascular complications (Yang et al., 2001). 
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1.2 Interacting factors in inflammatory bowel disease 
 
The etiology of IBD involves the interaction of genetic, environmental and immunological factors. 
1.2.1 Genetic factors 
 
There are many studies that support the influence of genetic background in IBD; in some cases 
genetic factors differentially influence the two disease subtypes, UC and CD. The fact that IBD is a 
complex polygenic disease, rather than a monogenic disease, is best highlighted by differential 
concordance rates in twins. In CD, monozygotic twins have a concordance rate of 58%, while 
dizygotic twins have rates similar to siblings. In UC, the concordance rates are lower than in CD 
(monozygotic twins, 6-17%; dizygotic twins, 0-5%) (Orholm et al., 2000; Thompson et al., 1996; 
Tysk et al., 1988). It is thought that non-genetic factors, such as the environment, have an influence 
on the incidence of IBD, since the concordance rate for monozygotic twins is not 100% (Yang et al., 
2001). Further evidence for the genetic component of IBD is reflected in the nine susceptibility loci 
that have been identified for IBD, as outlined in Table 1.1. Most prominently, variations in CARD15 
(IBD1), an innate immunity receptor, have been strongly associated solely with CD pathogenesis. 
Homozygotes carrying two risk mutations have a 44 times greater probability of contracting CD 
than non-carriers of the mutations (Hugot et al., 2001). In the case of IBD5, a 250 kb haplotype 
block on 5q31 was identified to have an association with CD (Rioux et al., 2001) and subsequently 
variants in the organic cation transporter (OCTN) family (SLC22A4, SLC22A5) on 5q31 were found 
to confer susceptibility to CD and UC (Dring et al., 2006; Peltekova et al., 2004). Outside the major 
susceptibility loci, variants in discs, large homolog 5 (DLG5; 10q23) were found to be associated 
with IBD (Stoll et al., 2004) and polymorphisms in mucin 3 (MUC3; 7q22) and anterior gradient 2 
(AGR2; 7p21.3) were associated with UC (Kyo et al., 1999; Zheng et al., 2006). 
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Table 1.1.  Susceptibility loci for inflammatory bowel disease 
Locus Chromosomal 
Location 
Candidate genes located in or near locus 
IBD1 16p12-q13 CARD15, CD11 integrin cluster (ITGAM, 
ITGAX, ITGAL, ITGAD), CD19, IL4R, SPN 
IBD2 (Satsangi et al., 1996) 12p13.2-q24.1 IFNG (12q14), SLC11A2 (NRAMP2: 12q13) 
IBD3 (Hampe et al., 1999b) 6p Major histocompatibility complex (MHC) 
region, TNF 
IBD4 (Duerr et al., 2000) 14q11-q12 T-cell receptor alpha/gamma complex  
IBD5 (Rioux et al., 2000) 5q31 SLC22A4, SLC22A5, cytokine gene cluster 
(IL3, IL4, IL5, IL13, CSF2), SPINK5 
IBD6 (Rioux et al., 2000) 19p13 ICAM1, complement component 3, 
thromboxane A2 receptor, leukotriene B4 
hydroxylase, TYK2, JAK3 
IBD7 (Cho et al., 2000) 1p36  
IBD8 (Hampe et al., 2002) 16p  
IBD9 (Duerr et al., 2000; 
Hampe et al., 2001) 
3p26  
unnamed 10q23 (Hampe et 
al., 1999a) 
DLG5 (Stoll et al., 2004) 
unnamed 7q21.1 ABCB1 (MDR1) 
unnamed 7q22 (Satsangi et 
al., 1996) 
MUC3, HGF, EGFR 
unnamed 7p21.3 AGR2 (Zheng et al., 2006) 
unnamed 3p21.2 (Satsangi et 
al., 1996) 
GNAI2 
 
Animal models also strongly support the genetic component of IBD. The mice strains Samp/Yit and 
C3H/HeJBir are murine models of intestinal inflammation and spontaneous colitis, respectively 
(Kosiewicz et al., 2001; Kozaiwa et al., 2003). In particular, the C3H/HeJBir strain was also shown 
to be sensitive to chemically induced colitis by administration of dextran sulfate sodium (DSS) in 
comparison to other strains of mice (Mahler et al., 1998). Furthermore, though no one single model 
manifests all the characteristics of human IBD, different genetic defects in transgenic animal 
models (knock-in or knock-out) can reproduce the same clinical phenotype. For example, knocking-
out interleukin 10 (IL10), a cytokine that suppresses macrophage function, yields a mouse model 
with an over-production of type 1 helper T cell (Th1) cytokines, resulting in intestinal inflammation 
(Mahler et al., 2002; Weinstock et al., 2003). An interleukin 2 (IL2; stimulates T-cell proliferation) 
knock-out mouse results in increased transforming growth factor-beta 1 (TGFB1), CD14 and 
inducible NOS, and ultimately, colitis (Harren et al., 1998; Meijssen et al., 1998; Sadlack et al., 
1993; Schultz et al., 1999). Finally, cross-breeding a DSS-susceptible mouse strain (C3H/HeJ) with 
a partially resistant strain (C57BL/6) yielded significant genetic linkage to colitis at marker 
D5Mit216, a locus which is syntenic with the human linkage on chromosome 5 (Ma et al., 1999). 
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Together, these examples illustrate that genetic changes have the ability to cause colonic 
inflammation. 
1.2.2 Environmental factors 
 
A wide variety of environmental factors has been suggested as risk factors to developing IBD, 
including smoking, diet, hygiene, and technological advances that cause changes in bacterial flora. 
Indeed, IBD may generally be described as a side effect of 20th century industrialization, since 
incidence of IBD has increased within industrialized nations since the 1950's (Mayberry and 
Rhodes, 1984). 
 
Of all environmental factors, smoking has the strongest influence on IBD, with opposite effects in 
CD and UC. Whereas smoking increases the risk of development, relapse, and the need for 
surgical intervention in CD, smoking is viewed as beneficial against UC (Lindberg et al., 1988; 
Regueiro et al., 2005). The mechanism by which smoking influences different effects in CD and UC 
is unknown; however, one possibility is that smoking may impair antimicrobial response in CD, 
while promoting protective effects of luminal bacteria in UC (Birrenbach and Bocker, 2004). 
 
With respect to diet, breastfeeding is suggested to be protective against IBD, (Klement et al., 
2004), whereas increased intake of simple carbohydrates and fast food are risk factors for CD 
(Persson et al., 1992). High sucrose intake is a risk factor for IBD, while high fat intake is a risk 
factor for UC (Reif et al., 1997). Factors which affect availability, transport or metabolism of the 
major energy source of the colonocytes, the short chain fatty acids (SCFA) (and in particular, 
butyrate), may introduce a risk for IBD by causing colonocyte starvation. For example, increased 
ingestion of food containing sulfur may be associated with UC, since sulfur compounds inhibit 
metabolism of butyrate (Roediger et al., 1993). Lack of dietary fiber to breakdown into SCFA by 
bacterial flora or impaired transport of SCFAs can cause colon pathology (Cuff et al., 2005; 
Scheppach et al., 1997). 
 
Changes in hygiene have also been hypothesized to be related to the increasing rate of IBD. It has 
been suggested that overall improvements in public sanitation may predispose to IBD by removing 
the stimulus for a mucosal immune response, which would normally be required in an unsanitary 
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environment (Rotter, 1994). It is postulated that the predisposing immune response genes, when 
not sufficiently activated in a 'clean' environment, may lead to hyperstimulation of the immune 
response if challenged by a microbial antigen later in life. Alternatively, the lack of exposure to 
microbial antigens may leave the mucosal immunological system in a perpetually primed state 
which makes the system vulnerable to dysregulation in the form of an autoimmunity reaction (Wills-
Karp et al., 2001). The loss of the intestinal parasite, the helminth, is an example of the hygiene 
hypothesis. As an integral part of the intestinal flora, helminths affect T regulatory cells to prevent 
over-activation of T cells. The absence of the helminth upsets T cell regulation, a process that is 
probably common in diseases with an autoimmune component (IBD, asthma, multiple sclerosis, 
allergies) (Korzenik, 2005; Weinstock et al., 2004). 
 
Interestingly, the advent of refrigeration has been proposed to cause CD in genetically susceptible 
individuals. The use of refrigeration in commercial and domestic food preparation encourages the 
growth of psychrotrophic bacteria, such as Yersinia enterocolitica and Listeria monocytogenes, 
which are able to grow at cold temperatures (between -1°C and 10°C). The "cold chain hypothesis" 
proposes that chronic ingestion of psychrotrophic bacteria from refrigerated foods invokes a over-
active host reaction in genetically susceptible individuals who have lost the ability to tolerate the 
bacteria (Hugot et al., 2003). 
 
Lifestyle changes in the last century have influenced hygienic practices, what we eat and how we 
store our food. Though all of these environmental factors are thought to contribute to IBD 
susceptibility, smoking remains the most dominant factor. 
1.2.3 Immunological interaction 
 
The gut immune system must maintain a delicate balance between tolerating food antigens and 
commensal bacteria, while being able to respond appropriately to pathogens. Oral tolerance is 
thought to occur by three mechanisms: 1) clonal selection takes place to eliminate the effector T 
cells that recognize commensal bacterial as 'self-antigen'; 2) clonal anergy is induced (i.e. 
lymphocytes are rendered unresponsive to the oral antigen); and 3) suppressor T-cells (Th3 cells) 
are induced (Bouma and Strober, 2003). In IBD, different defects in the maintenance of oral 
tolerance have the potential to cause chronic inflammation. Though there are no prospective 
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studies to definitively show that oral tolerance is defective in IBD, there are studies that suggest 
that there is some truth to the hypothesis. In one example, a non-prospective study has shown that 
T-cells from IBD patients proliferated and produced cytokines in response to their own microflora, 
whereas T-cells from control subjects did not (Duchmann et al., 1995). In a more recent example, 
IBD patients and controls were administered an oral antigen (keyhole limpet hemocyanin) before 
initial immunization and booster (Kraus et al., 2004). In contrast to the control group, tolerance was 
not induced in CD and UC patients, as shown by enhanced levels of T-cell proliferation after 
immunization, suggesting a defect in suppression response in IBD. In a follow-up study, the same 
authors repeated the protocol on IBD patients and first-degree relatives and found that intestinal 
permeability could not be faulted for the lack of tolerance induction and suggested that there is a 
genetic defect responsible for oral tolerance in IBD (Kraus et al., 2006). 
 
An upset in balance between effector T-cells (Th1 or Th2), which cause inflammation, and 
regulatory T-cells, which prevent inflammation, can also result in mucosal inflammation. According 
to mouse models, inflammation may result from either an over-active effector T-cell response or a 
weakened regulatory T-cell response (Bouma and Strober, 2003). Within the effector T-cells, 
mucosal inflammation can be a consequence of excessive T helper 1 cell (Th1) response, which 
induces secretion of interleukin 12 (IL12), interferon γ (IFNG) and/or tumor necrosis factor alpha 
(TNF). Alternatively, inflammation may result from an excessive Th2 response, which induces 
secretion of interleukins 4, 5 and/or 13 (IL4, IL5, IL13). These cytokine profiles are clear 
distinguishing characteristics of the two subtypes of IBD. The cytokine profile for CD is similar to 
that observed in Th1-mediated inflammation. Many studies have showed that macrophages 
isolated from CD, but not UC patients, produce increased amounts of IL12, which activates Th1 
cells (Monteleone et al., 1997; Parronchi et al., 1997). In addition, T cells from CD patients show 
increased levels of IFNG and decreased levels of IL4 in comparison to controls (Fuss et al., 1996; 
Monteleone et al., 1997; Parronchi et al., 1997). A final piece of evidence supporting the role of Th1 
response in CD is the finding that CD patients treated with an antibody against the p40 chain of 
IL12 show an immediate reduction in inflammation, which is paralleled by decreased IL12 and 
IFNG levels in mononuclear cells from colonic lamina propria (Mannon et al., 2004). In contrast to 
CD, the UC cytokine profile resembles that of a Th2-mediated inflammation. Although the hallmark 
cytokine of Th2 response, IL4, has not been shown to be increased in UC Th2 cells, studies 
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suggest that UC is driven by Th2-mediated inflammation (Bouma and Strober, 2003). For example, 
the development of autoantibodies, such as anti-neutrophil cytoplasmic antibody (pANCA), is more 
prevalent in UC in contrast to CD (Saxon et al., 1990), while the anti-Saccharomyces cerevisiae 
antibody (ASCA) is more prevalent in CD than in UC, which provides a possibility to distinguish UC 
and CD by serological testing (Beaven and Abreu, 2004). Moreover, Th2-related subclasses of IgG 
(IgG1 and IgG4) are associated with UC, as opposed to Th1-related subclasses (IgG2), which are 
more associated with CD (Kett et al., 1987). Together, these studies support the hypothesis of 
distinct Th-responses in CD and UC. 
 
Abnormalities in any aspect of the innate immune response may ultimately lead to inflammation in 
IBD. The most prominent case in point is the association of mutations in CARD15 with CD. The 
protein encoded by this gene, NOD2, is an intracellular receptor for bacterial peptidoglycan, in 
particular, muramyl dipeptide. NOD2 is expressed in epithelial cells, dendritic cells, granulocytes 
and monocytes. There are three hypotheses as to how defects in NOD2 act to cause CD (Bouma 
and Strober, 2003): 1) the lack of functional NOD2 leads to impaired macrophage activation and 
infection; 2) lack of functional NOD2 in epithelial cells negates activation of an epithelial cell 
defense response (in the form of chemokine and defensin secretion), allowing bacterial colonization 
of the crypt and penetration through the epithelial barrier; 3) impaired recognition of bacterial 
antigen leads to inappropriate activation of antigen presenting cells, resulting in an imbalance 
between effector and regulatory T cells. 
 
Various defects in the regulation of the immune response are observed in IBD patients. Tolerance 
to an external antigen appears to be different in IBD patients compared to normal controls, while 
other studies identify defects that appear to characterize CD or UC. CD is typified by a 
dysregulation of innate immune response, such as Th-1-mediated immune response or impaired 
function of the bacterial receptor NOD2. On the other hand, the IgG subclass profile and the 
prevalence of autoantibodies support UC as a Th-2 mediated-mediated immune response. 
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1.2.4 Epithelial barrier function 
 
The mucosal epithelium provides a physical barrier separating the outside environment (food 
antigens, microflora, pathogens) from the inner workings of the body. This physical barrier consists 
of a thick glycocalyx mucous layer coating the apical surface of the epithelial cell layer and the 
epithelial cells themselves, which are joined laterally by tight and adherens junctions and basally to 
the extracellular matrix of the lamina propria. Breaches of the epithelial barrier can allow 
components of the outside environment to come into direct contact with the gut immunological 
machinery, thereby causing an overwhelming immune response. In the case of IBD, it is not clear 
whether impaired barrier function first causes a chronic inflammation or if an impaired immune 
response leads to degradation of the barrier. Due to the multifactorial nature of IBD, it is possible 
that one or both events contribute to the initiation of chronic inflammation, depending on the 
characteristics of the individual patient. Many animal models support the hypothesis that the loss of 
barrier function causes inflammation. In one example, severe inflammation is observed in 
transgenic mice expressing a dominant negative N-cadherin transgene that impairs intra-epithelial 
cell adhesion (Hermiston and Gordon, 1995). Not only does the intestinal epithelial layer provide a 
physical barrier, it also plays an active role in immune response. Epithelial cells are able to detect 
microbial antigens and further transmit the appropriate response. For example, Toll-like receptor 5 
(TLR5) is specifically expressed on the basolateral side of the epithelial cell, where, if it is activated 
by bacterial flagellin, it initiates an inflammatory response to combat the bacterial breach (Gewirtz 
et al., 2001). And finally, recent in vitro studies show that the epithelial tight junction can alter its 
structure in response to cytokines such as TNF (Ye et al., 2006) or IFNG (Utech et al., 2005). 
1.2.5 Wnt signaling pathway 
 
The Wnt signaling pathway has been widely studied for its role in developmental processes of 
model organisms such as Drosophila, Xenopus and C. elegans. Mammalian homologues of the 
Wnt pathway have been found to play roles in stem cell development, embryonic development, and 
cancer. The role of the WNT pathway in the pathology of IBD is potentially interesting for two 
reasons: 1) IBD patients, and in particular, UC patients, show an increased risk for colon cancer 
(van Hogezand et al., 2002); 2) Wnt pathway is instrumental in gastrointestinal stem cell 
development and maintenance of the colon (Batlle et al., 2002; van de Wetering et al., 2002). 
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The Wnt genes, of which there are 19 in humans (Miller, 2002), encode secreted glycoproteins that 
bind and activate a transmembrane receptor complex formed by the lipoprotein-receptor-related 
proteins 5 and 6 (LRP5/6) and Frizzled (FZ) transmembrane family, of which there are 10 
members. Wnt binding may be enhanced by binding to heparan sulphate proteoglycans (HSPG), 
which act as co-receptors for Wnt binding, and cell surface sulfatases that have been shown to 
modify HSPG (Ai et al., 2003). Secreted antagonists, such as Dickkopf (DKK) family, secreted 
Frizzled-related protein (sFRP) family and Wnt-inhibitory factor-1 (WIF1), prevent Wnt activation by 
preventing Wnt ligands from binding to the LRP/FZ receptor complex (Moon et al., 2004). The wide 
range of tissue specific functions of Wnt can be attributed to the specfic combinations of Wnt 
ligands, receptors, and effectors. 
 
Wnt signaling pathways can be divided into two types: 1) β-catenin-dependent signaling (canonical 
Wnt pathway); and 2) β-catenin-independent signaling, which includes non-canonical pathways 
such as the planar polarity and Wnt/Ca2+ pathways. The Wnt ligands can be classified according to 
the Wnt pathway that is activated when expressed in Xenopus embryos (Strutt, 2003). The first 
group, including Wnt1, Wnt3a, Wnt8 and Wnt8b, activates signals through the canonical Wnt 
pathway and is able to transform mammalian cells. The second group, including Wnt4, Wnt5a, and 
Wnt11, transmits signals through the non-canonical Wnt/Ca2+ pathway, but cannot transform cells. 
 
Canonical Wnt signaling is well-characterized and is summarized in Figure 1.1. In the inactive 
state, free cytoplasmic β-catenin protein levels are minimized by protein degradation (Nelson and 
Nusse, 2004). A pro-degradation complex of axin, adenomatous polyposis coli (APC), casein 
kinase I (CKI) and glycogen synthase-3 (GSK3) phosphorylates β-catenin and targets it for 
ubiquitination and degradation. Upon activation of Wnt signaling by binding of Wnt ligands to the 
LRP/FZ complex, dishevelled (DSH or DVL) becomes activated and is recruited to the 
transmembrane receptor complex, which then attracts axin and the degradation complex to the 
membrane. From this point on, a combination of axin degradation and inhibition of GSK3 by DSH 
decreases degradation of β-catenin. Activation of the Wnt pathway stabilizes β-catenin by inhibiting 
GSK3B activity. As a result, cytoplasmic β-catenin protein accumulates and translocates from the 
cytoplasm to the nucleus, where it interacts with T-cell-specific (TCF) and lymphoid enhancer-
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binding (LEF) transcription factors. The transcription factors then activate transcription of Wnt target 
genes, such as cell cycle regulators that control cell growth or proliferation (cyclin D1, MYC, FOS 
and JUN). Of particular interest in the canonical Wnt pathway is the involvement of β-catenin and 
APC, which take part in both gene transcription of Wnt signals and cell-cell adhesion and 
cytosketetal rearrangements (Logan and Nusse, 2004). 
 
 
 
 
Figure 1.1  Canonical Wnt signaling pathway. 
Panel A. In the inactivated state, extracellular inhibitors sFRP and DKK prevent binding of W
ligands to the receptor complex LRP5/6 and Frizzled. The degradation complex consisting of 
axin, APC, GSK3, and CK1 phosphorylates β-catenin, which marks it for ubiquitin-mediated 
degradation. Panel B. Wnt ligand binds to the receptor complex (LRP5/6 and Frizzled), 
activating DSH and recruiting the degradation complex to the plasma membrane. This inhibits 
phosphorylation of β-catenin, which allows β-catenin to escape ubiquitin-mediated degradation 
and accumulate in the cytoplasm. β-catenin then translocates to the nucleus, where
nt 
 it binds the 
co-activator CBP (CREB-binding protein) and the transcription factor TCF to initiate transcription 
 of 
he 
of Wnt target genes. This figure was taken from a Wnt review (Moon et al., 2004). 
 
 
As IBD patients demonstrate an increased risk for colon cancer, it is of interest that mutations 
which cause the constitutive activation of the canonical Wnt pathway are responsible for most colon 
cancers (Peifer and Polakis, 2000). Loss-of-function mutations in APC can be attributed to 85%
all sporadic colorectal cancers, whereas mutations that stabilize β-catenin accumulation in t
cytoplasm can be attributed to 10% of sporadic colorectal cancers (Giles et al., 2003). Cell 
proliferation leading to tumour formation is thought to be driven by the constant Wnt activation of 
 
 11
cyclin D1 and the proto-oncogene MYC. In addition to its role in cancer, the Wnt pathway regulate
normal colon cell proliferation in a space-dependent manner, a process which is essential for the 
constant regeneration of the intestinal epithelial cells, which shed every three to five days (Peifer, 
2002). Wnt pathway is activated in the base of proliferative colon crypts. Conversely, Wnt pat
is deactivated in colon epithelial cells that undergo differentiation and migrate to the villi tips. 
Protein p21, a cell-cycle inhibitor, was identified to be the pivotal target of Wnt pathway in the 
regulation of colon proliferation (van de Wetering et al., 2002). In the colon crypts, Wnt activat
down-regulated p21, thus allowing proliferation. Away from the crypts, in the absence of Wnt 
activation, p21 expression induced cell-cycle arrest and differentiation. Therefore, inappropriate 
activation or deactivation of the Wnt pathway has the pote
s 
hway 
ion 
ntial to disrupt orderly formation of the 
olon epithelial barrier or to encourage tumour formation. 
-
ldahl et 
roteins 
r 
 regulate cytoskeletal 
rganization and polarity during embryonic development (Miller, 2002). 
.3 Microarray expression screening 
g 
d 
has 
 
c
 
Less has been elucidated about the β-catenin independent Wnt pathways, namely the planar-cell
polarity or the Wnt/calcium pathways, which may prove to be overlapping pathways (She
al., 2003). In these alternate pathways, Wnt binds Frz receptors and activates DSH, but 
downstream signals are mediated by different components, such as the small GTPase p
Rac and Rho, Rho kinase (ROK), c-Jun N-terminal kinase (JNK), or activation of 
calcium/calmodulin-regulated protein kinase II and PKC, mediated by an increase in intracellula
Ca2+. The β-catenin independent Wnt pathways in vertebrates function to
o
 
1
 
Given that the pathogenesis of IBD results from a complex interaction of different factors, it is fittin
that a battery of screening methods, such as genome-wide linkage and association analysis an
microarray expression screening, are employed to investigate this disease at the DNA or RNA 
level. Genetic analysis has identified nine IBD loci and markers within numerous genes (CARD15, 
SLC22A4, SLC22A5, DLG5, AGR2) that are associated with one or both IBD subtypes. While gene 
linkage approaches have been in use for over a two decades, microarray expression screening 
emerged within the last six years to become a mainstay technology in the research laboratory. 
Microarray technology has been used in various applications, such as tumour classification and
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prediction of clinical outcomes (Beer et al., 2002; Middleton et al., 2002; Nielsen et al., 2002), 
identification of genes involved in various diseases, cellular processes or induced responses to
external stimuli (McDonald and Rosbash, 2001; Middleton et al., 2002; Ohki et al., 
 
2002), and 
econvolution of biological pathways (Yoshimoto et al., 2002), to name but a few. 
e points 
nd 
abases 
as ArrayExpress 
mation on 
omprehensible format for biologists and bioinformatic specialists alike (Stoeckert et al., 2002). 
le, 
ve addressed the compatibility of data sets generated by 
ifferent expression screening platforms. 
 
d
 
The power of microarray expression screening is its ability to monitor the gene transcript levels of 
tens of thousands of genes in a single experiment. A typical microarray study involves comparing 
global mRNA expression profiles of different groups of samples, for example, different tim
or stages of disease. Needless to say, the advent of microarrays has resulted in a rapid 
accumulation of raw data and necessitated the development of analysis methods (i.e. normalization 
techniques, application of statistical tests to determine regulated genes, classification methods) a
data management structures to handle the immense volume of microarray data. To manage the 
flood of microarray data, there is a growing consensus in the scientific community of the benefit in 
establishing public repositories for gene expression data, analogous to freely available dat
for sequence information, such as GenBank and EMBL. This endeavor has already been 
undertaken with the creation of public depositories for expression data, such 
(http://www.ebi.ac.uk/arrayexpress/) and Gene Expression Omnibus (GEO; 
http://www.ncbi.nlm.nih.gov/geo/). Common standards for data input, annotation, infor
experimental design, and data normalization are implemented so that the data is in a 
c
 
The volume and diversity of microarray data available from public repositories offers tremendous 
opportunities for large-scale data analysis. Mining of public data sets can increase the confidence 
in a particular result (Geschwind, 2001) and conserve resources by redirecting research efforts in 
other directions, if meaningful data can already be extracted from existing data sets. For examp
a statistical model for performing meta-analysis of independent microarray data sets has been 
developed using prostate cancer microarray data (Rhodes et al., 2002). Though the opportunity for 
meta-analysis is promising, few studies ha
d
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1.4 Aims of the study 
 
Since the inception of DNA microarrays (Gress et al., 1992; Lennon and Lehrach, 1991; Schen
al., 1995), technological advances have lead to the development of two main types of arrays, 
namely cDNA clone-based and oligonucleotide-based arrays (Jordan, 2002). Both expression 
systems, each with different experimental designs, are routinely used to compile compar
global mRNA expression profiles of tissues or cell lines. Various technical aspects of microarrays 
have been examined, including probe length and composition, cross-hybridization, and 
hybridization effects from immobilized substrate (Kane et al., 2000; Okamoto et al., 2000; Stillman 
and Tonkinson, 2001). To date, direct comparisons between the two systems have only been 
carried out using publicly available data sets (Kuo et al., 2002) or differential expression of defined 
model systems in smaller genes sets, all using fluorescent labeling methods (Yuen et al
a et 
ative 
., 2002). 
he first aim of the present study (Figure 1.2, Panel 1) was to evaluate how the performance of the 
e 
 
ntrast, 
e 
 
flamed 
l 
T
two most widely used platforms compare with regard to genes identified as expressed. 
 
The second objective of this study (Figure 1.2, Panel 2) was to use microarrays to investigate 
differential gene expression in both inflamed and non-inflamed IBD samples and normal controls. 
Within the field of IBD research, two main studies have been published, in which microarrays wer
used to detect differential gene expression between: 1) controls (3 normal and 3 inflamed control 
individuals) and UC (7 patients) (Dieckgraefe et al., 2000); or 2) normal controls (6 patients) and 
IBD samples (6 patients of each subtype), which were pooled for microarray analysis (Lawrance et
al., 2001). Both studies used arrays that were capable of monitoring ~7000 transcripts. In co
the present work expands the microarray analysis to > 22 000 transcripts, includes more samples 
and does not pool the samples for microarray analysis. In order to decipher changes in th
molecular profiles of inflamed and non-inflamed IBD, three distinct and comprehensive microarray
experiments were carried out. In the first part (Figure 1.2, Panel 2.A; Section 3.2), cDNA 
microarrays (Human UniGene Set RZPD 1 clone set) were used to detect differential expression 
between 11 samples from normal controls and 10 samples from each of inflamed UC and in
CD. The second part (Figure 1.2, Panel 2.B; Section 3.3.2) involves using oligonucleotide arrays 
(Affymetrix Human Genome U133A) to examine differences between 10 matched UC non-
/inflamed samples from the same patient and 10 normal controls. The last part (Figure 1.2, Pane
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2.C; Section 3.3.3) involves using oligonucleotide arrays (Affymetrix Human Genome U133A and
chips) in the expression analysis of 7 inflamed CD, 8 non-inflamed CD (4 of which are matched
 B 
 
amples from the same patient) and 25 normal controls. The results from the three approaches 
 
mber of 
 samples and disease specificity 
ontrols). To date, this cohort represents the largest real-time cohort ever collected for the 
ning 
n the pathogenesis of 
s
contribute to our understanding of molecular mechanisms in IBD in a complementary manner. 
1. Microarray comparison 
•cDNA array (Human Unigene I) 
•oligonucleotide array (Affymetrix) 
2. Microarray expression screening in IBD 
A. cDNA arrays 
(Human Unigene 
Set RZPD I) 
•normal control 
•inflamed IBD 
3. Real-time PCR analysis 
B. oligonucleotide 
arrays (Affymetrix) 
•normal control 
•inflamed and non-
inflamed UC 
C. oligonucleotide 
arrays (Affymetrix) 
•normal control 
•inflamed and non-
inflamed CD 
Figure 1.2  Flow diagram illustrating the methodology used in this study. 
 
As a follow-up to the microarray results, high-throughput 384-well plate format real-time PCR 
(Figure 1.2, Panel 3) was used to further verify the gene transcript expression in a larger nu
patient samples (>300 samples, including normal controls, IBD
c
purposes of verifying differential transcript expression in IBD. 
 
In summary, the objectives of this study were three-fold: 1) to assess the comparability of data 
generated from two microarray expression platforms; 2) to use microarray expression scree
(both cDNA and oligonucleotide platforms) to identify novel genes involved i
 
 15
IBD; 3) to focus on processes identified by microarray screening and to analyze transcript 
expression in a larger number of patients using quantitative real-time PCR. 
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2 Methods 
 
The work contained in this thesis was completed as several separate microarray projects. To 
facilitate the description of methods, methods for each project will be described as a separate unit. 
General materials, laboratory equipment, and solutions used in the course of this study are listed in 
Sections 8.1, 8.2, and 8.3. For all parts of the study, patients were recruited for the studies through 
the First Medical Clinic, University Clinic of Schleswig-Holstein, Campus Kiel. The study 
procedures were approved by the hospital ethical committee, and patients consented in writing to 
the additional research biopsies being taken 24 h prior to endoscopy. All colonic mucosa biopsies 
were obtained from the lower bowel unless otherwise indicated. 
 
2.1 Microarray comparison 
 
2.1.1 Patient cohort for microarray expression screening 
 
In order to compare two different microarray platforms, five patients (2 females, 3 males; age 
range: 55-70 y) undergoing colonoscopy for routine cancer screening were selected. All biopsies 
were obtained from the sigmoid colon. An additional two biopsies from each patient, from the same 
region of the colon, were formalin-fixed and paraffin embedded. Pathohistological examination was 
performed by an independent pathologist who was given no information about the patients’ health 
status. Clinical evaluation yielded no significant pathological findings in this group; therefore, these 
patients were classified as a normal population. 
 
2.1.2 Isolation of total RNA from biopsies 
 
All reagents, glassware and laboratory utensils to be used for RNA isolation were specially treated 
in order to minimize RNA degradation by RNAses. Solutions were prepared with 0.1% DEPC-
treated distilled water and sterilized by autoclaving. All glassware, ceramic mortar and pestles, 
Teflon pestles and metal spatulas were cleaned with common laboratory washing detergent, rinsed 
thoroughly in distilled water and air-dried before wrapping in aluminum foil and baking at 180°C for 
12-16 h before use, in order to inactivate any contaminating RNAses. All plasticware was 
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purchased as UV-sterilized consumables (50 mL conical tubes, pipet tips with aerosol filters) or 
RNAse-free consumables (microfuge tubes). 
2.1.2.1 Homogenization of colon mucosa biopsies 
 
Mucosal biopsies were stored in liquid nitrogen prior to use. To minimize premature thawing of the 
biopsies during RNA isolation, homogenization equipment (mortar, pestle, polyethylene tubes) was 
cooled with liquid nitrogen prior to the start of the procedure. A commercial kit was used to isolate 
total RNA from biopsy material (RNeasy mini-kit, Qiagen) according to the manufacturer’s protocol. 
Briefly, one mucosal biopsy was ground into a fine powder using a cooled Teflon mortar in a 1.5 mL 
microfuge tube. The powder was then mixed with 650 µL of RLT lysis solution, incubated at room 
temperature for 10 min and vortexed for 30 s. The sample was then further treated by centrifuging 
the lysate through a QIA shredder column for 2 min at 14000 rpm (16000 xg) in a microfuge. The 
eluate was centrifuged for 3 min at 14000 rpm (16000 xg) and the cleared lysate was transferred 
into a new microfuge tube. One volume of 70% ethanol was then added to the lysate, mixed well by 
vortexing and loaded onto an RNA binding column fitted in a 2 mL collection tube. The solution was 
centrifuged through the binding column for 15 s at 10000 rpm (8000 xg). The mini-column was 
washed once by pipetting 350 µL of RW1 wash buffer on to the column, incubating for 10 min at 
room temperature and then centrifuging 15s at 10000 rpm (8000 xg).  
2.1.2.2 DNAse treatment of RNA and final isolation of RNA 
 
DNAse treatment of the RNA was carried out while the RNA was still bound on the column. First, 
DNAse stock solution was prepared by reconstituting lyophilized DNAse enzyme (Qiagen) by the 
addition of 550 µL of RNAse-free water. This DNAse stock solution (10 µL, 2.7 Kunitz units/µL) was 
further diluted in 70 µL RDD buffer (as provided in RNAse-free DNase Kit). The diluted DNAse (80 
µL) was pipetted directly on to the spin column membrane and allowed to incubate at room 
temperature for 15 min. Upon completion of the digestion time, the mini-column was washed once 
with 350 µL buffer RW1 and twice with 500 µL buffer RPE. Each wash step was completed by 
centrifuging the tube 15 s at 10000 rpm (8000 xg). To completely rid the column of wash solution, 
the column was then centrifuged 1 min at 14000 rpm (16000 xg). Total RNA was eluted from the 
mini-column into an RNAse-free microfuge tube by pipetting 50 µL of RNAse-free water directly 
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onto the membrane, allowing to completely soak through the membrane at room temperature for 5 
min and then centrifuging 1 min at 10000 rpm (8000 xg). 
2.1.2.3 Quality control of RNA 
 
RNA concentration was determined by measuring the absorbance of a diluted RNA sample (1:40) 
in a spectrophotometer at 280 nm and 260 nm. The concentration and was calculated using the 
following formula: 
[RNA]µg/µL = A260 X 40 µg RNA /mL/A260 X 1000 µL/mL
 
Typically, the A260/280 ratio was between 1.8-2.2, indicating a good yield of nucleic acid to protein 
ratio. The integrity of the RNA was assessed by one of two methods: 1) denaturing RNA gel 
electrophoresis; or 2) electrophoresis on an RNA 6000 Nano LabChip (Agilent). In the first 
instance, a 1.5% agarose gel was prepared in 1 X MOPS and 0.9225 M formaldehyde. 
Approximately 1 µg of total RNA was heat-denatured in 10 µL of RNA loading solution at 70°C for 
10 min and cooled on ice. RNA samples were electrophoresed on the agarose gel at 4-5 V/cm in 
running buffer of 0.1 X MOPS. After one hour of migration, the gel was photographed under UV 
light. In the second instance, RNA quality was measured by the Agilent 2100 Bioanalyzer, which 
used electrophoresis through channels in a microfluidic chip (Nano LabChip) to separate RNA 
molecules based on size. In both methods, the strong presence of 18S and 28S RNA molecules 
and the absence of smears at lower molecular weights indicated intact, high quality RNA suitable 
for further studies. 
 
Genomic DNA contamination of RNA was assessed by amplification of a housekeeper gene 
(GAPDH) using the following primers: GAPDH_F2, 5'-ACCCACTCCTCCACCTTTGAC-3'; 
GAPDH_R2, 5'-CTGTTGCTGTAGCCAAATTCGT-3'. Approximately 1 µg of total RNA was used as 
a template for a PCR reaction containing 1X PCR Buffer, 1.5 mM MgCl2, 0.2mM dNTPs, 0.4 µM 
forward primer, 0.4 µM reverse primer, and 0.1 µL Taq polymerase in a total reaction volume of 50 
µL. The cycling program was used as follows:  95°C at 2 min, then 40 cycles of 95°C 30s, 60°C 30 
s, 72°C 30 s, and a final extension step of 72°C for 5 min. PCR product was mixed with 10 X DNA 
loading dye before electrophoresis on a 3% agarose mini-gel in 1X TAE buffer. After 45 min of 
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electrophoresis, the gel was photographed under UV light. The presence of a 101 bp band 
indicated that a genomic contamination was present in the RNA. 
 
If the total RNA failed to meet any of the quality criteria, the total RNA was re-isolated from 
additional biopsies or RNA solution was subject to another round of binding, washing and DNAse I 
digest on a fresh mini-column. 
 
2.1.3 Production of cDNA microarray: Human Unigene Set RZPD1 
 
The production of the cDNA microarrays was carried out by Dr. Christine Costello and Brigitte 
Mauracher in collaboration with Dr. Holger Eickoff at Department Lehrach in Max Planck Institute 
for Molecular Genetics, Berlin (Mah et al., 2004). In brief, amplified PCR products from the Human 
Unigene Set RZPD 1 clone set (German Resource Center for Genome Research (RZPD), 
http://www.rzpd.de/), which consisted of approximately 34 000 cDNA clones and represented 20 
000 UniGene clusters (Build #160), were spotted on 23 X 23 cm Hybond N+ nylon membranes 
(Amersham, Freiburg, Germany) using a Genetix robot (Genetix, München-Dornach, Germany) 
attached to a 384 pin gadget-head (250 mm pins). Each cDNA clone was spotted in duplicate 
within a 6X6 pattern including four blank spots and two Arabidopsis thaliana (Genbank Accession 
U29785) guide spots for gridding orientation. Two hundred and fifty-eight clones representing 
known genes of interest were additionally spotted to complement the Human Unigene Set 1. A 
complete description of the clone-based microarray platform is available under GEO accession 
GPL284. 
 
2.1.4 Hybridization of cDNA microarrays 
 
Using a commercial kit (Qiagen), 100-250 ng poly (A)+ RNA was isolated from 15 µg of total RNA 
from each patient. Reverse transcribed target cDNA from patients was labeled with 33P-dCTP as 
previously described (Eickhoff et al., 2000), with the modification that the labeling reaction was 
incubated at 42°C for 1 h. RNA was hydrolyzed under alkaline conditions (0.3 M NaOH at 68°C for 
20 min) and neutralized. A. thaliana cDNA (25 ng) was labeled with 50 mCi 33P-dCTP (≥2500 
Ci/mmol, Amersham) as previously described (Feinberg and Vogelstein, 1983). Unincorporated 
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radio-nucleotides were removed using MicroSpin G50 columns (Amersham). Prior to the first 
hybridization, unused filters were washed three times in 1 X SSC; 0.1% SDS at RT for 10 min 
followed by three washes in 0.1 X SSC; 0.1% SDS for 20 min at 80°C. Filters were pre-hybridized 
for 2 h at 50°C in hybridization solution (7% SDS, 50% formamide, 5 X SSC, 2% blocking reagent 
(Roche Diagnostics, Mannheim, Germany), 50 mM sodium phosphate (pH 7.0) and 100 mg/mL 
denatured salmon sperm DNA). Radiolabeled A. thaliana and patient cDNA were heat-denatured 
and cooled on ice prior to addition to pre-hybridized filter. Following overnight hybridization at 42°C, 
filters were washed three times in 1 X SSC; 0.1% SDS buffer for 10 min at room temperature 
followed by two washes for 30 min in 0.2 X SSC; 0.1% SDS at 65°C. Filters were exposed to 
imaging plates (BAS-MS 2325, Fujifilm, Kanagawa, Japan) for 24 h and scanned at 50 µm 
resolution on a FLA-3000G imaging system (Fujifilm). There were no saturated probe data points 
after exposure and scanning. Image gridding was carried out using VisualGrid® software 
(http://www.gpc-biotech.com), and the spot quantitations were imported into a custom-made 
laboratory information management system (LIMS) database for normalization. A complete 
description of the sample labeling, hybridization and raw output from spot quantitation software is 
available under GEO accession numbers GSM5994-GSM5998 (Mah et al., 2004). 
 
2.1.5 Normalization of clone-based microarray data using Zipf's Law 
 
A normalization procedure was developed in-house for the Human Unigene Set 1 RZPD array. 
Microarray data normalization was conducted in two stages, intra-array normalization and inter-
array normalization. Because of the comparatively large size of this membrane-based system, it 
was observed that some portions of the array displayed higher intensity measures than others 
(patchiness). Intra-array normalization removed spatial intensity measurement biases by dividing 
the microarray into 2304 fields, each containing 36 spots (15 duplicated data spots, 4 background 
controls, and 2 positive controls for grid positioning). The minimum intensity value for the 
background spots in each field was used to normalize the 30 data points in that field using a simple 
log transformed global mean method. Data spots for which at least one duplicate was below the 
filter background median were removed from analysis. Outliers (data spots where duplicate 
measures were not similar) were identified from a distribution of the difference between duplicates 
(duplicate 1 minus duplicate 2). This distribution was divided into centriles and the tails of the 
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distribution where centriles contained less than 10 data points were considered outliers whose 
value were removed from analysis. 
 
Inter-array normalization was conducted in accordance with the observation that microarray 
intensity distributions follow Zipf's law (Lu et al., 2005). Genes on the array system were ranked 
according to median expression intensity over all arrays. Normalization was conducted such that 
the regression coefficients of the log expression intensity vs. log rank distribution for each 
microarray was the same as that of the median data distribution of all microarrays. A scaling factor 
was applied to the pre-normalized data to prevent negative log values from occurring during data 
transformation, and the same scaling factor was applied to the post-normalized data to return the 
values to their original magnitude. As an indicator of confidence as to whether a gene could be 
considered ‘present’, detection p-values were calculated for each clone probe based on the 
distribution of background values on each filter. Signals with a detection p-value <0.05 were 
considered to be ‘present’. All relevant raw data values and normalized values are publicly 
available under GEO accession numbers GSM5994-GSM5998. 
 
2.1.6 Isolation of plasmid DNA 
 
Bacterial clones of interest were cultured in 96-deep-well plates containing 1.4 mL of LB media and 
100 µg /mL ampicillin per well. Cultures were grown 20-24 h at 37°C with shaking (220 rpm). 
Bacterial freezer stocks of the cultures were made by mixing 100 µL of overnight culture with an 
equal amount of 30% glycerol in LB in a 96-well plate and storing at –80°C. A commercial mini-prep 
kit (Montage Plasmid Miniprep96 Kit, Millipore) was used to isolate plasmid DNA from the 
remainder of the bacterial culture. First, the bacteria were pelleted by centrifuging the deep well 
blocks at 1500 g for 5 min. The culture supernatant was discarded and the bacterial pellets were 
resuspended in 100 µL solution 1 (cell resuspension solution containing RNase) by vortexing. Cells 
were then lysed by adding 100 µL of solution 2 (cell lysis solution) to each well, vortexing for one 
minute and then incubating at room temperature for 2 min to allow lysis to complete. Next, 100 µL 
of solution 3 (neutralization solution) was added to each well and mixed vigorously on a plate 
shaker for 2 min. The resulting lysate was then cleared by pipetting the lysate into a MultiScreen 
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lysate clearing plate, placing this plate on top of the MultiScreen96 plasmid plate, and then applying 
vacuum (0.27 bar) for 3 minutes or until the lysate was drawn through the clearing plate and into 
the plasmid plate. The clearing plate was discarded. To isolate the plasmid DNA, the eluate in the 
plasmid plate was drawn through the DNA-binding membrane by applying vacuum (812.7 millibar) 
for 5 min or until the all liquid was completely drawn through. Next, the plasmid plate wells were 
washed by pipetting 200 µL of solution 4 (nuclease-free water) into each well and applying vacuum 
as before. Plasmid DNA bound to the plasmid plate was then isolated by applying 50 µL of solution 
5 (tris buffer for storage) to each well, incubating the plate for 30 min at room temperature and 
finally pipetting the resuspended plasmid DNA from the plasmid plate into a fresh 96-well plate for 
storage. Plasmids were stored at –20°C until use. 
2.1.7 Sequence verification of bacterial clones 
 
Plasmid DNA was sequenced using Big Dye Terminator chemistry on an ABI 9700 Sequencer in 
96-well plate format. Reactions for each well were prepared on ice using the components in Table 
2.1. Various sequencing primers were used, including M13 forward/reverse and T7/T3 primers 
(Section 8.4 Primer and probe sequences). 
Table 2.1  Components for sequencing of plasmid DNA 
Component Volume (µL) 
Big Dye Terminator enzyme mix 3 
Sequencing Primer (10 pmol/µL) 1 
Water (HPLC grade) 1 
Plasmid DNA (~80 ng/µL) 5 
  
Total volume 10 µL 
 
Reactions were carried out in 96-well Costar plates sealed with plastic foil. The clone inserts were 
amplified using the following cycling profile: 96°C for 10 s, then 30 cycles of 95 °C for 20 s, 53°C for 
30 s, and 60°C for 4 min. PCR products were then allowed to extend at 60°C for 7 min, and finally 
the reaction was stopped by pausing at 4°C.  
 
Excess fluorescent dye was removed from the reaction by eluting the PCR reaction through a G-50 
Sephadex column into a Microarray Optical 96-well reaction plate (Applied Biosystems). The 
resulting eluate was then subject to capillary sequencing on an ABI Prism 9700 Sequencer. 
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Chromatograms of the plasmid sequence were analysed using Sequencher 4.0.5 software 
(GeneCodes). 
2.1.8 Hybridization and data analysis of Affymetrix U 95Av2 microarrays 
 
Total RNA was isolated from sigmoid biopsies of five normal controls (Sections 2.1.1 and 2.1.2). 
For the purpose of the microarray comparison, the RNA from each patient was divided into two 
aliquots. One aliquot was sent to a collaboration partner (Dr. Anders Thelin, AstraZeneca R&D, 
Mölndal, Sweden), where the RNA samples were hybridized to Affymetrix U95Av2 microarrays, 
and the resulting normalized microarray data was shared with the Institute for Clinical Molecular 
Biology in Kiel. The second aliquot of RNA was hybridized in-house to cDNA microarrays (Sections 
2.1.4) and normalized using procedures developed in-house (Section 2.1.5). 
2.1.8.1 Hybridization of Affymetrix U 95Av2 microarrays 
 
Affymetrix arrays were hybridized according to standard manufacturer's protocol. Briefly, 15 µg of 
total RNA was used to generate double-stranded cDNA using Superscript reagents (Life 
Technologies) and a T7-linked oligo(dT) primer. cRNA were synthesized using the Enzo Bioarray 
High Yield RNA transcript labeling kit from Affymetrix, resulting in biotinylated cRNA. Labeled cRNA 
were cleaned using Qiagen RNeasy kit and fragmented into 35-200 bp lengths using fragmentation 
buffer supplied by Affymetrix. Spike controls B2, bio-B, bio-C, bio-D and Cre-x were added to the 
hybridization cocktail before overnight hybridization at 45°C for 16 hrs. Arrays were stained and 
washed using the EukGE-WS2 protocol (a dual staining) before being scanned on an Affymetrix 
scanner. 
2.1.8.2 Microarray suite software (MAS) 5.0 
 
Absolute analysis (Affymetrix Microarray Analysis Suite 5.0) was performed on the arrays using the 
target intensity value of 150 (global scaling, no baseline) and Tau=0.015 (default parameter which 
affects discrimination between match/mismatch probe pairs). Target intensity of 150 was chosen 
based on previous experience with Affymetrix arrays, which showed that this value typically yielded 
adequate scaling factors (between 0.5 and 10). In contrast to the conventional cutoff of p < 0.05 
used for the clone-based platform, a signal for an oligonucleotide probe set was determined to be 
‘present’ if the detection p-value of the probe set was less than 0.06, which, for the purposes of this 
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comparison, included ‘present’ and ‘marginal’ calls assigned by MAS5.0 default criteria. The 
complete datasets are available under GEO accession numbers GSM5999-GSM6003. 
 
2.1.9 Matching of clone-based PCR products to corresponding 
oligonucleotide probes 
 
For the purpose of the microarray platform comparison, it was necessary to identify a set of genes 
that were common to both the cDNA and the oligonucleotide microarray platforms. A detailed 
flowchart of the experimental setup and probe-matching procedure is outlined in Figure 2.1. Two 
different methods were used to identify probes that theoretically represented the same gene. In a 
more general approach, cDNA clones or Affymetrix exemplar sequences were matched to human 
UniGene clusters (build 160) through batch web search tools (http://genome-www5. 
stanford.edu/cgi-bin/SMD/source/sourceBatchSearch). As each UniGene cluster should represent 
a nonredundant gene (http://www. ncbi.nlm.nih.gov/UniGene/), the term “gene” and “UniGene 
cluster” will be used interchangeably in this thesis. Probes from either system that were grouped to 
the same UniGene cluster were considered as “matched probes.” In cases where a gene was 
represented by multiple probes, gene detection was only counted once, based on the probe that 
gave the lowest P value, and was expressed in the highest number of patients. Using this UniGene 
method of matching, a set of 6645 genes were defined to be present on both platforms. The 
second approach of gene matching was more sequence specific. Full clone sequences were 
assembled from sequence-verified data from the 5' and 3' insert ends (up to 700 bp from each 
end). Public sequence data was used to bridge short gaps (less than 100 bp) between the ends of 
5' and 3' sequences in cases where the clone ends did not overlap, giving rise to 272 
“reconstructed” full-length clones. The corresponding probes in the Affymetrix platform were 
identified through BLAST homology searching in the target and probe databases available from 
NetAffx Analysis Center (http://www.affymetrix. com/analysis/index.affx). Probes were considered 
to be matched if the clone sequence had a BLAST homology score greater than 200 in the target 
database or if the clone sequence matched more than 10/16 probe pairs with >75% identity. All full-
length clone sequences were screened for Alu repeat sequences using the Repeatmasker Web 
Server (http://repeatmasker.genome.washington.edu/cgi-bin/ RepeatMasker). 
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RNA from 5 normal controls
A B C D E
clone-based hybridization Affymetrix hybridization 
6645 non-
34560 probes 12626 probe sets
20406 probes representing non-
redundant genes
8602 probes representing non-
redundant genes
redundant genes 
overlap
(Table 3.1A)
Probe matching based on UniGene Build 160
sequence-verified pool 
of ~2000 clones
715 sequence-verified, UniGene
matched clones (Table 3.1B)
169 full-clone sequences, BLAST-
matched (Table 3.2A)
BLAST matching of 272 
available full-length clones to 
Affymetrix probe database
eliminate sequences 
containing Alu repeats
137 full-clone sequences, 
BLAST-matched, no Alu
repeats (Table 3.2B, Figure 
3.3)
 
Figure 2.1 Flow-chart of comparison analysis. 
 
After normalization of microarray data in each respective protocol, the datasets were tested for 
normality. The distribution of the mean expression data from each expression platform was tested 
e the extent of correlation in expression levels between the two systems. To obtain a 
n P value for each probe on the array from all five samples, individual P values for each 
 
Schematic diagram shows the flow of analysis starting from hybridization of five patient samples to 
both microarray platforms and progresses through probe matching steps with increasing 
stringency. 
 
2.1.10 Statistical analysis of expression data for microarray comparison 
by Kolmogorov-Smirnov test using Analyse-it software in Microsoft Excel. As the mean expression 
data from each platform were not normally distributed, Spearman rank order coefficients were used 
to determin
detectio
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gene were combined according to the Fisher method for combining probabilities (Sokal and Rohlf,
1995). 
 
2.1.11 Real-time PCR quantitation of selected transcripts 
 
 
elected genes (ACTB, CDH11, MMP1, APOA1, PPBP, CLDN4, CEACAM1, MPG, PRKCBP1, 
 microarrays 
were s antification. Primers and probes for real-time PCR were labeled 
ith the fluorescent reporter dye 6-carboxyfluorescein (6-FAM) and the quencher dye 6-
entec, Seraing, 
Belgium; or Applied Biosystems), and the sequences are supplied in section 8.4. Total RNA (1 µg) 
om each patient sample was reverse transcribed to cDNA according to manufacturer’s 
ms) in 
°C 
gene 
nd 
t 
 a 
S
TIMM17B, MMP3, ALDOB, and MUC1) observed to be present and/or absent on the
elected for real-time PCR qu
w
carboxytetramethylrhodamine (TAMRA) at the 5' and 3' ends, respectively (Eurog
fr
instructions (MultiScribe Reverse Transcriptase, Applied Biosystems). Patient cDNA was diluted 
1:10, and 5 µL of the cDNA was pipetted in duplicate into a 384-well plate format. Real-time PCR 
was carried out using the ABI Prism 7900HT Sequence Detection System (Applied Biosyste
the following 10-µL reaction: 0.9 µL Universal TaqMan Master Mix (Applied Biosystems), 200 nM 6-
FAM probe, 300 nM forward and reverse primers, and 5 µL cDNA diluted template. The PCR 
cycling profile was as follows: 2 min at 50°C, 10 min at 95°C and 40 cycles of 95°C for 15 s, 60
for 1 min. 
 
All patient samples for each gene assay were analysed in duplicate on one plate, and each 
assay was done in triplicate (except for MMP1 and TIMM17B). Real-time runs were recorded a
analyzed using SDS 2.1 software (Applied Biosystems). For an absolute determination of transcrip
levels, the number of cycles (Ct) required to reach the threshold (set to 0.2) was taken to be
measure of transcript abundance. 
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2.2 Identification of genes involved in IBD using cDNA 
microarrays 
 microarray expre  screenin tient coh  
t cohort for cDNA microarray expression screening 
d 31 individuals (Table 2.2) for expression profiling on cDNA microarrays. 
ividuals (5 female (F); mean age: 51.4 y (range )) were ded in the study as 
end c a ologi al examination gnificant 
l findings in this group. Indic r colonosc y in this group ded colonic cancer 
nd previous non-specific c nges in stool habits. To investigate gene expression in 
 patients with active CD (4F; me  age: 33.6 y (ra an en patients with 
active UC (2F; mean age: 34.8 y (range: 27-51 y)) were recruited. All endoscopic biopsies were 
ken from a defined area of the sigmoid colon (at 20-30 cm measured during withdrawal), and 
r 
 
 
2.2.1 cDNA ssion g pa orts
 
2.2.1.1 Patien
 
Group 1 patients include
Eleven ind : 25-84 y inclu
the normal population, with oscopi nd hist c  yielding no si
pathologica ations fo op  inclu
surveillance a ha
IBD, ten an nge: 19-66 y)) d t
ta
immediately snap-frozen in liquid nitrogen. Clinical disease activity was documented using 
established clinical parameters of the Crohn’s disease activity index (CDAI) in CD (Best et al., 
1976) and using the colitis activity index (CAI) (Rachmilewitz, 1989; Truelove and Witts, 1955) fo
UC patients. In order to qualify for inclusion into the study, IBD patients had to be clinically 
(CDAI>150 or CAI≥4) and endoscopically active at the time of sampling, but free of all medication
(other than low dose 5-ASA) for a minimum of 6 weeks prior to endoscopy. 
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Table 2.2  Clinical characteristics of the IBD patient group for cDNA microarray analysis 
Hospitalized 
normal controls  
CD patients UC patients 
 
 
No of patients 11 10 10 
Sex (F/M) 
Age (y) (mean (range)) 51 ) 33.6 (18-66) 34.8 (27-51) 
 
  
* 
 0 
 
   
  
  
 
(5/6) 
.4 (25-84
(4/6) (2/6) 
Region of biopsy 
olon
   
  Sigmoid c 11 10 10 
  Descending colon 0 
0
0 
0 
0 
0   Caecum 
on 
 
  Transverse col 0 0
 
0
 Inflammation activity  
  Active 0 10 1
  Inactive 11 0 0 
Medication 
tment   No trea 10 6 6
  Steroids 0 
0
0
2
0
3   5-ASA 
  NSAID 
 
1 1 1 
  Antibiotic 0 1 0 
  Other 0 0 0 
 
2.2.1.2 Patient cohort for real-time PCR verification
 verify the cDNA array finding he initial patient collection described in Table 2. s 
 100 individuals for real-time PCR analysis (Table 2.3). IBD patients used in G p 2 
 selected using similar criteria as outlined 
tion in the colon and were clinically active (CDAI>150 
rCAI≥4). Patients were allowed 5-ASA or glucocorticoids, but not immunosuppressants or 
 
ce. As disease specificity controls, 17 patients (9F; mean age 56 y (range 17-80 y) with 
olonic disease but not IBD, were also included (Table 2.3). These disease specificity controls (DC) 
patient 
4.3). 
 
 
In order to s, t 2 wa
extended to rou
consisted of 27 CD patients (17F; mean age 32.1 y, (range: 17-45 y) and 35 UC patients (20F; 
ean age 33.8 y, (range: 18-74 y). All patients werem
above i.e. all patients had active inflamma
o
biologicals. The hospitalized normal control population consisted of 21 individuals (11F; mean age
48.9 y (range 16-84 y) which yielded no significant pathological findings following endoscopic 
examination for changes in stool habits, abdominal pain, upper gastrointestinal bleeding or cancer 
surveillan
c
included 9 non-inflamed and 8 inflamed biopsies samples from patients with infectious diarrhea, 
other forms of gastrointestinal inflammation or irritable bowel syndrome. No restriction on 
medications was specified in the inclusion criteria for disease specificity controls and all 
concomitant medications are listed in Table 2.3. A minimum of 19 normal controls, 16 UC, 19 CD 
and 14 DC samples were used for each real-time assay, depending on the availability of the 
samples and the plate layout at the time the real-time cDNA plates were produced (Section 2.
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Table 2.3  Characteristics of extended patient group for real-time PCR verification of cDN
microarray results 
 
normal 
A 
 Hospitalized 
controls 
CD patients UC patients DC patients 
No of patients 21 27 35 17 
Sex (F/M) (11/10) (17/10) (20/15) (9/8) 
Region of biopsy     
  Descending colon 1 1 0 0 
7 0 0 0 
  Transverse colon 0 0 0 1 
flammation activity*     
  Active 0 27 35 8 
Diagnosis (applicable to DC     
  Infectious diarrhea NA NA NA 8 
  Irritable Bowel Syndrome NA NA NA 2 
  No treatment 14 9 11 9 
1 
  5-ASA 0 9 18 1 
0 1 3 
  Antibiotic 1 2 0 4 
Other 4 2 4 4 
Age (y) (mean (range)) 48.9 (16-84) 32.1 (17- 45) 33.8 (18-74) 56 (17–80) 
  Sigmoid colon 13 26 35 16 
  Caecum 
In
  Inactive 21 0 0 9 
patients) 
  Gastrointestinal inflammation NA NA NA 7 
Medication     
  Steroids 0 14 11 
  NSAID 2 
  
* Inflammation activity of biopsied site, as observed by the endoscopist 
ol patient, 5-ASA: 5-Aminosalicylic 
cid, NSAID: Non-steroidal anti-inflammatory drug 
2.2.2 Microarray data analysis 
(Lu 
 the 
re 
n 
ized to five 
eparate arrays of one production batch. Fold changes were calculated between all pairwise 
Abbreviations used: NA = not applicable, DC = Diseased contr
a
 
 
Total RNA was isolated from biopsies of patients as described in Sections 2.1.2 and 2.2.1.1, and 
hybridization to Human Unigene I cDNA microarrays was carried out as previously described in 
Section 2.1.4. The cDNA microarrays were washed and scanned as previously described (Section 
2.1.4). 
 
The microarray datasets were normalized according to an in-house method based on Zipf's law 
et al., 2005). A background cut off, set to the mean background plus two standard deviations of
background, was used to distinguish detectable, 'present' signals from 'absent' signals, which we
set to zero. A fold-change cut off was determined based on the technical variance obtained whe
the same RNA sample (obtained from a intestinal surgical specimen) was hybrid
s
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combinations of the five arrays for all 33 792 spotted cDNA probes. For each unique pairwise 
combination, the fold change observed at the 95th percentile of the distribution was noted. The 
d for 
mal 
h 
r subgroup could be determined using a statistical test based on a 
ypergeometric distribution (Tavazoie et al., 1999). 
2.2.3 Prediction of function in unknown genes 
nd Pfam 
Fs 
average of these values (fold change of 1.2) was taken to be the threshold fold change value for 
differential expression using these cDNA microarrays. Significantly differentially regulated genes 
were defined to be those genes whose expression was statistically different in two groups 
(distribution-free Mann-Whitney U–test) and whose fold change was greater than the threshol
technical variance, 1.2. The reported fold changes were calculated based on the median of each 
experimental group. 
 
To identify broad functional groups of genes that were significantly regulated between nor
controls and the IBD subtypes, the frequency of differentially regulated genes associated with a 
particular functional group was compared to the total number of genes on the array associated wit
the particular functional group. In this manner, an enrichment of differentially regulated genes 
belonging to a particula
h
 
 
Selected clone probes that were differentially regulated but not associated to known genes were 
further analysed in detail to decipher possible function. First, cDNA clone sequences, obtained by 
methods as described in Sections 2.1.6 and 2.1.7, were searched for homology against the 
GenBank nonredundant database using BLAST alignment. Next, the highest scoring BLAST hit 
(sequence identity close to 100%) was used to extend the sequences to longer mRNA transcripts. 
InterPro (http:// www.ebi.ac.uk/InterProScan), SMART (http://smart.embl-heidelberg. de) a
(http://www.sanger.ac.uk/Software/Pfam) search methods (with standard parameter sets) were 
used to detect known protein domains and functional sequence motifs in putative open reading 
frames (ORFs) longer than 100 amino acids. Additionally, close homologies of the ORFs were 
found through association to UniGene clusters in humans and other species. In cases of OR
without a detectable homology to known genes, these transcripts were mapped to genomic 
locations by BLAST searching and examined in terms of their genomic context. 
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2.2.4 Verification of cDNA microarray results by fluorogenic real-time PCR 
 
Selected genes from the microarray results were independently quantitated by real-time PCR on an 
to non Applied Biosystems, Foster City, 
alifornia. United States), or ordered from Applied Biosystems as Assays-on-Demand Gene 
Multi- Scribe Reverse Transcriptase, Applied 
Biosystems). Reactions were carried out on the ABI PRISM Sequence 7700 Detection System 
(Applied Biosystems) and relative transcript levels were determined using β-actin as the 
endogenous control gene. A detailed description of the cDNA preparation and real-time PCR 
procedure is described in Section 2.1.11. Statistically significant differences between control and 
IBD samples were determined using a Mann-Whitney U test. A p-value of less than 0.05 was 
considered significant. 
 
2.2.5 Immunohistochemistry 
mbedded biopsies from n (n nd from patients with CD (n=5) and UC 
(n=6), which were obtained in par  the same sites as the biopsies used for the expression 
, were analysed by Drs. Philip Rose el and Ralph Lucius. Immunohistochemical 
accordin col and co-workers (Waetzig et al., 2002). 
m sections were subjected to heat-induce antigen retrieval in 0.01 M EDTA solution, 
r blocking in 0.75% BSA solution in PBS for 20 min binding, the sections were 
 PBS, and incu ted for 1 hr with the respective primary antibodies 
carcinoembryonic antig related cell sion molecule 1 (CEACAM1) 4D1/C2, 
RKCB1; Pharmingen, San iego, CA, USA), and casein kinase 1, delta 
 Santa Cruz, Santa Cruz, CA, USA). The ctions were washed in PBS (3 times for 10 
ated with peroxidase-conj ated rabbit a mouse secondary antibody (Sigma, 
ofen, Germany; 1:100) for 30 min, washed, d stained with goat anti-rabbit IgG (Sigma, 
1:200, 30 min), before processing with diaminobenzidine and embedding in Aquatek (Merck, Inc., 
Hawthorne, NY). For specificity controls, (i) the primary antibodies were omitted and (ii) normal 
extended patient cohort (Section 2.2.1.2 and Table 2.3). Probes and primers were either designed 
-redundant sequences using Primer Express V2.0 (
C
Expression Assays (Section 8, Appendix, Table 8.3). Total RNA (1 µg) was reverse-transcribed to 
cDNA according to the manufacturer’s instructions (
 
Paraffin-e ormal controls 
allel from
=5) a
analysis studies nsti
staining was completed g to a proto  by Waetzig 
Briefly, 7-µ d 
pH 8 for 10 min. Afte
washed three times in ba
(monoclonal en- adhe
protein kinase C beta 1 (P D
(CSNK1D; se
min), incub ug nti-
Deisenh an
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sera wer  used from the species in which the primae ry antibodies were raised. No specific staining 
d be detected using either of these combinations (data not shown). 
2.3 Identification of genes involved in inflamed/non-inflamed IBD 
s 
es were taken from both a non-inflamed and an inflamed region 
from each patient. Additionally, 10 healthy normal controls were also recruited (Table 2.4). All 
s taken from sigmoid colon or 
ceacum. Total RNA was prepared ch of the biopsies (Section 2.1.2) and sent to a 
rtner (Dr. Jun Li, R&D Center, Boehri  Ingelheim Pharmaceuticals, Ridgefield, 
on on HG-U133A Affyme
cohort for UC ex ssion study 
He y 
no al 
control  
UC
coul
 
using Affymetrix HG-U133 arrays 
 
2.3.1 Patient cohorts for microarray analysis on HG-U133 Affymetrix array
2.3.1.1 Inflamed and non-inflamed UC cohort 
 
In order to determine differential gene expression in UC patients, 10 UC patients were recruited for 
this section of the study. Biopsi
biopsies were taken the lower bowel, with the majorit
 from ea
y of biopsie
collaboration pa nger
CT, USA), for hybridizati trix arrays. 
 
Table 2.4  Patient pre
 alth
rm
  
No. of patients 10 10 
Sex (F/M) 5/
n (range)) 30 ( 2) 37 (2 ) 
  
1 
7 
lon 1 
ding colon 2 
9 
n activity  
10
10 
edication   
5-ASA 0 3 
  NSAID 1 1 
  Other 0 0 
5/5 
2 -4
5 
Age (y) (mea
Biopsied reg
0
 
0- 66
ion
  Rectum 
  Sigmoid 
0 
10 
  Ascend
  Descen
ing co 0 
0 
  Caecum 
Inflammatio
0 
 
0   
 Inactive 10 
Active  
 
M
  No treatment 9 6 
  Steroids 0 0 
  
  Antibiotic 0 0 
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2.3.1.2 Inflamed and non-inflamed CD cohort 
 
In order to determine differential gene expression in CD patients, 25 healthy normal controls and 15 
iopsies were obtained from 
) or non-inflamed (n=7) regions of 11 untreated CD patients. Of these 15 biopsies 
rtner 
hort for CD expression study 
 Healthy 
control  
CD 
CD patients were recruited for this section of the study (Table 2.5). B
inflamed (n=8
from the untreated CD patients, four pairs of inflamed/non-inflamed biospies were obtained from 
the same patient (matched samples). In the remaining four CD patients, non-inflamed biopsies 
(n=4) were obtained from immunosuppressive-treated CD patients. Total RNA from each of the 
biopsies was isolated from each of the biopsies (Section 2.1.2) and sent to a collaboration pa
(Dr. Stefan Pierrou, AstraZeneca R&D, Mölndal, Sweden), for hybridization on HG-U133A and HG-
U133B Affymetrix arrays. 
Table 2.5  Patient co
normal 
No. of patients 25 15 
Sex (F/M) 11/14 10/5 
Biopsied region   
  Sigmoid 25 12 
  Transverse colon 0 2 
n 0 0 
  Caecum 0 3 
flammation activity   
  Active 0 8 
Medication   
  Steroids 0 2 
  5-ASA 0 6 
  Antibiotic 0 1 
Age (y) (mean (range)) 28 (19-50) 35 (22-56) 
  Rectum 0 0 
  Ascending colon 0 2 
  Descending colo
In
  Inactive 25 11 
  No treatment 22 9 
  Azathioprine 0 3 
  NSAID 2 0 
  Other 1† 0 
†
 
2.3.2 Microarray hybridization and image processing 
 
Using methods described in Section 2.1.2, total RNA was isolated from biopsies of patients 
described above (Sections 2.3.1.1 and 2.3.1.2) and sent to collaboration partners for hybridization 
on Affymetrix HG-U133A arrays, which contain 22 000 probe sets and represent 13 239 unique 
topical treatment for nasal congestion 
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genes. Hybridization and scanning of the arrays was carried out according to manufacturer's 
protocols (Section 2.1.8.1). 
2.3.3 Affymetrix HG-U133 microarray data analysis 
 
uage R 
d 
nd 
n overview of the steps taken in Affymetrix microarray data analysis is shown in Figure 2.1. 
 
array 
shing, 
k for 
) 
tes the use of statistical methods which summarize the match 
nd mismatch oligonucleotide pairs into a single expression value. The normalization methods 
, vsn) 
 of 
n to reduce 
 
All microarray analysis, including normalization and data exploration (determination of differentially
expressed genes, Gene Ontology analysis) was done using open-source tools from Bioconductor 
(version 1.7; http://www.bioconductor.org/) (Gentleman et al., 2004) and the statistical lang
(version 2.2.0; http://www.r-project.org/). Additionally, scripts in Perl (version 5.8.7; 
http://www.cpan.org/) and MySQL (version 4.1.15; http://www.mysql.com/) databases were use
for data processing, storage and retrieval. Gene Ontology database (September 2005 version) a
Affymetrix annotations (June 2005 version) were used for all analyses. 
 
A
Starting out with the raw Affymetrix datafiles (*.CEL files), the files were read into an R object using
the Bioconductor package affy (Gautier et al., 2004). Next, the false colour image of each 
was inspected to identify any gross image defects caused by incomplete hybridization or wa
dust particles, saturated or low signals. The raw signals were plotted in a histogram to chec
over-saturation. 
 
In contrast to the spotted cDNA microarrays that contain a single clone insert (spotted in duplicate
to represent a gene transcript, the Affymetrix U133 microarrays use 11 pairs of 
matched/mismatched oligonucleotides to make a probeset which represents the gene transcript. 
This technical difference necessita
a
available from the Bioconductor package affy contain different methods to first summarize the 
probe level data and then normalize the summarized probe data. To determine the best 
normalization method, four different normalization methods were used, including the method 
provided by Affymetrix (MAS5.0) and three other methods from Bioconductor (GC-RMA, loess
(Bolstad et al., 2003; Huber et al., 2002; Irizarry et al., 2003; Wu et al., 2004). The performance
each normalization was determined by the following criteria:  1) ability of normalizatio
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variance without increasing bias; 2) ability of the normalization procedure to be carried out 
reasonable amount of computing time. 
 
The normalized datasets were subject to filtering by background and variability cutoffs. A 
background cutoff was calculated for each array, based on a group of bacterial probesets present 
on the U133 array
within a 
s. Since these probesets were bacteria-specific and did not hybridize to human 
rget sequence, signals arising from hybridization of the human targets to these bacterial 
 at 
 
lly 
-
ss of 
y Rate (FDR) (Benjamini and Hochberg, 1995) as an additional 
easure of statistical stringency. 
Though lists of differentially regulated genes reveal many individual gene changes between two 
groups, an overall biological context for the differential regulation may be obscured from view. 
Gene Ontology (GO) is a set of controlled vocabulary intended to standardize the naming of 
biological processes, molecular functions and cellular components associated with all genes. 
nd 
enes may not yet be annotated in GO, either because the associations are not yet 
manually/electronically curated in the GO database, or associations may be misleading because 
ta
probesets could be taken as a measure of random hybridization. The background cutoff was set to 
two standard deviations above the mean background. Based on these cutoffs, probesets were 
considered 'present' if the signal was higher than the background cutoff. Probesets that were
least 70% present in all arrays and were in the top 25% of the most variable genes (as determined
by interquartile range) were considered for further analysis. 
 
A key step in the analysis of microarray data is the determination of genes which are differentia
regulated between two defined groups. For pairwise comparisons (between two groups), 
distribution-free methods, such as permutation tests and rank-based tests, and distribution
dependent methods, such as t-test, were available. In cases were matched samples were 
available, paired statistical tests were applied. Finally, a linear modeling method (R package: limma 
(Smyth, 2004)) was used to make multiple comparisons within a dataset. Since the proce
testing multiple hypotheses increases the chance of committing false positives, a multiple testing 
correction was applied to reduce the possibility of false positives. This was accomplished by 
controlling the False Discover
m
 
Though GO contains many associations to genes, many associations between GO terms a
g
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they are specific to an organism or set of experimental conditions or they are predicted by 
r 
s may be gleaned by examining functionally related 
groups of genes (as classified by Gene Ontology) and their enrichment in the subset of differentially 
ulated probesets into a biological context, the Fisher test for a 
X2 contingency table was used to calculate p-values for the likelihood that differentially regulated 
ory. First, the 
ry probeset associations teg cted otation
ffymetrix. These prim cia s only repr ed the mo pecific GO m. 
obtain all higher level associations in  tree, P ts wer to follo
tree ary  to  te a
ociations to a gene were obtained sets wit ations to GO
itted from the anal , and in case here a single p obeset ha
rms, all asso ations were in ded in the an lysis. Next, a 2X2 contingency 
created for each of the 18 824 GO term isting as of September 2  Using R scripts, 
 deemed 'present' we  classified for differential expr ssion (true/fa e) and 
e/false). The Fisher Ex t test was th d to cal te the pro ility 
equencies varied from those expected by chance. A p-value of less than 0.05 was 
 to be significant. 
 
electronic annotation. Despite these disadvantages, GO can still be used in an exploratory manne
to try to identify broader functional groups from lists of differentially regulated genes. Clues to the 
functional basis of differentially regulated gene
regulated genes. 
 
In order to place the differentially reg
2
genes were enriched (better than chance) within a given Gene Ontology categ
prima to GO ca
ary asso
ories were extra from the HG-U133 ann  file 
as supplied by A tion esent st s  ter
In order to  the GO erl scrip e used w all 
branch points in the GO from the prim  association  the root GO rm. In this w y, all 
possible GO ass . Probe hout any associ  
terms were om ysis s w r d multiple 
associations to GO te ci clu a
table was s ex 005.
all probesets re e ls
association to GO term (tru ac en use cula bab
that the fr
considered
 
 
 
 
Figure 2.2 Flow diagram of HG-U133A microarray analysis in R statistical language 
Raw Affymetrix 
Data 
(22283 probe sets on 
HG-U133A arrays) 
Normalization 
 
• MAS5.0  
• GC-RMA 
• vsn 
• loess 
Exploratory Data Analysis 
 
• Differentially regulated genes 
between groups 
• Gene Ontology analysis 
Quality Control 
Background filter 
Variability filter 
Visual 
Inspection 
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2.4 Real-time PCR analysis 
 
To assay the gene transcript levels in an extended cohort of a total of 312 patients, cDNA from 
ealthy normal controls, IBD patients and disease-specificity controls was arrayed on three 384-
r real-time PCR quantitation. 
eal-time PCR analys
sisted of Section 2.2.1.2, and included an al group of 
ent and Sample Data for Complete Real-time PCR coho
Healthy 
normal 
Hosp d 
normal co l 
CD  UC DC  
h
well plates fo
2.4.1 Patients for r is 
 
The full real-time PCR cohort con  addition
healthy normal controls (Table 2.6). 
 
Table 2.6.  Pati rt 
 italize
ntro
control 
No. of patients 
 
25 34 100 96 57 
Sex (F/M) 
 
13/12 18/16 58/42 50/46 31/28 
Age (y) (mean (range)) 
 
28 (19-50) 55 (27-84) 37 (17-69) 37 (16-74) 47 (16-80
Biopsied region     
  Large bowel 25 34 100 96 57 
  Small bowel 
 
0 0 0 0 
Inflammation activity      
  Active 0 0 42 57 15 
  Inactive 
 
25 34 51 39 44 
Medication      
  No treatment 19 10 19 16 20 
  Steroids 0 1 36 26 2 
  5-ASA 
  NSAID 
) 
 
0 
0 0 20 44 2 
1 2 0 2 4 
  Antibiotic 0 2 4 3 5 
5 4 29 22 11   Other 
 
Due to the availability of the samples at the time the cDNA plates were produced (six plate batches 
 
2.4.2 cDNA synthesis 
 
00 µL 
were produced in the course of the present study), the plated number of samples per group was
not constant between plate batch productions. Ranges of sample numbers used for the assays are 
listed in the relevant results tables. 
 
Total RNA was isolated from patient biopsies from patients as described in Section 2.1.2. For each
patient sample, cDNA was reverse-transcribed from 1 µg of total RNA in a total volume of 1
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using the MultiScribe™ Reverse Transcriptase reagents (Applied Biosystems). Components of the 
Table 2.7  Components for first-strand cDNA synthesis 
reverse transcriptase reaction were mixed on ice (Table 2.7). 
 
Component Volume for one 
reaction (µL) 
Concentration in Final 
Reaction 
10 X TaqMan RT buffer 10 1 X 
25 mM MgCl2 22 
dNTPs (2.5 mM) 20 
5.5 mM 
500 µM 
0 µM random hexamer primers 5 2.5 µM 
µ 2 0.4 U/µL 
1.25 U/µL 
ater 
variable  
0 
5
Rnase inhibitor (20 U/ L) 
Multiscribe reverse transcriptase (50 U/µL) 2.5 
RNase-free w
  
variable  
 
1 µg total RNA 10 ng/µL
   
Total volume 10  
 
As a negative control for the reverse transcripta action, the above amounts were halved and 
ptase was omitted from the reaction. All reactions were prepared on ice and 
d at 25°C for 10 min, 48°C for 30 . Th
 EDTA. The success of the first strand cDNA sy as then 
L of the first stand synth s a template for PCR tion with 
2.1. he amplification of the GAPDH PCR 
rse transcriptase rea n, but not in the negativ  reverse transcriptase 
production 
pared 
ic 
te in 
se re
the reverse transcri
then incubate min and 95°C for 5 min e reaction was stopped 
by addition of 2 µL of 0.5 M nthesis w
checked by using 2.5 µ esis a  amplifica
GAPDH as previously described in section 2.3. T  101 bp 
product in the positive reve ctio e
reaction, indicated successful first stand synthesis without contamination from genomic DNA. The 
final theoretical concentration of cDNA, assuming 100% efficiency of reverse transcription, was 10 
ng cDNA/ µL. 
2.4.3 Plate 
 
cDNA prepared in section 2.4.2 was diluted 1:5 to a theoretical concentration of 2 ng/µL before 
being added to 384-deep well plates. For relative quantitation, standard curve cDNA was pre
from reverse-transcription of a mixture of total RNA obtained from inflamed IBD and normal colon
mucosa to provide the greatest range of gene transcript expression. The standard curve was 
serially diluted in ten dilutions from 1:1 to 1:200 or 1:1000, in a total volume of 250 µL per deep 
well. For the real-time PCR reaction, 5 µL of the cDNA solution was added to the 384 well pla
quadruplicate: two wells for β-actin quantitation and two wells for target gene quantitation. 
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2.4.4 Gene expression assays on ABI prism 7900HT 
Real time PCR assays were carried out using either commercial (Table 2.8) or self-designed 
primers and fluorescent probes (Table 2.9). Sufficient volumes of reaction mix were prepared in 
bulk and then dispensed by multipipet to 384-well PCR plates containing 5 µL of cDNA (2 ng/µL). 
All reagents were kept cooled on ice during the pipetting procedure. Plates were sealed with PCR 
film and stored at 4 °C or –20°C if they were not immediately run. 
 
Table 2.8  Components for Assay-on-Demand products 
Component Volume per well (µL) Concentration in Final 
Reaction 
 
cDNA template (2 ng/µL) 5 1 ng/µL 
20 X Assay-on-Demand 0.5 1 X 
2 X TaqMan® Universal PCR Master Mix 4.5 0.9 X 
   
Total volume 10  
 
Table 2.9  Components for self-designed primers and probes 
Component Volume per well (µL) Concentration in Final 
Reaction 
cDNA template (2 ng/µL) 5 1 ng/µL 
20 µM forward primer 0.15 300 nM 
20 µM reverse primer 0.15 300 nM 
10 µM FAM-labeled probe 0.2 200 nM 
2 X  TaqMan® Universal PCR Master Mix 4.5 0.9 X 
   
Total volume 10  
 
Plates were briefly centrifuged and then run on an ABI 7900HT Sequence Detection System using 
the following thermocycling profile: 50°C for 2 min; 95°C for 10 min; and 40 cycles of: 95°C for 15 s; 
60°C for 1 min. 
 
Upon completion of the run, the data was analysed by the Sequence Detection System (SDS) 2.0 
software using the following parameters: 1) threshold line set as low as possible such that the line 
intersects the amplification curves in the exponential phase yet any amplification in the non-
template controls is reduced to negligible levels; 2) baseline set separately for housekeeper and 
target such that the baseline starts at three cycles and ends just before the first amplification curves 
rise above threshold; 3) extreme outliers in the standard curve eliminated from the calculation of 
the standard curve. Upon adjusting all of these parameters, the SDS software automatically 
calculated the relative quantities, which were then exported as a tab-delimited text file for further 
data processing. 
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2.4.5 Real-time PCR data processing 
 of the real-time PCR data, the SDS text files were 
ported into a self-designed MySQL database and analysed by scripts in Perl and R languages. 
Figure 2.3  Flow diagram showing the data storage and processing of real-time PCR data. 
 
 
 
To facilitate systematic analysis and storage
im
Gene transcript levels were measured using the standard curve method (Livak, 1997). A flow chart 
of the data storage and analysis is shown in Figure 2.3. 
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3 Results 
3.1 Microarray comparison 
 
To compare microarray results from different microarray platforms, RNA was extracted from coloni
mucosa biopsies of five normal controls. Exactly the same RNA was used for subsequent 
hybridization on both the cDNA and Affymetrix oligonucleotide arrays (HG-U95Av arrays). 
c 
.1.1 Variation in expression signals 
sent” in samples of normal individuals, as demonstrated by median and 
verlapping semiquartile ranges. 
 
3
 
The overall distribution of variation in detected signals among the five patient samples was 
determined by calculating a scaled measure of variation (coefficient of variation) for all “present” 
signals in both platforms (Figure 3.1). Both systems had a similar range of variation in the 
distribution of “pre
o
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Figure 3.1 Variation in 
probe detection on both 
platforms. 
Coefficients of variation 
were calculated for each 
“present” signal and were 
found not to be normally 
distributed by Kolmogorov-
Smirnov test. The median 
coefficients of variation for 
the clone-based platform 
(black line) and the 
Affymetrix platform (gray 
line) were 0.15 ± 0.11 and 
0.26 ± 0.18, respectively, 
and were not statistically 
different. 
 
T
a
f ing 
r method, resulting in a combined detection p-value. Gene probes with a combined 
o facilitate comparison between the microarray platforms, a single call (“present” or “absent”) was 
ssigned to each probe, based on the probability of the probe’s expression signal in each of the 
ive biological replicates. For each probe, p-values were combined from each patient sample us
the Fishe
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detection p-value of p < 0.05 or p <0.06 in the clone-based or Affymetrix platforms, respectively, 
ere defined as “present”. A plot of the coefficient of variation against the log10 mean expression 
 
w
signal illustrated the distribution of overlapping “clouds” formed by groups of “present” signals 
stratified by three equal groups of combined detection p-values (Figure 3.2). As expected, a higher 
range of variation was predominantly seen in samples with low expression levels within each 
platform. Genes called “present” in the top third percentile were expressed at higher levels than 
those that could be detected in the middle or bottom third percentile of combined p-values. 
 
To obtain an estimate of the actual numbers of genes detected by the platforms, each probe was 
assigned to a gene using UniGene cluster identifications (Section 2.1.9). A total of 13 639 and 4 
660 nonredundant genes were detected (based on combined detection p-values from all samples),
representing about two-thirds of the clone-based platform and half of the Affymetrix platform, 
respectively. 
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Coefficient of variation and log10 mean expression of present signals are shown for the clone-based 
and Affymetrix platforms. Varying p-values of probe detection in the clone-based platform are 
on 
p-values. Similarly, the Affymetrix platform values are separated by top (dark blue), middle (pink), 
les 
measured extended 3 logs in the clone-based system (1:564 arbitrary units) and 4 logs in the 
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Figure 3.2  Distribution of coefficient of variation and mean expression in present signals. 
colored according to top (cyan), middle (purple), or bottom (brown) third percentiles of the detecti
and bottom (yellow) third percentiles of the detection p-values. The dynamic range of the samp
Affymetrix system (1:2092 arbitrary units). 
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3.1.2 Overlap between gene detection on both platforms 
 
Overlap between the two microarray platforms was defined to be the proportion of calls that were 
concordantly called “present” or “absent” in genes represented by both platforms. From the 20 40
known and putative genes represented by the clone-based array and the 8 602 known genes 
represented on the Affymetrix platform, probe matching via UniGene (Section 2.1.9) identified   
6 645 genes which were re
6 
     
presented on both systems. The 6 645 overlapping genes were 
lassified according to the present/absent calls assigned by combined detection p-values (Table 
ere 
Table 3.1  Distribution of UniGene cluster detection 
c
3.1A and Figure 2.1). Of the 6 645 overlapping genes on both arrays, 4 805 and 4 014 genes w
called “present” in the clone-based and Affymetrix platforms, respectively, from which 3 088 genes 
(46%) were called “present” in both platforms. Overall, 4 002 genes (60%) were in call agreement 
(overlap) between the two systems. In the remaining discordant fraction, almost twice as many 
present calls (1 717) were made by the clone-based system compared with the Affymetrix system 
(926). 
 
  Frequency of Call in 
Affymetrix Array 
  
  
Present Absent Total
Overlap 
(calls in 
agreement) 
Spearman 
Rank Order 
Coefficient 
 A: Platform-overlapping, nonredundant 
Present 3 088 1 717 4 802 60% 0.151* Frequency of call in 
clone-based array 
 
 Total 4014 2 631 6 645   
 B: Platform-overlapping, sequence-verified, nonredundant 
Present 384 114 498  Frequency of call in 
 Absent 144 73 217 64%‡ 0.131†
 
Absent 926 914 1 840   
 
clone-based array 
 
Total 528 187 715   
Assignm
e
ent of UniGene cluster is based on non-sequence-verified clone annotation. *Based on median 
xpression signal of 3 088 present calls in both platforms. †Based on median expression signal of 384 present 
calls in both platforms. ‡p < 10-14, assuming a binomial distribution of probability. 
 
Since discrepancies in the detection of the same genes between two different platforms could be 
caused by the 20– 30% error rate in cDNA clone annotation (Halgren et al., 2001; Taylor et al., 
2001), further analysis was completed using data from only sequence-verified clones. 
Approximately 2 000 cDNA clones were sequenced in-house. Sequences were matched to known 
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Genbank sequences using BLAST homology search. Subsequently, 715 cDNA probes were 
matched to the corres onding probes o throu h association to UniGene 
lusters (Table 3.1B and Figure 2.1). Using sequence-verified clon , the fractio ement 
sed slightly to 64% (457 genes). Additionally, the discordant e re of 
enes appeared to be 4 s in 
d  platform ctively) than previously observed with the non-
nce-verified ge
s verified sequence ordant calls 
yst role of probe sequenc  ove was investigated. Available fully 
nced cDNA clones (272) were matched to Affymetrix probe sets by BLAST searching. Over 
ne-third of the probe ) that were formerly mat d to e  clusters no nger matched 
.e., probe matches did not meet cutoff criteria because probe locations were not sufficiently 
-
NA 
re 
 by 
n 
p n the Affymetrix array g  
c es n of call agre
increa calls in th
4
maining 36% 
 present callg  more evenly split between the two platforms (114 and 1
the clone-based an
seque
Affymetrix s, respe
nes. 
 
A  identity only appeared to play a small role in overlap of conc
between the two s
eque
ems, the e in rlap 
s
o s (103 che UniG ne  lo
under stringent BLAST matching, due to the representation of completely different parts of the gene 
(i
overlapping). About one-half of the full-length cDNA sequences (142) matched the same probe, 
and 16% (27) of the fully sequenced clones matched to different probes, for a total of 169 BLAST
matched probes (Table 3.2A, Figure 2.1). Detailed analysis of the differences in detection of the 
same genes represented between platforms indicated that genes which were present in the cD
platform were represented by cDNA clones containing Alu repeats in 33 cases (24%) of clone 
present calls, whereas none of the absent clone calls contained Alu sequences. When Alu repeat-
containing clone sequences were excluded from the analysis, 67% of the calls for 137 genes we
in agreement (Table 3.2B). This would suggest that although overlap may be slightly improved
increased matching stringency, the same genes on the two systems are still not consistently 
detected in the remaining 33% of genes, even if the same region of the gene is represented o
both arrays. 
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Table 3.2  Distribution of BLAST-matched full-length clones with and without Alu repeats 
  Frequency of Call in 
Affymetrix Array 
  
    
  
Present Absent Total
Overlap 
(calls in 
agreement) 
Spearman 
Rank Order 
Coefficient 
 A:  BLAST-matched, full-length clones with Alu repeats 
Present 102 31 133   Frequency of call 
in clone-based 
array 
 
Absent 23 13 36 68%‡ 0.015* 
 Total 125 44 169   
 B:  BLAST-matched, full length clones without Alu repeats 
Present 79 22 101   Frequency of call 
in clone-based 
array 
 
Absent 23 13 36 67%** 0.289† 
 Total 102 35 137   
*
s
< bution of probability. 
 
T
v 37 probes, 
Table 3.2B). The distribution of the discordant calls shows that decreasing the combined p-value 
cutoff to more stringent values did not increase the level of agreement between the platforms 
(Figure 3.3). For example, increasing the log10 p-value cutoff to 2 increased the number of genes 
called absent in both platforms, but also increased the number of discordant calls. At this cutoff, the 
net effect was an overlap of 65%. In the MAS 5.0 analysis of Affymetrix data, it was possible to 
influence the stringency of the calls by changing the Tau parameter. Lowering the Tau value 
increases the number of present calls, at the risk of creating false positives, whereas raising the 
Tau value decreases the number of present calls, at the risk of calling more false negatives. 
Decreasing the Tau value to 0.0 did increase the overlap to 72%, but increasing Tau to 0.06 
decreased the overlap to 58%. These results were primarily achieved by shifting the Affymetrix p-
v
the data point scordant calls were not borderline present/ absent 
c
n spectrum. 
Based on median expression signal of 102 present calls in both platforms. †Based on median expression 
ignal of 79 present calls in both platforms. ‡p < 1.6 X 10-6, assuming a binomial distribution of probability. **p 
 3.7 X 10-5, assuming a binomial distri
o further investigate the discordant calls from both platforms, the role of combined detection p-
alue cutoffs was examined in the subset of probes matched by BLAST searching (1
alues to values above or below the cutoff (Figure 3.4 and Figure 3.5). Looking at the distribution of 
s, it was clear that most of the di
alls, but rather, genes whose p-values from either platform were at the opposite ends of the 
detectio
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Figure 3.3  One-hundred thirty-seven BLAST-matched genes, without Alu repeats, analyzed 
in MAS5.0 with Tau=0.015. 
Data were generated using combined detection p-value cutoff of 0.05 for clone-based system and
p-value cutoff of 0.06 and Tau = 0.015 for the Affymetrix system. Genes present on both platforms 
(blue diamonds), absent in both platforms (pink triangles), absent in clone-based but present in 
Affymetrix platform (yellow squares), and present in clone-based but absen
 
t in Affymetrix platform 
(cyan crosses) were plotted according to log10 of the combined detection p-values. 
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Figure 3.4  One-hundred thirty-seven BLAST-matched clones without Alu repeats, analyzed 
in MAS5.0 with Tau=0.0. 
Data point colors represent calls based on default cutoffs and parameters (clone-based: p<0.05;
Affymetrix: Tau=0.015, p<0.06). Decreasing the Tau parameter to 0.0 in MAS5.0 analysis results 
in less stringent calls by decreasing the combined detection p-values of the genes. 
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Figure 3.5  One-hundred thirty-seven BLAST-matched clones without Alu repeats, analyz
Data point colors represent calls based on default cutoffs and parameters (clone-based: p
Affymetrix: Tau=0.015, p<0.06). Increa
in more stringent calls by increasing
Affymetrix
ed 
in MAS5.0 with Tau=0.060. 
<0.05; 
sing the Tau parameter to 0.060 in MAS5.0 analysis results 
 the combined p-values of the genes. 
Closer inspection of the probe sequences used to detect the discord
of these probes showed some characteristics that could have cause
least one-fourth of discordant calls, the probes from either array wer often 
represented exons not found on the alternative array. In the case of
based but not Affymetrix platform, the cDNA probe sequences were
Cross-hybridization was also a potential problem for two genes that 
belonged to a family of highly similar genes. However, in the remain
irregularities in probe representati re observed. 
3.1.3 Comparison of expression levels between plat
 
Spearman rank order correlation coefficients were used to determin ene 
expression levels in the two platforms. Probes matched by UniGene
to their median expression values in the sequence-verified subsets o
first instance, the calculation was restricted to sequence-verified, Un
were called “present” in both systems. The Spearman rank order coefficient (rs) was 0.131, based 
 
ant genes showed that some 
d the discordant calls. In at 
e overlapping, but 
 two genes expressed in clone-
 chimeric with 28S rRNA. 
were highly polymorphic or 
ing discordant cases, no 
forms 
e the relation between g
 cluster were ranked according 
f probes (Figure 2.1). In the 
iGene-matched probes that 
on we
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on 384 genes matched by UniGene cluster (Figure 3.6, Table 3.1B). The correlation did no
improve in the BLAST-matched subset (r
t 
at 
s-
 3.2B). 
gative 
s = -0.015), when it was further limited to 102 genes th
were called present in both systems (Table 3.2A). In the last subset, rank order coefficients were 
calculated for BLAST-matched probes without Alu repeat sequences and called present in both 
platforms (79 genes, Table 3.2B). Despite elimination of cDNA probes with potential for Alu cros
hybridization and limitation to concordantly called present genes, the rank orders of the mean 
expression values obtained in both platforms displayed weak positive correlation (rs = 0.289). As a 
final test, rank order coefficients were calculated based on the rank order of individual patient 
expression levels within each platform for 79 genes called present in both platforms (Table
In both platforms, patients were ranked by expression level for each gene, such that each of the 79 
genes had its own rank order correlation. The rank order correlations ranged from strongly ne
(rs = -1.00) to strongly positive (rs = 0.80), with a median and semi-quartile range of rs = -0.10 ± 
0.45. These results imply that the expression values from the two technologies did not correlate 
with regard to median expression values or with respect to rank order of individual patient 
expression values within a platform. 
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Figure 3.6  Spearman rank 
order based on mean 
expression signals for 715 
sequence-verified, UniGene-
matched genes. 
from both array platforms is 
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Plot of Spearman rank orders 
shown for concordant present 
concordant absent calls (pink 
 
[absent in Affymetrix but 
present in clone-based 
platform (cyan crosses); 
present in clone-based but 
absent in Affymetrix (yellow 
triangles)]. Rank order 
correlation coefficients display 
only weak to moderate positive 
correlation between the two 
platforms: for the 384 
concordant present calls, rs = 
0.131; for all 715 genes, rs = 
0.191; for the 457 concordant 
present and absent calls, rs = 
0.465. Genes selected for 
independent real-time PCR 
quantitation are marked in red. 
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Independent verification of transcript levels in the five patient samples was carried out by 
quantitative real-time PCR on 13 selected genes with varying calls between the two platforms 
(Figure 3.7). Results indicate that for this small subset of genes, the rank order correlation of the 
median expression values amongst patient samples was strongly positive between the Affymetrix 
and real-time PCR methods (rs = 0.884) and only moderately to weakly positive between clone-
based array and real-time PCR (rs = 0.593) or clone-based and Affymetrix array (rs = 0.384). When 
the rank order correlation was calculated only for genes called present in either Affymetrix or clone-
based arrays, the correlation improved between the clone-based and Affymetrix platforms (rs = 
0.900) and between the clone-based and real-time PCR platforms (rs = 0.733) but slightly 
decreased between the real-time PCR and Affymetrix platforms (rs = 0.857). Expression levels from 
real-time PCR and overall detection within the array platforms were somewhat consistent. In 
general, highly expressed genes tended to be present on both array platforms, and low expressed 
genes were absent in both platforms. However, in two cases, an elevated expression signal from 
the clone-based platform could have been caused by a cDNA chimeric with 28S rRNA (MPG) or a 
spliced-in Alu repeat (PRKCBP1). A diminished expression signal from the Affymetrix platform 
could have been caused by a probe set which, unlike all the other 12 probe sets, was located in the 
middle of the gene (PRKCBP1), rather than in the last 3' exon, which incurs a slight labeling bia
over the 5' end of the gene. Comparison of the gene sequences detected by each system showed 
that for each of the 13 genes, all three methods were capable of detecting the same splice variant. 
F
c
p
o
 
s 
or the most part, the sequences used for clone-based array probes and real-time PCR probes or 
lone-based probes and Affymetrix probes were overlapping, but Affymetrix and real-time PCR 
robes were not necessarily overlapping, although they often detected parts of the same exon in 
ver half of the genes tested. 
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Figure 3.7  Ranking of the 13 genes quantified by real-time PCR, clone-based array, and 
Genes were ranked according to the median expression signals obtained from quantitative 
time PCR (blue diamonds), the clone-based array (pink squares), and the Affymetrix array (cyan 
triangles). The table under the graph indicates the clone-based and Affymetrix platform calls and 
the extent of probe sequence overlap between all three detection methods. For two of the clone-
based probes, cross-hybridization likely influenced the rank due to chimerism with 28S rRNA 
(MPG) or Alu repeats (PRKCBP1). In over half of the genes tested, all methods detected parts o
the same exon. When considering the all 13 genes, regardless of present or absent calls, the ra
order correlations were weak between clone-based and Affymetrix arrays (rs = 0.385) and 
moderate between clone-based arrays and real-time PCR (rs = 0.593), but correlation was high
between Affymetrix platform and real-time PCR (rs = 0.884). In contrast, Spearman rank order 
coefficients showed high correlation when only present genes were considered between clone-
based and Affymetrix platforms (rs = 0.900, 5 genes), clone-based array and real-time PCR (rs = 
0.733, 9 genes), and Affymetrix array and real-time PCR (rs = 0.857, 7 genes). 
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3.2 Molecular profiling of IBD using cDNA microarrays 
3.2.1 Expression profiles of the IBD colonic mucosa 
 
Differences between gene expression in sigmoid biopsies taken from normal controls (n=11) and 
inflamed IBD patients (n=10 for each of CD and UC) were determined by hybridizing the samples to 
the Human Unigene Set RZPD1 cDNA arrays. Statistically significant differential gene expression 
was calculated by applying a pairwise statistical test (Mann Whitney U test). Genes which had a p-
value ≤ 0.0015 and a fold change ≤ 1.2 were considered to be differentially regulated. Based on 
these cutoff criteria, 650 genes were identified to be differentially regulated between normal 
controls and at least one of the IBD subtypes. Of these genes, 122 were differentially regulated in 
both subtypes compared to normal controls. Interestingly, none of the 122 genes were regulated in 
opposite directions within the two IBD subtypes. Comparing CD to normal controls yielded 500 
differentially regulated genes (81 up-regulated), whereas comparing UC to normal controls yielded 
270 differentially regulated genes (155 up-regulated). Unknown genes represented 43% (277) of all 
differentially regulated genes. Overviews of the top 40 up-/down-regulated genes in CD and UC 
compared to normal controls are shown in Figure 3.8 and Figure 3.9 , respectively. 
 
To identify broad functional processes represented by the differentially regulated genes in each IBD 
subtype, the genes were assigned to functional groups using Gene Ontology classifications 
obtained through NCBI Gene database. To complement the database information, genes were also 
manually assigned to groups based on references in the literature (Table 3.3). Using methods 
described in Section 2.2.2, the significance of differentially regulated genes representing certain 
functional groups was tested. The functional group "immune and inflammatory responses" was 
found to be enriched by mostly up-regulated genes in both CD and UC (p=0.0006). In the group 
"cell proliferation and growth" (p=0.0404), enrichment was driven by genes up-regulated in UC. 
Finally, structure and permeability (p=0.0309) was largely represented by genes up-regulated in 
CD. 
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Symbol NameNormal CD p-
Value
Fold-
change
low high expression value
BASP1
B2M
CLDN3
TAF4
SAT2
FRZB
ALG6
ASS
FOXF2
ENO1
CLDN4
SPARC
ZNF198
INSIG2
HLA-DRB3
RCOR3
DHRS9
ITGB2
RRM2
LOC146174
COL6A2
DAF
ANXA4
TIMP1
PFKP
ZYX
DCN
COL6A1
TNFRSF6B
Prkcz
MMP2
SLC39A9
MUC1
PPP2R1B
JUNB
IER3
ZFP36
IGHG1
PLA2G2A
DNAJB5
HLA-A
HLA-B
IGH@
ITM2C
CSNK1D
ZNF24
HNMT
TNFRSF10B
CLMN
WDR10
FLJ21919
SLC6A2
CPD
SLC9A6
POGZ
VPS13D
COL8A2
PKD1
CHST1
FLJ11000
KIF5C
NEDD9
RQCD1
LOC285540
ALOX5
TAC3
DKFZp547A023
ALB
DKFZp762E1312
APRG1
FLJ32440
PVRL3
AIM1L
TLE4
LTB4R2
PRLR
Brain abundant, membrane attached signal protein 1
Beta-2-microglobulin
Claudin 3
TAF4 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 135kDa
Spermidine/spermine N1-acetyltransferase 2
Frizzled-related protein
Asparagine-linked glycosylation 6 homolog (yeast, alpha-1,3-glucosyltransferase)
Argininosuccinate synthetase
CDNA clone IMAGE:4807381, partial cds; Acc: BM972881
Transc. seq.; Acc: BX115981
Forkhead box F2
Enolase 1, (alpha)
Claudin 4
Secreted protein, acidic, cysteine-rich (osteonectin)
Zinc finger protein 198
Insulin induced gene 2
Major histocompatibility complex, class II, DR beta 3
Transc. seq. with strong similarity to prot. pir:I38067; nitric-oxide synthase; Acc: AA393074
REST corepressor 3
Dehydrogenase/reductase (SDR family) member 9
Integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1 (...)
Ribonucleotide reductase M2 polypeptide
Hypothetical protein LOC146174
CDNA clone IMAGE:5092935, partial cds; Acc: W45240
Collagen, type VI, alpha 2
Decay accelerating factor for complement (CD55, Cromer blood group system)
Annexin A4
Tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor)
Phosphofructokinase, platelet
Zyxin
Decorin
Collagen, type VI, alpha 1
Tumor necrosis factor receptor superfamily, member 6b, decoy
Protein kinase C, zeta
Matrix metalloproteinase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase)
Solute carrier family 39 (zinc transporter), member 9
Mucin 1, transmembrane
Protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), beta isoform
Jun B proto-oncogene
Immediate early response 3
Zinc finger protein 36, C3H type, homolog (mouse)
Immunoglobulin heavy constant gamma 1 (G1m marker)
Phospholipase A2, group IIA (platelets, synovial fluid)
DnaJ (Hsp40) homolog, subfamily B, member 5
Major histocompatibility complex, class I, A
Major histocompatibility complex, class I, B
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Figure 3.8  Heatmap of differentially regulated genes between normal controls and C
disease. 
rohn's 
The expression values of the top 40 up-/down-regulated genes are graphically depicted for each of 
11 normal controls and 10 inflamed CD samples. Low to high expression values are colored from 
green to red, respectively. 
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 TSSC1 Tumor suppressing subtransferable candidate 1 -1.51 0.000068   
 
 Rock1 Rho-associated, coiled-coil containing protein kinase -1.48 0.00017   
 
protein 
 
 
 FLJ13352 Hypothetical protein FLJ13352 -1.4 0.00038   
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(avian)-like 2 
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TIMP1 Tissue inhibitor of metalloproteinase 1  2.35 0.000068 4.
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74 0.000011 
0.000023 
 type 2, OB-cadherin (osteoblast) 1.59 0.00004 1.48 0.00017 
 DKFZp547A0
23 
Hypothetical protein dkfzp547a023 -1.65 0.000011 -1.47 0.00055 
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 FLJ25778 Hypothetical protein FLJ25778 -1.33 0.0011   
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0.000788 
 
 CLDN4 Claudin 4 1.70
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 COL8A2 Collagen, type VIII, alpha 2 -1.62 0.00038 
 COL15A1 Collagen, type XV, alpha 1 -1.55 0.00055 
 PRKCB1* Protein kinase C, beta 1 -1.5 0.000788  
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 RDX Radixin -1.42 0.00055  
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Minus sign in the fold-change column indicates down-regulation between normal controls (NC) a
IBD individuals. Asterisk (*) indicates a gene previously reported to be differentially expressed in
IBD (Dieckgraefe et al., 2000; Dooley et al., 2004; Lawrance et al., 2001). All data based on 
microarray results. 
nd 
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3.2.2 Functional prediction of unknown genes 
 
In order to decipher potential roles for unknown genes, some of the top differentially expressed 
unknown genes between normal controls and IBD were further analysed as described in Section 
2.2.3 (Table 3.4). All but one of the unknown genes in Table 3.4 yielded protein domains or were 
homologous to known proteins. The genes represented by N48794 and AF087994 contained 
protein domains (cadherin and leucine-rich repeats, respectively) commonly involved in protein-
protein interactions and may be involved in cell adhesion. Two genes represented by N39296 and 
AW953679 contain zinc fingers motifs and are therefore predicted to be transcription factors. 
Another two genes represented by AK056932 and AB067499 are predicted to be involved in 
enzymatic function (acyltransferase or hydrolase). BC008744 may represent a gene involved in 
intracellular signaling, as many proteins with pleckstrin homology domains are involved in 
intracellular signaling. AK022544 and AL117511 share protein homology with other known proteins 
and may be involved in structure and protein sorting, respectively. BC006384 was the only 
transcript without protein domains or homology to other proteins. This transcript was located in an 
intron of a heparin sulfate sulfotransferase, and it may represent an poorly characterized splice 
variant of this gene. All other genes have homologues in other species, which lends credibility to 
the hypothesis that these uncharacterized genes must have important functions, since they are 
conserved in the evolutionary process. 
 
3.2.3 Independent quantitation by fluorescent real-time PCR 
 
Microarray results were independently verified in a larger patient cohort by a more sensitive 
technique, real-time PCR. The initial cohort of 31 patients (Group 1) used in the cDNA microarray 
studies was extended to 100 patients (Group 2) for the real-time PCR experiments. No significant 
differences between the initial and verification cohort were found. As an additional control for the 
suitability of the samples and the stability of the overall approach, two hallmark genes of IBD 
pathophysiology (IL8 and TNF) were quantitated by real-time PCR. As expected, IL8 was 
overexpressed in CD and UC samples, and TNF was only overexpressed in CD samples. Next, 15 
additional genes were selected for real-time PCR verification in the extended cohort (Group 2), 
based on their differential regulation in IBD from the microarrays and their representation in the 
 
  
57
three main al groups described in Section 3.2.1. Uncharacterized genes we l cluded 
in the analysi . The real-time PCR exp riments are s m zed i igure 3.10 and Table 3.
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Fold changes are derived from microarray analysis. All reported fold changes are significant unless otherwise indicated. A minus sign in the fold-change columns indicates dow
regulation between normal controls (NC) and disease. Single dagger (†) indicates direction of fold change verified by quantitative real-time PCR in Group 2 samples. The fold 
changes as reported by quantitative PCR for AK022544 (DKFZp547A023) were -1.96 for CD and -1.80 for UC, for BC008744 (PLEKHQ1) were 1.37 for CD and 1.60 for UC and 
for N39296 (ZCCHC4) were -1.61 and -1.46, respectively. Th
n-
e prediction of the function was based on two criteria: sequence homologies and expression pattern similarities. 
o a p ≤ 0.05. 
elanogaster; Ce: Caenorhabditis elegans; ORF: Open 
Expression pattern similarities were calculated based on cosine correlation, accepted similarity had to be > 97% and enrichment significance for the putative function based on 
Gene Ontology was set t
Abbreviations used:  Hs: Homo sapiens; Pt: Pan troglodytes; Mm: Mus musculus; Rn: Rattus norvegicus; Dm: Drosophila m
reading frame; NC = normal control; CD = Crohn’s disease; UC = ulcerative colitis; n.s. = non-significant. 
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Figure 3.10  Microarray results and corresponding quantitative real-time PCR for 
differentially regulated genes in CD or UC compared to normal controls. 
s from 
es that real-time PCR result was not significant (P-value > 
 
oth 
 
subtypes and in both microarray and real-time experiments was the 
ncharacterized gene DKFZp547A023 (Genbank accession number AK022544, Table 3.4). The 
remaining genes showed contrasting results between the microarray and real-time PCR 
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Genes were chosen based upon their dysregulation in IBD and represent both known gene
the functional groups discussed and genes of unknown function. Quantitative real-time PCR was 
carried out on individual samples from Group 2 patients (14-18 normal controls, 19-33 UC and 17-
22 CD samples, depending on the availability of the patient samples at the time the plates were 
produced), except for IL8 and TNF (not on array), which were tested in Group 1 patients (11 
normal controls, 10 UC and 10 CD patient samples) as a proof-of-principle measure. The 
extended cohort of Group 2 patients includes those with active disease and using anti-
inflammatory drugs (but not immunosuppressants or biologicals), whereas Group 1 patients had 
active disease and were medication-free for 6 weeks. Results are summarized by a ratio of 
medians (CD:normal or UC:normal). All results were significantly differentially regulated except for 
marked results; single dagger (†) indicates that array result was not significant (P-value > 0.0015 
or fold change < 1.2); asterisk (*) indicat
0.05). A dashed line represents the fold change level of 1.2. 
Genes that were significantly up-regulated in both microarray and real-time PCR methods in b
IBD subtypes compared to normal controls include cadherin-11 (CDH11), decay accelerating factor
for complement (DAF), immunoglobulin heavy constant gamma 1 (IGHG1), mucin 1 (MUC1), 
phospholipase A2, group IIA (PLA2G2A), and tissue inhibitor of metalloproteinase 1 (TIMP1). 
Trefoil factor 1 (TFF1), was found to be significantly up-regulated in UC on the microarray but not in 
CD, a result that was confirmed by real-time PCR in the extended group 2 samples. The only 
down-regulated gene in both 
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experiments. In the case of cylindromatosis (CYLD calcitonin gene-related peptide receptor 
component protein (RCP9), PDZ and LIM domain 5 (PDLIM5), occludin (OCLN), Rho-associated, 
coiled-coil containing protein kinase 1 (ROCK1), and zinc finger, CCHC domain containing 4 
(ZCCHC4), the microarray results indicated that these genes were significantly down-regulated in 
CD, but did not reach significance in the UC cohort. However, results from the real-time analysis in 
the extended cohort showed that these six genes were significantly down-regulated in both IBD 
subtypes. Pleckstrin homology domain containing, family Q member 1 (PLEKHQ1, BC008744; see 
Table 3.4) was up-regulated in both subtypes on the microarray, but the microarray cutoff criteria 
were not reached in the CD population. Real-time analysis on the extended IBD population 
demonstrated this gene was significantly up-regulated in both IBD subtypes. These results illustrate 
the importance of using an independent technique in larger patient numbers to confirm gene 
expression identified by microarray experiments.  
 
3
 
A
i
ntrols and IBD. Real-time PCR was carried out on patients that had colonic disease (so-called 
 Table 3.5). These DC samples were 
rther stratified into non-inflamed and inflamed samples. No significant difference was observed 
A, 
), 
.2.4 Expression profiles in non-IBD disease samples 
s inflammation may result from different initiating processes, the extent of disease-related 
nflammation is an important issue in the detection of differential gene expression between normal 
co
disease controls (DC), n = 17), but not IBD (Figure 3.11 and
fu
between the expression of any of the 15 genes tested between normal controls and non-inflamed 
disease specificity controls. Eight genes (CYLD, DAF, DKFZp547A023, MUC1, OCLN, PLA2G2
TIMP1, and ZCCHC4) were significantly differentially regulated between normal controls and 
inflamed DC, and the direction of change was the same as that observed in IBD. This observation 
suggests that these eight gene findings probably reflect general inflammation pathophysiology 
rather than events specific for IBD. In contrast, IBD-specific gene expression is presented in the 
expression of the remaining seven genes (CDH11, IGHG1, PLEKHQ1, TFF1, PDLIM5, ROCK, and 
RCP9). In these cases, gene transcripts were not significantly different between normal controls 
and the inflamed DC group. 
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Figure 3.11  Quantitative real-time PCR results between norm d both non-
inflamed and inflamed disease specificity controls. 
Quantitative real-time PCR was carried out on individual sam
seven or eight inflamed and seven to nine non-inflamed DCs
cDNA at the time the plates were produced). The DCs includ
gastrointestinal inflammation, or irritable bowel syndrome. P
immunosuppressants or biologicals, but the use of anti-inflam
are summarized by a ratio of medians (inflamed DC:normal s 
marked with an asterisk (*) indicate that the real-time PCR re
 
 
3.2.5 Localization by immunohistochemistry 
 
As expression analysis in complex tissues does not allow an le 
for the signal, immunohistochemistry was used to exemplify th
Paraffin-embedded sections of samples from the group 1 pati es, 
which were selected because they were not previously assoc
represented a gene from each of the functional groups presen  
increased transcript levels measured by microarrays, a marke AM1 protein 
was seen in IBD when compared to normal controls (Figure 3 n 
the apical epithelial lining in the normal mucosa, whereas it ex al cells 
of the crypts in the inflamed tissue of CD and UC patients. A s
mononuclear cells, most likely with a lymphocytic phenotype, was only detected in the lamina 
propria of inflamed biopsies. CSNK1D immunohistochemistry staining (Figure 3.12B) demonstrated 
al controls an
ples from group 2 patients (including 
, depending on the availability of 
e patients with infectious diarrhea, 
atients in this group were not on 
matory drugs was allowed. Results 
or non-inflamed DC:normal). Result
sult was significant (p < 0.05). 
identification of the cells responsib
e approach to genes of interest. 
ents were examined for three gen
iated with IBD etiopathogenesis and 
ted in Section 3.2.1. Consistent with
d up-regulation of CEAC
.12A). Immunoreactivity was found i
tended down into the epitheli
taining of vascular structures and 
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expression in the colon, but the modest up-regulation seen in CD in the microarray was not 
ex of the 
rypts could be observed. Immunoreactivity revealed a strong granular staining pattern of intestinal 
was located basolaterally. Staining of PRKCB1 
igure 3.12C), that appeared to be down-regulated in the microarray results showed only a weak 
rlying 
detected by immunohistochemistry. In the biopsies from CD patients, staining of the ap
c
epithelial cells in the normal and UC group, which 
(F
staining in the apical epithelial layer in the normal and CD mucosa, whereas a stronger staining 
was present in the UC group. Furthermore, scattered lamina propria mononuclear cells unde
the epithelial layer were also positive. Interestingly, in the CD group, immunoreactivity was found 
nearly exclusively in the marginal zone of small lymph follicles. 
 
 
Figure 3.12  Immunohistochemical 
CSNK1D, and PRKCB1 in colonic 
Staining of a representative mucosal 
tissue samples from five normal 
controls (N), five Crohn disease (CD), 
and six ulcerative co
using antibodies aga
localization of CEACAM1, 
mucosa 
litis (UC) patients 
inst (A) 
CEACAM1, (B) CSNK1D, and (C) 
PRKCB1. (A) CEACAM1 
immunoreactivity was found in the 
apical epithelial lining (1), crypts of 
inflamed tissue (2, 4). Additional 
staining was detected in immune 
cells (3) and blood vessels (5). (B) 
CSNK1D immunoreactivity showed a 
strong granular
normal (6) and 
which was loca
Weaker stainin
crypts could be
(C) For PRKCB
could be obser
epithelial layer 
CD (10) mucos
immunoreactivi
exclusively in th
small lymph fol
the lamina prop
immunonegativ
staining was de  the apical 
epithelial layer of UC mucosa (12). 
Furthermore, lamina propria 
mononuclear cells underlying the 
epithelial layer were also positive in 
the UC mucosa (13). 
 
 staining pattern in 
the UC group (8), 
ted basolaterally. 
g of the apex of the 
 detected in CD (7). 
1, weak staining 
ved in the apical 
in the normal (9) and 
a and, interestingly, 
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licles (11), whereas 
ria was 
e. In contrast, strong 
tected in
 
 
 64
3.3 Molecular profiling of IBD samples using Affymetrix 
microarrays 
 
3.3.1 Microarray data pre-processing 
 
Four normalization methods (MAS5.0, GC-RMA, vsn, and loess; Section 2.2.
use. Normalization was carried out separately for the UC and CD microarray 
performance was determined by the following criteria: 1) ability of the normali
reduce variance without increasing bias; 2) ability of the normalization proced
within a reasonable amount of computing time. To assess the variability of sig on of 
al intensity, the log-intensity ratio (M) and the log-intensity average (A) was computed for each 
 
 
2) were evaluated for 
datasets. The 
zation procedure to 
ure to be carried out 
nals as a functi
sign
probe set between a pair of arrays. The resulting MA plot showed how the log-intensity ratios were
distributed over signal intensity. In unnormalized data, the signals form a thick cloud centred along
the x-axis, which tended to have many outlying signals (Figure 3.13). A good normalization method 
reduces the cloud to a more uniform distribution over all intensities (Figure 3.14).  
 
 
Figure 3.13  MA
raw data from one pair of 
arrays in the UC data
is plotted against
(A) for the first two a
 plot of 
set. 
Raw log-intensity ratio (M) 
 raw log-
intensity average signal 
rrays 
(1N_U133A.CEL and 
2N_U133A.CEL) of the UC 
dataset. The median value 
of M and the interquartile 
range (IQR) of M are 
r left 
corner. 
 
 
displayed in the lowe
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Figure 3.14  MA plot of 
normalized data from 
one pair of arrays in the 
UC dataset. 
Normalized log-intensity 
st 
 
 UC 
t 
ather than plotting many MA plot pairwise comparisons (e.g. 30 x 30 arrays) and examining the 
rized by taking the 
edian and interquartile range of M for each pairwise comparison. These values were then plotted 
 
n 
ere degraded compared to 
st of the arrays (not shown). No samples were removed from the CD dataset. 
ratio (M) is plotted again
normalized log-intensity
average signal (A) for the 
first two arrays 
(1N_U133A.CEL and 
2N_U133A.CEL) of the
dataset. The median value 
of M and the interquartile 
range (IQR) of M are 
displayed in the lower lef
corner. 
 
R
variability of each pairwise comparison individually, the MA plots were summa
m
for each normalization method (Figure 3.15). Ideally, the median and interquartile range of M 
should be as close to zero as possible, which would indicate the lowest possible overall variability 
between two arrays. Considering computing time, all procedures except loess could be performed 
on a desktop computer within one hour. The loess normalization required overnight calculation, but
was still feasible for the desktop computer. Of all normalization methods attempted (MAS5.0, GC-
RMA, vsn and loess), the loess normalization showed the most compact distribution of points 
around zero. Vsn and GC-RMA also performed satisfactorily. MAS5.0 yielded the greatest variatio
between arrays. The normalization procedures yielded similar results for both the UC and CD 
datasets (CD not shown), and as a result, the loess normalization method was chosen for further 
data analysis for both datasets. 
 
Density plots of the normalized data identified outlier arrays. In the UC dataset, two samples from 
one patient were removed from analysis because the overall signals w
re
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Figure 3.15  Median and 
interquartile ranges for 
all pairwise compariso
between arrays in the
dataset. 
Each point represents 
statistics (interquartile 
range and median of the
log intensity ratio) for on
pairwise compari
 
 
 
3.3.2 Expression profiling
 
ns 
 UC 
 
e 
son. 
Points are colored 
according to normalization 
method: vsn (black), loess 
(red), MAS 5.0 (green), 
and GC-RMA (blue).  
 of the non-/inflamed UC mucosa 
nd 18 UC samples (9 paired non-inflamed and inflamed samples from the same 
sons wer een three gr  controls (NC ed UC 
flamed UC epicted in Fi e normalize s further 
with 
 
besets 
as set to 
d for differential gene determination. At the 
nd of pre-processing, 5616 probesets remained for further analysis. 
 
After normalization and quality control, the UC dataset consisted of 28 arrays, including 10 healthy 
normal controls, a
patient). Compari e made betw oups: normal ), non-inflam
(UC_ NI) and in  (U  dC_I), as gure 3.16. Th d a dataset w
processed by defining which probesets were ‘present’ on the arrays and eliminating probesets 
low variability. A background cutoff was applied to eliminate signals that could not be distinguished
from noise. To calculate the background cutoff, a background subset of 27 Affymetrix pro
representing bacterial sequences was extracted from the dataset. The background cutoff w
the mean of the background subset plus two standard deviations. Next, all probesets were defined 
to be ‘present’ if signals were above the background cutoff in at least 70% of arrays in any one 
group (NC, UC_NI, UC_I). As a final step, only probesets which had an interquartile range in the 
top 25th percentile of interquartile ranges were selecte
e
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Normal 
Control 
(n=10) 
 
3.3.2.1 Differentially regulated genes in the UC dataset 
Table 3.6  Number of significantly differentially regulated probesets in the UC dataset, from
limma analysis* 
Down-regulated 2315 (172) 1435 (144) 2352 (220) 
 
The R package limma was used to apply a linear model to the UC dataset, using a three-factor, 
one level design. P-values were adjusted for multiple testing using the false discovery rate 
(Benjamini & Hochberg method). The frequencies of differentially regulated probesets from limma 
analysis are shown in Table 3.6. 
 
 
Regulation UC_NI-NC UC_I-UC_NI UC_I-NC 
Not regulated 2643 (202) 2205 (142) 1908 (105) 
4) 1976 (132) 1356 (93) Up-regulated 658 (4
* padj <0.05, false discovery rate adjustment applied; unknown gene probesets in parentheses 
The paired inflamed/non-inflamed samples (from the same patient, but different regions) provided 
the opportunity to identify differentially regulated genes due to inflammation without the 
confounding effects of inter-individual differences due to factors such as genotype or local 
environment. Paired sample significance testing, in the form of t-test and Wilcoxon test, were used 
to identify differentially expressed genes between pairs of samples (Table 3.7). Paired significance 
testing yielded approximately 4-7% more differentially regulated probesets than the linear modeling 
method for UC_I-UC-NI comparison (Figure 3.17). 
 
 3.16  Comparisons made 
between the three groups in the 
UC dataset. 
 
Comparisons between the three 
groups (normal controls, non-
ed UC) 
reveal UC effects, inflammation 
 
inflammation effects. All 18 UC 
mples 
from the same patient. 
effect 
Figure
 
inflamed UC and inflam
effects, and cumulative UC +
samples were matched saUC Inflamed 
(n=9) 
UC Non-
inflamed Inflammation 
effect 
UC effect 
UC + 
inflammation 
(n=9) 
 
 
 68
Table 3.7  Number of significantly differentially regulated genes* in paired inflamed/non-
inflamed UC samples 
 UC_I-UC_NI 
Regulation Paired t-test Paired Wilcoxon test 
Down-regulated 1503 1465 
Not regulated 1953 
Up-regulated 2160 
2064 
2087 
* padj <0.05, false discovery rate adjustment applied
 
The top 50 up and down-regulated genes (p adj <0.0
comparison are listed in Table 3.8 (UC_NI-NC), Tab
and Table 3.11 (matched pairs of UC_I-UC_NI). Ov
known genes associated with intestinal mucosa bar enes 
representing adaptive or innate immune response, such as immunoglobulins (IGH@, IGHm, 
LC1, IGLC2, IGLJ), MHC genes (HLA-DRB4, HLA-DRA, HLA-DQA1), pro-inflammatory markers 
, S100A8) or anti-microbial peptides (ADM, CXCL9, CCL20, DEFA5, DEFA6), were up-
ssue compared to non-inflamed samples (UC or healthy). Additionally, 
 
pare -in ated in UC compared to 
fatty acid transport ( A1, S UC compared to 
and no s) an oxificat
d UC com d to no r non- served in the top 50 differentially 
 gene lists. The diff expre -related genes 
 the fact the mic s are etween 
 and healthy colon. 
 
5 and fold change>1.2) for each factor 
le 3.9 (UC_I-UC_NI), Table 3.10 (UC_I-NC), 
erall, mRNA expression was observed for 
rier and immune function. Many g
IG
(IL8
regulated in inflamed ti
genes involved in colonic mucosal functions such as epithelial repair (REG1A; up-regulated in
inflamed com d to non flamed), pH balance (CA1; down-regul
normal), SLC16 LC27A2; up-regulated in non-inflamed 
inflamed UC rmal d det ion (ABCB1, CES2, CYP2B6; all down-regulated in 
inflame pare rmal o inflamed UC) were ob
regulated erential ssion of these intestinal or immunity
validates  that roarray  detecting expected gene expression differences b
inflamed
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Table 3.8  Non-i ed UC ealthy tially regulated genes 
ma anal
gulated p sets fr paris normal controls 
nflam  vs. h  normal controls: top 50 differen
from lim ysis 
A. Up-re robe om com on of non-inflamed UC and healthy 
Probe id Log2Ratio 
l 
Gene 
symbo
Gene name 
209600_s_at 0.837 ACOX1 acyl-Coenzyme A oxidase 1, palmitoyl 
209869_at 
206561_s_a
1.34 ADRA2A 
0  member B10 (aldose reductase) 
 -bisphosphate 
, aminopeptidase M, microsomal 
 
t ll adhesion molecule 7 
t 
 
t 
t 
t sterase domain containing 3 
4875_s_at 0.838 GMDS GDP-mannose 4,6-dehydratase 
4607_at 1.601 HMGCS2 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (mitochondrial) 
5366_s_at 0.924 HOXB6 homeo box B6 
6294_at 1.659 HSD3B2 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 
214022_s_at 0.996 IFITM1 interferon induced transmembrane protein 1 (9-27) 
201601_x_at 0.95 IFITM1 interferon induced transmembrane protein 1 (9-27) 
202718_at 1.82 IGFBP2 insulin-like growth factor binding protein 2, 36kDa 
209374_s_at 1.21 IGHM immunoglobulin heavy constant mu 
219543_at 0.83 MAWBP MAWD binding protein 
207251_at 1.014 MEP1B meprin A, beta 
200632_s_at 0.902 NDRG1 N-myc downstream regulated gene 1 
218888_s_at 0.975 NETO2 neuropilin (NRP) and tolloid (TLL)-like 2 
210519_s_at 1.029 NQO1 NAD(P)H dehydrogenase, quinone 1 
201468_s_at 1.107 NQO1 NAD(P)H dehydrogenase, quinone 1 
206340_at 0.942 NR1H4 nuclear receptor subfamily 1, group H, member 4 
205552_s_at 0.89 OAS1 2',5'-oligoadenylate synthetase 1, 40/46kDa 
205660_at 0.971 OASL 2'-5'-oligoadenylate synthetase-like 
212768_s_at 2.662 OLFM4 olfactomedin 4 
207558_s_at 1.839 PITX2 paired-like homeodomain transcription factor 2 
204304_s_at 1.472 PROM1 prominin 1 
209752_at 3.628 REG1A regenerating islet-derived 1 alpha (pancreatic stone protein, pancreatic thread protein) 
205815_at 1.705 REG3A regenerating islet-derived 3 alpha 
203225_s_at 0.995 RFK riboflavin kinase 
203224_at 0.891 RFK riboflavin kinase 
217085_at 1.694 SLC14A2 Solute carrier family 14 (urea transporter), member 2 
209900_s_at 1.097 SLC16A1 solute carrier family 16 (monocarboxylic acid transporters), member 1 
202236_s_at 1.369 SLC16A1 solute carrier family 16 (monocarboxylic acid transporters), member 1 
202234_s_at 0.981 SLC16A1 solute carrier family 16 (monocarboxylic acid transporters), member 1 
adrenergic, alpha-2A-, receptor 
t 
211357_s_at 
1.113 AKR1B1 aldo-keto reductase family 1,
0.952 ALDOB aldolase B, fructose
204705_x_at 
202888_s_at 
0.852 ALDOB 
ANPEP 
aldolase B, fructose-bisphosphate 
alanyl (membrane) aminopeptidase (aminopeptidase N2.337 
aminopeptidase, CD13, p150) 
206784_at 1.164 AQP8 aquaporin 8 
215100_at 0.894 C6orf105 
CCL11 
chromosome 6 open reading frame 105 
chemokine (C-C motif) ligand 11 210133_at 1.158 
214038_at 0.862 CCL8 chemokine (C-C motif) ligand 8 
211848_s_a 0.957 CEACAM7 
CEACAM7 
carcinoembryonic antigen-related ce
carcinoembryonic antigen-related cel206198_s_a 0.96 l adhesion molecule 7 
Charcot-Leyden crystal protein 206207_at 1.006 CLC 
206755_at 0.97 CYP2B6 cytochrome P450, family 2, subfamily B, polypeptide 6 
cytochrome P450, family 2, subfamily B, polypeptide 7 pseudogene 1 206754_s_at 1.425 CYP2B7P1
207529_at 1.912 DEFA5 defensin, alpha 5, Paneth cell-specific 
207814_at 1.63 DEFA6 defensin, alpha 6, Paneth cell-specific 
208250_s_at 
219955_at 
1.687 DMBT1 deleted in malignant brain tumors 1 
1.054 ECAT11 hypothetical protein FLJ10884 
ethanolamine kinase 1 222262_s_at 
219017_at 
2.244 ETNK1 
2.734 ETNK1 ethanolamine kinase 1 
fibroblast growth factor receptor 2 208228_s_at 0.847 FGFR2 
203638_s_a 1.017 FGFR2 fibroblast growth factor receptor 2 
219954_s_a 0.864 GBA3 glucosidase, beta, acid 3 (cytosolic) 
219722_s_a 0.919 GDPD3 glycerophosphodiester phosphodie
Figure 3.17  Venn diagram showing differentially 
 the non-/inflamed UC 
Differentially regulated probesets between inflamed 
ed UC samples were found using 
ods. The limma analysis is 
nly, while the paired tests 
n test) consider 
mples are 
ired statistical tests 
tected 293 probesets that were not 
ethod. 
regulated probesets in
datasets from three analysis methods. 
and non-inflam
different statistical meth
d on inflammation obase
(paired t-test and paired Wilcoxo
that the inflamed/non-inflamed sa
matched pairs. The two pa
together de
found using the limma m
20
20
20
20
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20
20
1920_at 1.086 SLC20A1 solute carrier family 20 (phosphate transporter), member 1 
5769_at 1.007 SLC27A2 solute carrier family 27 (fatty acid transporter), member 2 
e, dibasic 
1.019 SLC9A3 solute carrier family 9 (sodium/hydrogen exchanger), isoform 3 
215125_s_at 0.963 UGT1A10 UDP glucuronosyltransferase 1 family, polypeptide A10  
U sferase 1 family, polypeptide A10  
U sferase 1 family, polypeptide A6 
   
205768_s_at 0.831 SLC27A2 solute carrier family 27 (fatty acid transporter), member 2 
205799_s_at 0.893 SLC3A1 solute carrier family 3 (cystine, dibasic and neutral amino acid transporters, activator of cystin
and neutral amino acid transport), member 1 
207212_at 
208596_s_at 0.993 UGT1A10 UDP glucuronosyltransferase 1 family, polypeptide A10  
207126_x_at 0.939 UGT1A10 UDP glucuronosyltransferase 1 family, polypeptide A10  
204532_x_at 
206094_x_at 
0.845 
0.911 
UGT1A10 
UGT1A6 
 
DP glucuronosyltran
DP glucuronosyltran
B. Down-regulated probesets from comparison of non and healthy normal controls  
 
-inflamed UC 
   
213921_at -2.544 --- 
G
r
2 a
A
t  b ning, class B, 3 
B
c
c activation-regulated) 
c  (pulmonary and activation-regulated) 
c ne 6-O) sulfotransferase 5 
cr
cl
c
E tracellular matrix protein 1 
f
 f
f
f
 f
f
g
g
 g nnexin 31) 
g ase/N-acetylmannosamine kinase 
h
 i
i
i
i
p ntaining 12 
2 p n containing 12 
 30 K
l
l percholesterolemia) 
1 l
l e, 2 (galectin 2) 
v molog F (avian) 
m
t N
 N
t p mber 2 
t O p
p
p
2 r
r
S
s
s
s
t s nucleoside transporter), member 2 
s
t s
 s
 tr
tr ancer, estrogen-inducible sequence expressed in) 
1110_s_at .912 HBS1 t mbospondin 1 
W
epresented by NM_001048 
e, enteric 202274_at -0.986 ACT ctin, gamma 2, smooth muscl
220468_at -1.182 ARF7 DP-ribosylation factor 7 
221530_s_a -1.012 BHLHB3 asic helix-loop-helix domain contai
213134_x_at 
t 
-0.952 BTG3 TG family, member 3 
205950_s_a -1.046 CA1 arbonic anhydrase I 
 (pulmonary and 32128_at -1.19 CCL18 hemokine (C-C motif) ligand 18
209924_at -1.045 CCL18 hemokine (C-C motif) ligand 18
221164_x_at -1.295 CHST5 arbohydrate (N-acetylglucosami
200884_at -0.928 CKB eatine kinase, brain 
214598_at -2.559 CLDN8 audin 8 
inal) 205081_at -1.759 CRIP1 ysteine-rich protein 1 (intest
 fibulin-like ex201842_s_at -1.015 EFEMP1 GF-containing
201889_at -1.007 FAM3C amily with sequence similarity 3, member C 
216442_x_at -2.274 FN1 ibronectin 1 
212464_s_at 
 
-2.18 FN1 ibronectin 1 
211719_x_at -2.255 FN1 ibronectin 1 
210495_x_at -2.176 FN1 
 
ibronectin 1 
203697_at -0.899 FRZB rizzled-related protein 
206422_at -2.604 GCG lucagon 
mone receptor 205498_at -0.958 GHR rowth hor
205490_x_at -0.904 GJB3 ap junction protein, beta 3, 31kDa (co
-N-acetyl)-2-epimer205042_at -1.057 GNE lucosamine (UDP
209844_at -2.044 HOXB13 omeo box B13 
210095_s_at -1.059 IGFBP3 nsulin-like growth factor binding protein 3 
211372_s_at -0.853 IL1R2 nterleukin 1 receptor, type II 
205403_at -0.938 IL1R2 nterleukin 1 receptor, type II 
221091_at -2.636 INSL5 
 
nsulin-like 5 
ion domain co212192_at -1.126 KCTD12 otassium channel tetramerisat
212188_at -0.914 KCTD1 otassium channel tetramerisation domai
212573_at 
t 
-0.844 KIAA08 IAA0830 protein 
203726_s_a -0.935 LAMA3 aminin, alpha 3 
ilial hy202068_s_at -1.239 LDLR 
Y
ow density lipoprotein receptor (fam
nation factor 1 206268_at -1.188 LEFT eft-right determi
208450_at -1.508 LGALS2 ectin, galactoside-binding, solubl
36711_at -0.847 MAFF -maf musculoaponeurotic fibrosarcoma oncogene ho
204673_at -1.13 MUC2 ucin 2, intestinal/tracheal 
207217_s_a -0.865 NOX1 ADPH oxidase 1 
206418_at 
a
-0.881 NOX1 
A2 
ADPH oxidase 1 
209803_s_ -0.947 PHLD leckstrin homology-like domain, family A, me
208121_s_a -0.869 PTPR rotein tyrosine phosphatase, receptor type, O 
211253_x_at 
t 
-1.287 PYY eptide YY 
207080_s_a -2.959 PYY eptide YY 
d) 2 209496_at -1.155 RARRES etinoic acid receptor responder (tazarotene induce
24kDa 202388_at -0.919 RGS2 egulator of G-protein signalling 2, 
204351_at -1.662 S100P 100 calcium binding protein P 
205979_at -0.852 SCGB2A1 ecretoglobin, family 2A, member 1 
drome) 205464_at -0.883 SCNN1B odium channel, nonvoltage-gated 1, beta (Liddle syn
206664_at -1.073 SI ucrase-isomaltase (alpha-glucosidase) 
207249_s_a -0.883 SLC28A2 
5 
olute carrier family 28 (sodium-coupled 
205185_at -1.338 SPINK erine protease inhibitor, Kazal type 5 
213994_s_a -1.086 SPON1 
1
pondin 1, extracellular matrix protein 
tracellular matrix protein 209436_at 
t 
-1.215 SPON pondin 1, ex
205547_s_a
05009_at 
-1.042 
.102 
TAGLN
FF1 
ansgelin 
oil factor 1 (breast c2 -1 T ef
20
21
-0
-0
T
T
hro
an5034_s_at .883 M4SF1 tr smembrane 4 L six family member 1 
209386_at -1.011 TM4SF1 transmembrane 4 L six family member 1 
214601_at -0.916 TPH1 tryptophan hydroxylase 1 (tryptophan 5-monooxygenase) 
203892_at -2.256 WFDC2 AP four-disulfide core domain 2 
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Table 3.9  Inflam nd non-inflamed U ally regulated genes from limma 
 
ulated p sets fr riso  and non-inflamed UC 
ed a C: top 50 differenti
analysis
A. Up-reg robe om compa n of inflamed
Probe id atio  
ol 
Log2R Gene
symb
Gene name 
202912_at 1.581 ADM adrenomedullin 
217238_s_at 
211357_s_at 
1.256 ALDOB 
t 
t 
V, autosomal dominant) 
ulating activity, alpha) 
nt) 
1289_at 1.366 CYR61 cysteine-rich, angiogenic inducer, 61 
1926_s_at 1.713 DAF decay accelerating factor for complement (CD55, Cromer blood group system) 
1925_s_at 1.556 DAF decay accelerating factor for complement (CD55, Cromer blood group system) 
1896_s_at 1.275 DCN decorin 
GREM1 gremlin 1, cysteine knot superfamily, homolog (Xenopus laevis) 
GREM1 gremlin 1, cysteine knot superfamily, homolog (Xenopus laevis) 
y locus 
211634_x_at 1.455 immunoglobulin heavy constant mu 
1 
 vial fluid) 
 1 beta (pancreatic stone protein, pancreatic thread protein) 
t 
5 , member 5 
4  transporter), member 14 
t ich (osteonectin) 
e inhibitor) 
aldolase B, fructose-bisphosphate 
1.351 ALDOB 
C1S 
aldolase B, fructose-bisphosphate 
208747_s_at 1.247 complement component 1, s subcomponent 
complement component 3 217767_at 1.554 C3 
210133_at 1.346 CCL11 chemokine (C-C motif) ligand 11 
205476_at 1.503 CCL20 chemokine (C-C motif) ligand 20 
209396_s_at 2.302 CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) 
209395_at 1.997 CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) 
202310_s_a 1.775 COL1A1 collagen, type I, alpha 1 
202404_s_a 1.769 COL1A2 collagen, type I, alpha 2 
202403_s_at 
215076_s_at 
1.782 COL1A2 collagen, type I, alpha 2 
1.349 COL3A1 collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant) 
collagen, type III, alpha 1 (Ehlers-Danlos synd201852_x_at 
201438_at 
1.387 
1.973 
COL3A1 
COL6A3 
rome type I
collagen, type VI, alpha 3 
205927_s_at 1.279 CTSE cathepsin E 
204470_at 1.728 CXCL1 chemokine (C-X-C motif) ligand 1 (melanoma growth stim
205242_at 1.897 CXCL13 chemokine (C-X-C motif) ligand 13 (B-cell chemoattracta
209774_x_at 1.43 CXCL2 chemokine (C-X-C motif) ligand 2 
207850_at 1.279 CXCL3 chemokine (C-X-C motif) ligand 3 
20
20
20
21
208250_s_at 1.29 DMBT1 deleted in malignant brain tumors 1 
219727_at 2.804 DUOX2 dual oxidase 2 
218469_at 2.393 
218468_s_at 2.62 
212671_s_at 1.242 HLA-DQA1 major histocompatibility complex, class II, DQ alpha  
210982_s_at 1.341 HLA-DRA major histocompatibility complex, class II, DR alpha 
factor binding protein 5 211959_at 
211430_s_at 
1.368 
1.688 
IGFBP5 
IGH@  
IGHM 
IGLC1 
insulin-like growth 
immunoglobulin heav
216560_x_at 
215214_at 
1.61 
2.223 
Immunoglobulin lambda constant 1 (Mcg marker) 
Immunoglobulin lambda variable 3-21 IGLC2 
IGLJ3 216853_x_at 1.598 Immunoglobulin lambda joining 3 
202859_x_at 1.477 IL8 interleukin 8 
212531_at 2.861 LCN2 lipocalin 2 (oncogene 24p3) 
204475_at 1.919 MMP1 
MMP12 
matrix metalloproteinase 1 (interstitial collagenase) 
matrix metalloproteinase 12 (macrophage elastase) 204580_at 1.452 
205828_at 2.095 MMP3 matrix metalloproteinase 3 (stromelysin 1, progelatinase) 
219630_at 1.86 PDZK1IP PDZK1 interacting protein 1 
41469_at 3.322 PI3 protease inhibitor 3, skin-derived (SKALP) 
protease inhibitor 3, skin-derived (SKALP) 203691_at 3.256 PI3 
203649_s_at 
205886_at 
1.605 PLA2G2A phospholipase A2, group IIA (platelets, syno
1.867 REG1B regenerating islet-derived
S100 calcium binding prot202917_s_a 1.883 S100A8 ein A8 (calgranulin A) 
S100 calcium binding protein P 204351_at 2.694 S100P 
204855_at 1.702 SERPINB serine (or cysteine) proteinase inhibitor, clade B (ovalbumin)
219795_at 2.037 SLC6A1 solute carrier family 6 (amino acid
200665_s_a 1.256 SPARC secreted protein, acidic, cysteine-r
207214_at 2.037 SPINK4 serine protease inhibitor, Kazal type 4 
205185_at 1.569 SPINK5 serine protease inhibitor, Kazal type 5 
trefoil factor 1 (breast cancer, estrogen-inducible sequence expressed in) 205009_at 1.767 TFF1 
201666_at 2.017 TIMP1 tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenas
205890_s_at 
205844_at 
2.373 UBD ubiquitin D 
1.675 VNN1 vanin 1 /// vanin 1 
    
    
B. Down-regulated probesets from comparison of inflamed and non-inflamed UC 
    
209735_at 
t 
-1.676 
8 
ABCG2 ATP-binding cassette, sub-family G (WHITE), member 2 
a polypeptide 
 renergic, alpha-2A-, receptor 
10  B10 (aldose reductase) 
e N, aminopeptidase M, microsomal 
C3B e, catalytic polypeptide-like 3B 
t 16 
 
ubfamily B, polypeptide 7 pseudogene 1 
t 
1 
t 
t 
 ynthase 2 (mitochondrial) 
 
2 
rotein 2, 36kDa 
8 
209600_s_a -0.98 ACOX1 
 
acyl-Coenzyme A oxidase 1, palmitoyl 
class I), gamm206262_at -1.74 ADH1C
A
alcohol dehydrogenase 1C (
209869_at -0.97 ADRA2 adrenergic, alpha-2A-, receptor /// ad
206561_s_at -1.077 AKR1B aldo-keto reductase family 1, member
202888_s_at -1.929 ANPEP alanyl (membrane) aminopeptidase (aminopeptidas
aminopeptidase, CD13, p150) 
zym206632_s_at -1.05 APOBE
8 
apolipoprotein B mRNA editing en
206784_at 
t 
-3.642 AQP aquaporin 8 
208677_s_a -0.954 BSG basigin (OK blood group) 
203571_s_a -1.098 C10orf1 chromosome 10 open reading frame 116 
209301_at -0.949 CA2 carbonic anhydrase II 
209668_x_at -0.969 CES2 carboxylesterase 2 (intestine, liver) 
50, family 2, subfamily B, polypeptide 6 206755_at 
t 
-0.993 CYP2B6 cytochrome P4
206754_s_a
a
-1.348 CYP2B7P1 
1 
cytochrome P450, family 2, s
222262_s_ -1.94 ETNK ethanolamine kinase 1 
219017_at -2.094 ETNK ethanolamine kinase 1 
208228_s_a -1.03 FGFR2 fibroblast growth factor receptor 2  
203638_s_a -1.284 FGFR2 fibroblast growth factor receptor 2  
207003_at -1.256 GUCA2A guanylate cyclase activator 2A (guanylin) 
204607_at -2.907 HMGCS2
2
3-hydroxy-3-methylglutaryl-Coenzyme A s
204130_at -1.061 
8 
HSD11B hydroxysteroid (11-beta) dehydrogenase 2 
204818_at -1.56 HSD17B hydroxysteroid (17-beta) dehydrogenase 2 
e, 3 beta- and steroid delta-isomerase 2 206294_at -1.681 HSD3B2 
 
hydroxy-delta-5-steroid dehydrogenas
202718_at -0.957 
 
IGFBP2 insulin-like growth factor binding p
206149_at -1.761 LOC6392 hepatocellular carcinoma antigen gene 520 
212741_at -1.107 MAOA monoamine oxidase A 
219543_at -1.125 MAWBP MAWD binding protein 
 
 72
207251_at -0.962 MEP1B 
1
meprin A, beta 
 dehydrogenase/reductase 218756_s_at -1.243 MGC4 72 
 onein 1F (functional) 
3629_x_at .244 T1F allothionein 1F (functional) 
t  
 
e 
t transcription factor 2 
1 
, member 1 
1 xylic acid transporters), member 1 
1 sporters), member 1 
A1 mber 1 
 (organic cation transporter), member 5 
2 porter), member 2 
er 10 
al amino acid transporters, activator of cystine, dibasic 
mino acid transport), member 1 
A10 osyltransferase 1 family, polypeptide A10 
A10 osyltransferase 1 family, polypeptide A10 
ltransferase 1 family, polypeptide A10 
 ypeptide A10 
 ptide A6 
 
short-chain
217165_x_at -1.051 MT1F metallothi
21 -1 M met
204745_x_at -1.253 MT1G metallothionein 1G 
206461_x_at -1.04 MT1H metallothionein 1H 
17546_at .008 T1K allothionein 1K 2 -1 M met
208581_x_a -1.019 MT1X metallothionein 1X 
212338_at -1.011 MYO1D myosin ID 
205660_at -1.022 OASL 2'-5'-oligoadenylate synthetase-like 
209791_at -1.206 PADI2 peptidyl arginine deiminase, type II 
208383_s_at -2.064 PCK1 phosphoenolpyruvate carboxykinase 1 (soluble) 
k213407_at -1.174 PHLPPL PH domain and leucine rich repeat protein phosphatase-li
A hydroxylase (Refsum disease) 203335_at -0.975 PHYH phytanoyl-Co
207558_s_a -1.806 PITX2 paired-like homeodomain 
204304_s_at -0.99 PROM prominin 1 
217085_at -1.662 SLC14A2 
1 
Solute carrier family 14 (urea transporter), member 2 
xylic acid transporters)209900_s_at -1.107 SLC16A solute carrier family 16 (monocarbo
202236_s_at -1.42 SLC16A solute carrier family 16 (monocarbo
202234_s_at -0.994 SLC16A solute carrier family 16 (monocarboxylic acid tran
 (phosphate transporter), me201920_at -1.66 SLC20 solute carrier family 20
rrier family 22205074_at -0.991 SLC22A5 solute ca
205097_at -2.085 SLC26A solute carrier family 26 (sulfate trans
220435_at -1.103 SLC30A10 
A1 
solute carrier family 30 (zinc transporter), memb
 family 3 (cystine, dibasic and neutr205799_s_at -1.02 SLC3 solute carrier
and neutral a
215125_s_at -1.298 UGT1 UDP glucuron
208596_s_at 
 
-1.145 UGT1 UDP glucuron
uronosy207126_x_at -1.314 UGT1A10 UDP gluc
204532_x_at -1.203 UGT1A10 UDP glucuronosyltransferase 1 family, pol
206094_x_at -1.303 UGT1A6 UDP glucuronosyltransferase 1 family, polype
219948_x_at -1.541 UGT2A3 UDP glucuronosyltransferase 2 family, polypeptide A3 
 
 
Table 3.10  Infla UC and healthy no ntially regulated genes 
ma anal
ulated p sets from co riso ealthy normal controls 
med rmal controls: Top 50 differe
from lim ysis 
A. Up-reg robe mpa n of inflamed UC and h
Probe id Log2Ratio  
ol 
Gene
symb
Gene name 
211637_x_at 1.372 --- Rearranged Ig mu-chain (V4-59/DIR1-D5'-D21-9/JH4b) 
217238_s_at 2.033 ALDOB -bisphosphate 
 -bisphosphate 
 -bisphosphate 
leukin 1, beta, convertase) 
 nterleukin 1, beta, convertase) 
1 poptosis-related cysteine protease (interleukin 1, beta, convertase) 
t 
ty, alpha) 
1 
t CD55, Cromer blood group system) 
t ent (CD55, Cromer blood group system) 
7529_at 2.672 DEFA5 defensin, alpha 5, Paneth cell-specific 
8250_s_at 2.977 DMBT1 deleted in malignant brain tumors 1 
219727_at 3.005 DUOX2 dual oxidase 2 
219117_s_at 1.325 FKBP11 FK506 binding protein 11, 19 kDa 
202269_x_at 1.572 GBP1 guanylate binding protein 1, interferon-inducible, 67kDa 
218469_at 1.831 GREM1 gremlin 1, cysteine knot superfamily, homolog (Xenopus laevis) 
218468_s_at 1.997 GREM1 gremlin 1, cysteine knot superfamily, homolog (Xenopus laevis) 
209728_at 1.531 HLA-DRB4 major histocompatibility complex, class II, DR beta 4 
201601_x_at 1.348 IFITM1 interferon induced transmembrane protein 1 (9-27) 
211959_at 1.36 IGFBP5 insulin-like growth factor binding protein 5 
211430_s_at 2.153 IGH@ immunoglobulin heavy locus 
216491_x_at 1.51 IGHM immunoglobulin heavy constant mu 
211634_x_at 1.342 IGHM immunoglobulin heavy constant mu 
216560_x_at 1.589 IGLC1 Immunoglobulin lambda constant 1 (Mcg marker) 
215214_at 1.9 IGLC2 Immunoglobulin lambda variable 3-21 
216853_x_at 1.482 IGLJ3 Immunoglobulin lambda joining 3 
202859_x_at 1.438 IL8 interleukin 8 
212531_at 3.261 LCN2 lipocalin 2 (oncogene 24p3) 
204475_at 2.038 MMP1 matrix metalloproteinase 1 (interstitial collagenase) 
204580_at 1.945 MMP12 matrix metalloproteinase 12 (macrophage elastase) 
205828_at 2.049 MMP3 matrix metalloproteinase 3 (stromelysin 1, progelatinase) 
212768_s_at 3.056 OLFM4 olfactomedin 4 
219630_at 1.682 PDZK1IP1 PDZK1 interacting protein 1 
41469_at 2.564 PI3 protease inhibitor 3, skin-derived (SKALP) 
203691_at 2.239 PI3 protease inhibitor 3, skin-derived (SKALP) 
205267_at 1.327 POU2AF1 POU domain, class 2, associating factor 1 
204279_at 1.506 PSMB9 proteasome (prosome, macropain) subunit, beta type, 9 (large multifunctional protease 2) 
212187_x_at 1.374 PTGDS prostaglandin D2 synthase 21kDa (brain) 
211748_x_at 1.422 PTGDS prostaglandin D2 synthase 21kDa (brain) 
209752_at 4.783 REG1A regenerating islet-derived 1 alpha (pancreatic stone protein, pancreatic thread protein) 
205886_at 2.37 REG1B regenerating islet-derived 1 beta (pancreatic stone protein, pancreatic thread protein) 
205815_at 2.775 REG3A regenerating islet-derived 3 alpha 
209071_s_at 1.328 RGS5 regulator of G-protein signalling 5 
202917_s_at 2.21 S100A8 S100 calcium binding protein A8 (calgranulin A) 
219795_at 1.842 SLC6A14 solute carrier family 6 (amino acid transporter), member 14 
207214_at 2.684 SPINK4 serine protease inhibitor, Kazal type 4 
aldolase B, fructose
211357_s_at 2.303 ALDOB aldolase B, fructose
204705_x_at 
t 
2.01 ALDOB aldolase B, fructose
202357_s_a 1.391 BF 
 
B-factor, properdin 
211368_s_at 1.452 CASP1
1
caspase 1, apoptosis-related cysteine protease (inter
poptosis-related cysteine protease (i211366_x_at 1.354 CASP caspase 1, a
209970_x_at 1.379 CASP caspase 1, a
210133_at 2.505 CCL11 chemokine (C-C motif) ligand 11 
209396_s_a 2.443 CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) 
lycoprotein-39) 209395_at 
t 
2.247 CHI3L1 
A2 
chitinase 3-like 1 (cartilage g
 type I, alpha 2 202404_s_a 1.593 COL1 collagen,
201438_at 1.591 COL6A3 collagen, type VI, alpha 3 
204470_at 1.757 CXCL1 
3 
chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activi
) 205242_at 1.68 CXCL1 chemokine (C-X-C motif) ligand 13 (B-cell chemoattractant
209774_x_at 1.381 CXCL2 chemokine (C-X-C motif) ligand 2 
207850_at 1.32 CXCL3 chemokine (C-X-C motif) ligand 3 
203915_at 1.523 CXCL9 chemokine (C-X-C motif) ligand 9 
cer, 6201289_at 1.459 CYR61 cysteine-rich, angiogenic indu
201926_s_a
925_s_a
1.958 
1.602 
DAF 
DAF 
decay accelerating factor for complement (
decay accelerating factor for complem201
20
20
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20
20
1666_at 1.495 TIMP1 tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor) 
5890_s_at 2.296 UBD ubiquitin D 
205844_at 1.604 VNN1 vanin 1 
    
B. Down-regulated probesets from comparison of inflamed UC and healthy normal controls 
    
213921_at -2.405 --- transcript represented by NM_001048 
t by AF078844 210524_x_at 
204719_at 
-1.106 
-1.188 
1.134 
--- 
ABCA8 
 
ranscript represented 
ATP-binding cassette, sub-family A (ABC1), member 8 
AP), member 1 
1.128  AP), member 1 
1.214 1C , gamma polypeptide 
2.477 
1.504 
1.896 
0.977 1  1 
0.989 2 
1.084 2 stine, liver) 
t 1.139 A 
1.563 
2.667 8 
1.084 
0.97 1L4B 
1.176 
1.151 
1.059 
1.116 
1.734 
1.961 
-1.426 CA2B vator 2B (uroguanylin) 
4607_at -1.306 HMGCS2 droxy-3-methylglutaryl-Coenzyme A synthase 2 (mitochondrial) 
05403_at -1.633 IL1R2 terleukin 1 receptor, type II 
.484  
.021 A0830 
.33 LS2 
.608 3928 
.204 A 
.124 4172 /reductase 
 .208 1E al) 
.649  
.73  
t .712 
.573 
.734 
8581_x_at -1.757 MT1X metallothionein 1X 
4326_x_at -1.495 MT1X metallothionein 1X 
212185_x_at -1.139 MT2A metallothionein 2A 
7080_s_at -2.499 PYY peptide YY 
1785_at -1.125 RNASE1 ribonuclease, RNase A family, 1 (pancreatic) 
205464_at -1.128 SCNN1B sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) 
205097_at -2.019 SLC26A2 solute carrier family 26 (sulfate transporter), member 2 
206059_at -1.138 ZNF91 zinc finger protein 91 (HPF7, HTF10) 
209993_at - ABCB1
B1
ATP-binding cassette, sub-family B (MDR/T
 cassette, sub-family B (MDR/T209994_s_at - ABC
H
ATP-binding
206262_at - AD alcohol dehydrogenase 1C (class I)
206784_at - AQP8 aquaporin 8 
220468_at 
t 
- ARF7 ADP-ribosylation factor 7 
205950_s_a - CA1 
AMK2N
carbonic anhydrase I 
kinase II inhibitor218309_at - C calcium/calmodulin-dependent protein 
stine, liver) 213509_x_at 
t 
- CES carboxylesterase 2 (inte
209668_x_a - CES carboxylesterase 2 (inte
204697_s_a - CHG chromogranin A (parathyroid secretory protein 1) 
ain 200884_at - CKB 
N
creatine kinase, br
214598_at - CLD claudin 8 
205081_at - CRIP1 
4
cysteine-rich protein 1 (intestinal) 
 4B 220161_s_at - EPB erythrocyte membrane protein band 4.1 like
216442_x_at - FN1 fibronectin 1 
212464_s_at 
t 
-
-
FN1 fibronectin 1 
211719_x_a FN1 fibronectin 1 
210495_x_at - FN1 fibronectin 1 
206422_at - GCG 
A2A 
glucagon 
e activator 2A (guanylin) 207003_at 
7502_at 
- GUC
GU
guanylate cyclas
anylate cyclase acti20
20
gu
3-hy
209844_at -1.657 HOXB13 homeo box B13 
211372_s_at -1.518 IL1R2 interleukin 1 receptor, type II 
2 in
221091_at -2 INSL5 insulin-like 5 
212573_at -1 KIA KIAA0830 protein 
208450_at -1 LGA
LOC6
lectin, galactoside-binding, soluble, 2 (galectin 2) 
206149_at -1 hepatocellular carcinoma antigen gene 520 
212741_at -1 MAO monoamine oxidase A 
short-chain dehydrogena218756_s_at -1 MGC se
metallothionein 1E (function212859_x_at -1 MT
217165_x_at -1 MT1F metallothionein 1F (functional) 
213629_x_at -1 MT1F metallothionein 1F (functional) 
204745_x_a -1 MT1G metallothionein 1G 
206461_x_at -1 MT1H metallothionein 1H 
217546_at -1 MT1K metallothionein 1K 
20
20
209791_at -1.442 PADI2 peptidyl arginine deiminase, type II 
208383_s_at -1.944 PCK1 phosphoenolpyruvate carboxykinase 1 (soluble) 
211253_x_at -1.158 PYY peptide YY 
20
20
214433_s_at -1.406 SELENBP1 selenium binding protein 1 
33322_i_at -0.999 SFN stratifin 
203908_at -1.305 SLC4A4 solute carrier family 4, sodium bicarbonate cotransporter, member 4 
214601_at -1.308 TPH1 tryptophan hydroxylase 1 (tryptophan 5-monooxygenase) 
219948_x_at -1.58 UGT2A3 UDP glucuronosyltransferase 2 family, polypeptide A3 
207432_at -1.033 VMD2L1 vitelliform macular dystrophy 2-like 1 
203892_at -1.849 WFDC2 WAP four-disulfide core domain 2 
214142_at -0.988 ZG16 zymogen granule protein 16 
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Table 3.11  Table of differentially regulated genes from paired statistica
and non-inflamed UC 
l analysis of inflamed 
. Up-regulated probesets from paired statistical analysis, not detected by limma, 17 genes A
Probe id Log2Ratio Gene symbol Gene name 
209001_s_at 0.263 ANAPC13 anaphase promoting complex subunit 13 
210427_x_at 0.381 ANXA2 annexin A2 
203951_at 0.338 CNN1 calponin 1, basic, smooth muscle 
213831_at 0.581 HLA-DQA1 major histocompatibility complex, class II, DQ alpha 1 
212999_x_at 0.324 HLA-DQB1 Major histocompatibility complex, class II, DQ beta 1 
209480_at 0.351 HLA-DQB1 Major histocompatibility complex, class II, DQ beta 1 
213674_x_at 0.321 IGHD immunoglobulin heavy constant delta 
201627_s_at 0.357 INSIG1 insulin induced gene 1 
201088_at 0.337 KPNA2 karyopherin alpha 2 (RAG cohort 1, importin alpha 1) 
218717_s_at 0.268 LEPREL1 leprecan-like 1 
212768_s_at 0.394 OLFM4 olfactomedin 4 
206214_at 0.292 PLA2G7 phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) 
211924_s_at 0.479 PLAUR plasminogen activator, urokinase receptor 
210845_s_at 0.577 PLAUR plasminogen activator, urokinase receptor 
214288_s_at 0.277 PSMB1 proteasome (prosome, macropain) subunit, beta type, 1 
209146_at 0.3 SC4MOL sterol-C4-methyl oxidase-like 
207249_s_at 0.433 SLC28A2 solute carrier family 28 (sodium-coupled nucleoside transporter), member 2 
204141_at 0.452 TUBB2 tubulin, beta 2 
    
201626_at 0.411 INSIG1 insulin induced gene 1 
218368_s_at 0.269 TNFRSF12A tumor necrosis factor receptor superfamily, member 12A 
B. Down-regulated probesets from paired statistical analysis, not detected by limma, 12 genes 
    
221484_at -0.265 B4GALT5 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 5 
213716_s_at -0.319 SECTM1 secreted and transmembrane 1 
207392_x_at -0.616 UGT2B15 UDP glucuronosyltransferase 2 family, polypeptide B15 
220421_at -0.321 BTNL8 butyrophilin-like 8 
211549_s_at -0.277 HPGD hydroxyprostaglandin dehydrogenase 15-(NAD) 
220834_at -1.164 MS4A12 membrane-spanning 4-domains, subfamily A, member 12 
220186_s_at -0.265 PC-LKC protocadherin LKC 
205593_s_at -0.439 PDE9A phosphodiesterase 9A 
219669_at -0.786 PRV1 polycythemia rubra vera 1 
204019_s_at -0.512 SH3YL1 SH3 domain containing, Ysc84-like 1 (S. cerevisiae) 
204981_at -0.342 SLC22A18 solute carrier family 22 (organic cation transporter), member 18 
207245_at -1.089 UGT2B17 UDP glucuronosyltransferase 2 family, polypeptide B17 
 
3.3.2.2 Functional grouping of differentially regulated transcripts for UC dataset 
 
In order to place the differentially regulated probesets into a biological context, the Fisher test 
2X2 contingency table was used to calculate p-values for the likelihood that differentially regulated 
genes were enriched (better than chance) within a given Gene Ontology category (Table 3.12). A 
total of 5616 probesets and 18824 GO terms were inp
for a 
utted into Fisher test analysis, resulting in 
281 GO terms being matched to the probesets. 
 
set comparisons 
oot GO term UC_NI-NC UC_I-UC_NI UC_I-NC 
4
Table 3.12  Frequency of significantly enriched GO terms* in the UC data
R
Biological process 313 (139)† 360 (80) 377 (83) 
Molecular function 225 (96) 274 (66) 215 (45) 
Cellular component 85 (41) 69 (12) 94 (15) 
* p<0.05, no multiple testing correction applied; †numbers in parentheses indicate number of 
significant GO terms unique for each comparison 
 
Significantly enriched GO terms that were present in all three UC comparisons included: response 
to stimulus (including defense response, immune response, humoral immune response), apoptosi
(including anti-apoptosis, negative regulation of apoptosis, negative regulation of programmed cell 
s 
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death), cell-cell signaling, caspase activity, MHC class II receptor activity, pattern binding, protein 
binding, extracellular matrix, membrane fraction, and basement membrane. 
 
More interesting were the significantly enriched GO terms that w
comparison. For example, UC-specific effects that were indepen
isolated from the comparison between non-inflamed UC and nor  
included various GO terms involved in transport (monocarboxyli
or pore class transporter activity, protein transporter activity, wat
symporter activity), functions associated with RNA (RNA processing, RNA splicing, mRNA 
catabolism, nonsense-mediated decay), and nuclear transport (nucleocytoplasmic transport, 
rotein-nucleus import, protein-nucleus import, docking). Inflammation effects within the context of 
rison) includ
 
l 
 
pathway), immune response (cell-
ediated immune response, innate immune response, positive regulation of cytokine biosynthesis, 
 
After normalization and quality control, the CD dataset consisted of 44 arrays, including 25 healthy 
normal controls, and 19 CD samples (8 inflamed, 7 non-inflamed and 4 inflamed and treated with 
immunosuppressives (steroids or azathioprine)). Four of the non-inflamed/inflamed samples were 
paired samples from the same patient, but taken from different regions. Comparisons were made 
between four groups: normal controls (NC), non-inflamed CD (CD_NI) and inflamed CD (CD_I), 
and inflamed CD patients treated with immunosuppressives (CD_IS) as depicted in Figure 3.18. 
 
ere specific for a particular 
dent of inflammation could be 
mal controls. These effects
c acid transporter activity, channel 
er channel activity, solute:sodium 
p
UC (UC_I-UC_NI compa ed GO terms for fatty acid biosynthesis/metabolism (butyrate 
metabolism, gamma-aminobutyric acid metabolism), innate immunity (immune cell mediated 
cytotoxicity, natural killer cell mediated cytotoxicity), and signaling (epidermal growth factor receptor 
signaling pathway, regulation of G-protein coupled receptor protein signaling pathway, nitric oxide
mediated signal transduction). The cumulative effects of UC and inflammation compared to norma
controls (UC_I-NC comparison) yielded a significant enrichment in signaling (intracellular signaling
cascade, enzyme linked receptor protein signaling pathway, Wnt receptor signaling pathway, 
transmembrane receptor protein tyrosine phosphatase signaling 
m
T-helper 1 type immune response), and cell junction. 
 
3.3.3 Expression profiling of the non-/inflamed CD mucosa 
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Normal control 
(n=25) 
 
As previously described for the UC dataset, the normalized CD dataset was further processed by 
defining which probesets were ‘present’ on the arrays and eliminating probesets with low variability. 
The background cutoff was set to the mean of the background subset plus two standard deviations. 
Next, all probesets were defined to be ‘present’ if signals were above the background cutoff in at 
least 70% of arrays in any one group (NC, CD_NI, CD_I, CD_IS). As a final step, only probesets 
which had an interquartile range in the top 25  percentile of interquartile ranges were selected for 
differential gene determination. At the end of pre-processing, 59
cumulative CD + inflammation ef
and effects of immunosuppressive
inflamed samples. 
th
85 probesets from U133 chip A and 
robesets from U133 chip B remained for further analysis. 
lated genes in t  were determ ing the limma R package with a 
e level design. Limma analysis was carried out s arately for chips A and B. P-
alues were adjusted for multiple testing using the false discovery rate (Benjamini & Hochberg 
method). Six possible unique comparisons (Contrasts 1 to 6) were possible using four factors 
(Table 3.13). In contrast to the UC dataset, much fewer differentially regulated genes were 
detected between inflamed and non-inflamed disease samples. 
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Table 3.13  Number of significantly differentially regulated genes in the CD dataset including 
results combined from chip A and B analysis* 
 Contrast 
 1 2 3 4 5 6 
Regulation CD_NI-NC CD_I-
CD_NI 
CD_I-NC CD_IS- CD_IS- CD_I-
CD_NI NC CD_IS 
Down-regulated 
 3575 (563) 96 (25) 3924 (719) 30 (13) 675 (146) 1065 (175) 
Not regulated 7580 
(1547) 
11247 
(2142) 
697
(136
9 
4) 
10621 
(2090) 
10707 
(2017) 
10194 
(1956) 
Up-regulated 
 320 (73) 132 (16) 572 (  100) 824 (80) 93 (20) 216 (52)
* padj <0.05, false discovery rate adjustment applied; u
 
Differential expression between matched samples of inflamed/non-inflamed regions of the same 
patient were analysed using paired significance testing, as previously done for the UC patient 
samples. In stark contrast to the paired UC dataset, the paired CD dataset revealed no significantly 
differentially expressed genes after a multiple testing correction was applied. Upon omitting the 
multiple testing correction, about 300 probesets were significantly regulated from raw paired t-test 
p-values, and none were significantly regulated from the raw paired Wilcoxon test p-values (Table 
3.14). The overlap between significantly regulated probesets derived from limma and raw paired t-
test was also much lower in the matched CD dataset compared to the matched UC dataset 
(compare Figure 3.17 and Figure 3.19). The dramatic reduction in significantly regulated probesets 
of the matched CD samples is likely influenced by the reduced power of the small sample size 
between the CD and UC datasets (4 matched CD pairs compared to 9 matched UC samples). 
Additionally, the matched CD pairs involved more comparisons being taken from different regions 
inflamed CD samples (combined results from chip A and B) 
CD_I-CD_NI 
nknown gene probesets in parentheses 
(Figure 3.20), which may result in additional variability. 
 
Table 3.14  Number of significantly differentially regulated genes in paired inflamed/non-
 
Regulation Paired t-test* Paired Wilcoxon test* 
Down-regulated 204 0 
Not regulated 10957 11475 
Up-regulated 314 0 
* praw <0.05 
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Top differentially expressed genes are shown in Table 3.15 (CD_NI-NC), Table 3.16 (CD_I-
CD_NI), Table 3.17 (CD_I-NC), Table 3.18 (CD_IS-CD_NI), Table 3.19 (CD_IS-NC) and Table 
3.20 (CD_I-CD_IS). Inspection of the top genes in these tables showed the that microarrays 
detected mRNA expression of genes involved in intestinal function, inflammation and immune 
response. For example, differential expression of gut endocrine hormones (PYY, GCG) and 
intestinal enzymes (ALDOB, CA1, CES2) was observed in various conditions. In comparisons 
involving inflamed CD samples and non-inflamed samples, augmented immune response was 
evidenced by the down-regulation of the pro-inflammatory antagonist IL1R2 and up-regulation of 
Figure 3.19  Venn diagram of differentially 
regulated probesets found using different 
statistical methods (limma, paired t-test, 
paired Wilcoxon test) for the CD dataset. 
Paired statistical tests identify additional 
probesets not detected by inter-individual 
statistical analysis (limma), but the overlap 
between limma and the paired t-test is much 
lower than in the matched UC dataset. 
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Figure 3.20  Regions of lower bowel that were involved in the matched samples of CD and UC 
datasets. 
The paired statistical tests were carried out between non-inflamed and inflamed regions of the same 
patient. The CD dataset involved 4 matched pairs, while 9 matched pairs were used in the UC dataset. 
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various immunoglobulin genes (IGHM, IGKC, IGLJ3, IGKV1-5, IGH@, IGHD, IGHA1, IGLC2, 
IGLV2-14), pro-inflammatory cytokines (CASP1), antimicrobial peptides (DEFA5, DEFA6) and 
nflamed colon (S100A8, OLFM4, 
REG3A) (Bea Abreu, 2004; Og
genes previously h  be ex shown in t e literature to pressed in i
REG1A, ven and awa et al., 2003; Shinozaki et al., 2001). 
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Table 3.15  Non-infla y nor p 50 differentially 
d genes from limma analysis 
gulated probe son of C
med CD and health mal controls (Contrast 1): To
regulate
A. Up-re sets from compari D_NI...NC 
Probe id Log2R ymbol atio Gene s Gene name 
214777_at 0.755 --- Anti-HIV-1 gp120 V3 loop antibody DO142-10 light chain variable region 
211643_x_at 0.645 --- Anti-rabies virus immunoglobulin rearranged kappa chain V-region 
Cationic anti-DNA autoantibody 211645_x_at 0.595 --- 
21
21
2
1650_x_at 0.510 --- IgM VDJ-region 
7281_x_at 0.498 --- IgM rheumatoid factor RF-TT9, variable heavy chain 
11908_x_at 0.491 --- IgM VDJ-region 
215176_x_at 0.487 --- HRV Fab 027-VL 
211637_x_at 0.474 --- Rearranged Ig mu-chain (V4-59/DIR1-D5'-D21-9/JH4b) 
202003_s_at 0.607 ACAA2 acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-Coenzyme A thiolase) 
217238_s_at 0.844 ALDOB aldolase B, fructose-bisphosphate 
202888_s_at 0.952 ANPEP 
alanyl (membrane) aminopeptidase (aminopeptidase N, aminopeptidase M, microsomal 
aminopeptidase, CD13, p150) 
202357_s_at 0.475 BF B-factor, properdin 
229070_at 0.482 C6orf105 chromosome 6 open reading frame 105 
211366_x_at 0.548 CASP1 caspase 1, apoptosis-related cysteine protease (interleukin 1, beta, convertase) 
210133_at 1.127 CCL11 chemokine (C-C motif) ligand 11 
206407_s_at 0.626 CCL13 chemokine (C-C motif) ligand 13 
214038_at 0.608 CCL8 chemokine (C-C motif) ligand 8 
206207_at 0.880 CLC Charcot-Leyden crystal protein 
210107_at 0.506 CLCA1 chloride channel, calcium activated, family member 1 
207529_at 1.807 DEFA5 defensin, alpha 5, Paneth cell-specific 
207814_at 1.005 DEFA6 defensin, alpha 6, Paneth cell-specific 
225458_at 1.989 DKFZP564I1171 DKFZP564I1171 protein 
208250_s_at 1.229 DMBT1 deleted in malignant brain tumors 1 
219017_at 0.679 ETNK1 ethanolamine kinase 1 
227194_at 0.540 FAM3B family with sequence similarity 3, member B 
202269_x_at 0.481 GBP1 guanylate binding protein 1, interferon-inducible, 67kDa 
227614_at 0.708 HKDC1 hexokinase domain containing 1 
202411_at 0.510 IFI27 interferon, alpha-inducible protein 27 
201601_x_at 0.549 IFITM1 interferon induced transmembrane protein 1 (9-27) 
202718_at 0.842 IGFBP2 insulin-like growth factor binding protein 2, 36kDa 
214916_x_at 0.639 IGH@ immunoglobulin heavy locus 
216557_x_at 0.621 IGHA1 immunoglobulin heavy constant alpha 1 
211644_x_at 0.593 IGKC immunoglobulin kappa constant 
214768_x_at 0.583 IGKV1-5 immunoglobulin kappa variable 1-5 
217235_x_at 0.569 IGLC2 Immunoglobulin lambda variable 3-21 
217148_x_at 0.532 IGLV2-14 immunoglobulin lambda variable 2-14 
212531_at 1.022 LCN2 lipocalin 2 (oncogene 24p3) 
229860_x_at 0.807 LOC401115 hypothetical gene supported by BC038466; BC062790 
200632_s_at 0.577 NDRG1 N-myc downstream regulated gene 1 
223217_s_at 0.639 NFKBIZ nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta 
210519_s_at 0.660 NQO1 NAD(P)H dehydrogenase, quinone 1 
212768_s_at 1.714 OLFM4 olfactomedin 4 
229230_at 0.858 OSTalpha organic solute transporter alpha 
230830_at 0.640 OSTbeta organic solute transporter beta 
226147_s_at 0.524 PIGR polymeric immunoglobulin receptor 
243669_s_at 0.946 PRAP1 proline-rich acidic protein 1 
204279_at 0.552 PSMB9 proteasome (prosome, macropain) subunit, beta type, 9 (large multifunctional protease 2) 
209752_at 1.719 REG1A regenerating islet-derived 1 alpha (pancreatic stone protein, pancreatic thread protein) 
205815_at 1.328 REG3A regenerating islet-derived 3 alpha 
202917_s_at 0.911 S100A8 S100 calcium binding protein A8 (calgranulin A) 
201061_s_at 0.604 STOM stomatin 
    
B. Down-regulated probesets from comparison of CD_NI...NC 
200729_s_at -0.347 ACTR2 ARP2 actin-related protein 2 homolog (yeast) 
200612_s_at -0.306 AP2B1 adaptor-related protein complex 2, beta 1 subunit 
200602_at -0.307 APP amyloid beta (A4) precursor protein (protease nexin-II, Alzheimer disease) 
200779_at -0.370 ATF4 activating transcription factor 4 (tax-responsive enhancer element B67) 
200078_s_at -0.401 ATP6V0B ATPase, H+ transporting, lysosomal 21kDa, V0 subunit c'' 
200041_s_at -0.269 BAT1 HLA-B associated transcript 1 
200777_s_at -0.362 BZW1 basic leucine zipper and W2 domains 1 
200614_at -0.393 CLTC clathrin, heavy polypeptide (Hc) 
200621_at -0.409 CSRP1 cysteine and glycine-rich protein 1 
200694_s_at -0.320 DDX24 DEAD (Asp-Glu-Ala-Asp) box polypeptide 24 
200033_at -0.555 DDX5 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 
200664_s_at -0.643 DNAJB1 DnaJ (Hsp40) homolog, subfamily B, member 1 
200762_at -0.277 DPYSL2 dihydropyrimidinase-like 2 
200606_at -0.419 DSP desmoplakin 
200004_at -0.396 EIF4G2 eukaryotic translation initiation factor 4 gamma, 2 
1438_at -0.290 EPHB3 EPH receptor B3 
200709_at -0.313 FKBP1A FK506 binding protein 1A, 12kDa 
200648_s_at -0.617 GLUL glutamate-ammonia ligase (glutamine synthase) 
200708_at -0.346 GOT2 glutamic-oxaloacetic transaminase 2, mitochondrial (aspartate aminotransferase 2) 
200696_s_at -0.380 GSN gelsolin (amyloidosis, Finnish type) 
200073_s_at -0.299 HNRPD heterogeneous nuclear ribonucleoprotein D (AU-rich element RNA binding protein 1, 37kDa) 
200775_s_at -0.331 HNRPK heterogeneous nuclear ribonucleoprotein K 
200052_s_at -0.302 ILF2 interleukin enhancer binding factor 2, 45kDa 
200791_s_at -0.398 IQGAP1 IQ motif containing GTPase activating protein 1 
200048_s_at -0.289 JTB jumping translocation breakpoint 
200698_at -0.444 KDELR2 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 2 
200673_at -0.291 LAPTM4A lysosomal-associated protein transmembrane 4 alpha 
200713_s_at -0.313 MAPRE1 microtubule-associated protein, RP/EB family, member 1 
200644_at -0.288 MARCKSL1 MARCKS-like 1 
200768_s_at -0.448 MAT2A methionine adenosyltransferase II, alpha 
200624_s_at -0.277 MATR3 matrin 3 
200797_s_at -0.439 MCL1 myeloid cell leukemia sequence 1 (BCL2-related) 
200027_at -0.291 NARS asparaginyl-tRNA synthetase 
200790_at -0.593 ODC1 ornithine decarboxylase 1 
200604_s_at -0.394 PRKAR1A protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific extinguisher 1) 
200730_s_at -0.580 PTP4A1 protein tyrosine phosphatase type IVA, member 1 
200677_at -0.419 PTTG1IP pituitary tumor-transforming 1 interacting protein 
200608_s_at -0.273 RAD21 RAD21 homolog (S. pombe) 
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200749_at -0.332 RAN RAN, member RAS oncogene family 
200060_s_at -0.296 RNPS1 RNA binding protein S1, serine-rich domain 
200631_s_at -0.333 SET SET translocation (myeloid leukemia-associated) 
200754_x_at -0.332 S
200718_s_at -0.282 S
FRS2 splicing factor, arginine/serine-rich 2 
KP1A S-phase kinase-associated protein 1A (p19A) 
hrocytic 1 
tochondrial membrane 20 homolog (yeast) 
conjugating enzyme E2D 3 (UBC4/5 homolog, yeast) 
200083_at -0.297 ubiquitin specific protease 22 
t 
HAZ tion protein, zeta polypeptide 
200672_x_at -0.286 SPTBN1 spectrin, beta, non-eryt
200620_at -0.301 TMEM59 transmembrane protein 59 
se of outer mi200662_s_at 
200668_s_at 
-0.373 
-0.286 
TOMM20 
UBE2D3 
USP22 
R1 
transloca
ubiquitin-
200611_s_a -0.281 WD WD repeat domain 1 
ptophan 5-monooxygenase activa200641_s_at -0.575 YW tyrosine 3-monooxygenase/try
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Table 3.16  Inflamed CD and Non-inflamed CD (Contrast 2): Top 50 differentially regulated 
genes from limma analysis 
A. Up-regulated probesets from comparison of CD_I...CD_NI 
Probe id Log2Ratio Gene 
symbol 
Gene name 
214777_at 0.699 --- Anti-HIV-1 gp120 V3 loop antibody DO142-10 light chain variable region 
211641_x_at 0.623 --- Immunoglobulin heavy chain VH3 (H11) 
211637_x_at 0.615 --- Rearranged Ig mu-chain (V4-59/DIR1-D5'-D21-9/JH4b) 
217227_x_at 0.541 --- Hepatitis B surface antigen antibody variable domain 
217179_x_at 0.535 --- Ig rearranged lambda-chain gene V-Jl2/l3-region 
211645_x_at 0.494 --- Cationic anti-DNA autoantibody 
217281_x_at 0.460 --- IgM rheumatoid factor RF-TT9, variable heavy chain 
217258_x_at 0.448 --- IgG to Puumala virus G2, light chain variable region 
202357_s_at 0.378 BF B-factor, properdin 
201641_at 0.414 BST2 bone marrow stromal cell antigen 2 
209970_x_at 0.473 CASP1 caspase 1, apoptosis-related cysteine protease (interleukin 1, beta, convertase) 
211980_at 0.373 COL4A1 collagen, type IV, alpha 1 
203915_at 0.808 CXCL9 chemokine (C-X-C motif) ligand 9 
207529_at 1.467 DEFA5 defensin, alpha 5, Paneth cell-specific 
207814_at 1.027 DEFA6 defensin, alpha 6, Paneth cell-specific 
219955_at 0.448 ECAT11 hypothetical protein FLJ10884 
217294_s_at 0.391 ENO1 enolase 1, (alpha) 
227194_at 0.640 FAM3B family with sequence similarity 3, member B 
202269_x_at 0.528 GBP1 guanylate binding protein 1, interferon-inducible, 67kDa 
209276_s_at 0.430 GLRX glutaredoxin (thioltransferase) 
210982_s_at 0.651 HLA-DRA major histocompatibility complex, class II, DR alpha 
201601_x_at 0.687 IFITM1 interferon induced transmembrane protein 1 (9-27) 
201315_x_at 0.501 IFITM2 interferon induced transmembrane protein 2 (1-8D) 
212203_x_at 0.492 IFITM3 interferon induced transmembrane protein 3 (1-8U) 
214916_x_at 0.470 IGH@ immunoglobulin heavy locus 
216557_x_at 0.435 IGHA1 immunoglobulin heavy constant alpha 1 
214973_x_at 0.750 IGHD immunoglobulin heavy constant delta 
211633_x_at 0.498 IGHG1 Immunoglobulin heavy constant gamma 1 (G1m marker) 
209374_s_at 0.959 IGHM immunoglobulin heavy constant mu 
211644_x_at 0.492 IGKC immunoglobulin kappa constant 
214768_x_at 0.830 IGKV1-5 immunoglobulin kappa variable 1-5 
217235_x_at 0.607 IGLC2 Immunoglobulin lambda variable 3-21 
211798_x_at 0.422 IGLJ3 immunoglobulin lambda joining 3 
217148_x_at 0.665 IGLV2-14 immunoglobulin lambda variable 2-14 
210029_at 0.816 INDO indoleamine-pyrrole 2,3 dioxygenase 
217933_s_at 0.397 LAP3 leucine aminopeptidase 3 
204580_at 0.938 MMP12 matrix metalloproteinase 12 (macrophage elastase) 
218698_at 0.413 MMRP19 likely ortholog of mouse monocyte macrophage 19 
210037_s_at 0.431 NOS2A nitric oxide synthase 2A (inducible, hepatocytes) 
204279_at 0.495 PSMB9 proteasome (prosome, macropain) subunit, beta type, 9 (large multifunctional protease 2) 
201762_s_at 0.415 PSME2 proteasome (prosome, macropain) activator subunit 2 (PA28 beta) 
212187_x_at 0.647 PTGDS prostaglandin D2 synthase 21kDa (brain) 
209752_at 1.584 REG1A regenerating islet-derived 1 alpha (pancreatic stone protein, pancreatic thread protein) 
205815_at 1.516 REG3A regenerating islet-derived 3 alpha 
201060_x_at 0.431 STOM stomatin 
211796_s_at 0.427 TRBV21-1 T cell receptor beta variable 21-1 
205890_s_at 0.673 UBD ubiquitin D 
201649_at 0.498 UBE2L6 ubiquitin-conjugating enzyme E2L 6 
200629_at 0.663 WARS tryptophanyl-tRNA synthetase 
    
B. Down-regulated probesets from comparison of CD_I...CD_NI 
230269_at -0.617 --- 
Transcribed locus, strongly similar to NP_001186.1 filensin; cytoskeletal protein, 115 KD [Homo 
sapiens] 
220645_at -0.550 C11orf33 chromosome 11 open reading frame 33 
223194_s_at -0.338 C6orf85 chromosome 6 open reading frame 85 
229964_at -0.268 C9orf152 chromosome 9 open reading frame 152 
209668_x_at -0.474 CES2 carboxylesterase 2 (intestine, liver) 
223942_x_at -0.517 CHST5 carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 5 
200884_at -0.887 CKB creatine kinase, brain 
224998_at -0.272 CKLFSF4 chemokine-like factor super family 4 
225809_at -0.429 DKFZP564O0823 DKFZP564O0823 protein 
229254_at -0.418 DKFZp761N1114 hypothetical protein DKFZp761N1114 
227676_at -0.327 FAM3D family with sequence similarity 3, member D 
225667_s_at -0.332 FAM84A family with sequence similarity 84, member A 
203697_at -0.300 FRZB frizzled-related protein 
207003_at -0.831 GUCA2A guanylate cyclase activator 2A (guanylin) 
209844_at -0.582 HOXB13 homeo box B13 
211372_s_at -0.466 IL1R2 interleukin 1 receptor, type II 
212573_at -0.405 KIAA0830 KIAA0830 protein 
208450_at -0.576 LGALS2 lectin, galactoside-binding, soluble, 2 (galectin 2) 
225270_at -0.293 NEO1 neogenin homolog 1 (chicken) 
213369_at -0.430 PCDH21 protocadherin 21 
228507_at -0.264 PDE3A Phosphodiesterase 3A, cGMP-inhibited 
230784_at -0.864 PRAC small nuclear protein PRAC 
200844_s_at -0.595 PRDX6 peroxiredoxin 6 
201481_s_at -0.323 PYGB phosphorylase, glycogen; brain 
232707_at -0.546 RAXLX RAX-like homeobox 
213994_s_at -0.294 SPON1 spondin 1, extracellular matrix protein 
222571_at -0.285 ST6GALNAC6 
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-
sialyltransferase 6 
223103_at -0.332 STARD10 START domain containing 10 
232914_s_at -0.336 SYTL2 synaptotagmin-like 2 
227642_at -0.425 TFCP2L1 Transcription factor CP2-like 1 
228716_at -0.294 THRB thyroid hormone receptor, beta (erythroblastic leukemia viral (v-erb-a) oncogene homolog 2, avian) 
224412_s_at -0.935 TRPM6 transient receptor potential cation channel, subfamily M, member 6 
228232_s_at -0.392 VSIG2 V-set and immunoglobulin domain containing 2 
203892_at -0.488 WFDC2 WAP four-disulfide core domain 2 
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Table 3.17  Inflamed CD and healthy normal controls (Contrast 3): Top 50 differentially 
regulated genes from limma analysis 
A. Up-regulated probesets from comparison of CD_I...NC 
Probe id Log2Ratio Gene symbol Gene name 
214777_at 1.454 --- Anti-HIV-1 gp120 V3 loop antibody DO142-10 light chain variable region 
211641_x_at 1.093 --- Immunoglobulin heavy chain VH3 (H11) 
211637_x_at 1.089 --- Rearranged Ig mu-chain (V4-59/DIR1-D5'-D21-9/JH4b) 
211645_x_at 1.089 --- Cationic anti-DNA autoantibody 
211643_x_at 1.035 --- Anti-rabies virus immunoglobulin rearranged kappa chain V-region 
224342_x_at 0.959 --- Ig rearranged lambda-chain gene V-Jl2/l3-region 
217281_x_at 0.958 --- IgM rheumatoid factor RF-TT9, variable heavy chain 
217179_x_at 0.949 --- Ig rearranged lambda-chain gene V-Jl2/l3-region 
217227_x_at 0.862 --- Hepatitis B surface antigen antibody variable domain 
211650_x_at 0.859 --- IgM VDJ-region 
204705_x_at 0.879 ALDOB aldolase B, fructose-bisphosphate 
209970_x_at 1.016 CASP1 caspase 1, apoptosis-related cysteine protease (interleukin 1, beta, convertase) 
210133_at 1.634 CCL11 chemokine (C-C motif) ligand 11 
206207_at 1.134 CLC Charcot-Leyden crystal protein 
203915_at 1.094 CXCL9 chemokine (C-X-C motif) ligand 9 
207529_at 3.275 DEFA5 defensin, alpha 5, Paneth cell-specific 
207814_at 2.033 DEFA6 defensin, alpha 6, Paneth cell-specific 
225458_at 2.186 DKFZP564I1171 DKFZP564I1171 protein 
208250_s_at 1.817 DMBT1 deleted in malignant brain tumors 1 
219727_at 1.180 DUOX2 dual oxidase 2 
222262_s_at 1.052 ETNK1 ethanolamine kinase 1 
227194_at 1.180 FAM3B family with sequence similarity 3, member B 
202269_x_at 1.008 GBP1 guanylate binding protein 1, interferon-inducible, 67kDa 
227614_at 0.894 HKDC1 hexokinase domain containing 1 
201601_x_at 1.235 IFITM1 interferon induced transmembrane protein 1 (9-27) 
202718_at 1.117 IGFBP2 insulin-like growth factor binding protein 2, 36kDa 
211430_s_at 1.194 IGH@ immunoglobulin heavy locus 
216557_x_at 1.056 IGHA1 immunoglobulin heavy constant alpha 1 
214973_x_at 1.211 IGHD immunoglobulin heavy constant delta 
216542_x_at 0.860 IGHG1 immunoglobulin heavy constant gamma 1 (G1m marker) 
209374_s_at 1.613 IGHM immunoglobulin heavy constant mu 
211644_x_at 1.084 IGKC immunoglobulin kappa constant 
214768_x_at 1.413 IGKV1-5 immunoglobulin kappa variable 1-5 
217235_x_at 1.177 IGLC2 Immunoglobulin lambda variable 3-21 
211798_x_at 0.874 IGLJ3 immunoglobulin lambda joining 3 
217148_x_at 1.198 IGLV2-14 immunoglobulin lambda variable 2-14 
210029_at 1.104 INDO indoleamine-pyrrole 2,3 dioxygenase 
212531_at 1.834 LCN2 lipocalin 2 (oncogene 24p3) 
204580_at 1.143 MMP12 matrix metalloproteinase 12 (macrophage elastase) 
223217_s_at 0.877 NFKBIZ nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta 
210519_s_at 0.907 NQO1 NAD(P)H dehydrogenase, quinone 1 
212768_s_at 2.474 OLFM4 olfactomedin 4 
229230_at 1.026 OSTalpha organic solute transporter alpha 
204279_at 1.047 PSMB9 proteasome (prosome, macropain) subunit, beta type, 9 (large multifunctional protease 2) 
209752_at 3.302 REG1A regenerating islet-derived 1 alpha (pancreatic stone protein, pancreatic thread protein) 
205815_at 2.844 REG3A regenerating islet-derived 3 alpha 
202917_s_at 1.491 S100A8 S100 calcium binding protein A8 (calgranulin A) 
201061_s_at 1.019 STOM stomatin 
205890_s_at 0.991 UBD ubiquitin D 
200629_at 0.857 WARS tryptophanyl-tRNA synthetase 
    
B. Down-regulated probesets from comparison of CD_I...NC 
200965_s_at -0.281 ABLIM1 actin binding LIM protein 1 
200974_at -0.503 ACTA2 actin, alpha 2, smooth muscle, aorta 
200612_s_at -0.429 AP2B1 adaptor-related protein complex 2, beta 1 subunit 
200602_at -0.322 APP amyloid beta (A4) precursor protein (protease nexin-II, Alzheimer disease) 
200950_at -0.307 ARPC1A actin related protein 2/3 complex, subunit 1A, 41kDa 
200779_at -0.275 ATF4 activating transcription factor 4 (tax-responsive enhancer element B67) 
200078_s_at -0.373 ATP6V0B ATPase, H+ transporting, lysosomal 21kDa, V0 subunit c'' 
200921_s_at -0.420 BTG1 B-cell translocation gene 1, anti-proliferative 
200953_s_at -0.494 CCND2 cyclin D2 
200884_at -1.690 CKB creatine kinase, brain 
200614_at -0.422 CLTC clathrin, heavy polypeptide (Hc) 
200086_s_at -0.282 COX4I1 cytochrome c oxidase subunit IV isoform 1 
200621_at -0.380 CSRP1 cysteine and glycine-rich protein 1 
1007_s_at -0.337 DDR1 discoidin domain receptor family, member 1 
200694_s_at -0.301 DDX24 DEAD (Asp-Glu-Ala-Asp) box polypeptide 24 
200033_at -0.371 DDX5 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 
200880_at -0.389 DNAJA1 DnaJ (Hsp40) homolog, subfamily A, member 1 
200666_s_at -0.543 DNAJB1 DnaJ (Hsp40) homolog, subfamily B, member 1 
200606_at -0.477 DSP desmoplakin 
200004_at -0.367 EIF4G2 eukaryotic translation initiation factor 4 gamma, 2 
1438_at -0.298 EPHB3 EPH receptor B3 
200709_at -0.352 FKBP1A FK506 binding protein 1A, 12kDa 
200648_s_at -0.413 GLUL glutamate-ammonia ligase (glutamine synthase) 
200708_at -0.364 GOT2 glutamic-oxaloacetic transaminase 2, mitochondrial (aspartate aminotransferase 2) 
200678_x_at -0.269 GRN granulin 
200696_s_at -0.512 GSN gelsolin (amyloidosis, Finnish type) 
200791_s_at -0.372 IQGAP1 IQ motif containing GTPase activating protein 1 
200699_at -0.415 KDELR2 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 2 
200851_s_at -0.294 KIAA0174 KIAA0174 
200915_x_at -0.376 KTN1 kinectin 1 (kinesin receptor) 
200644_at -0.380 MARCKSL1 MARCKS-like 1 
200797_s_at -0.355 MCL1 myeloid cell leukemia sequence 1 (BCL2-related) 
200816_s_at -0.286 PAFAH1B1 platelet-activating factor acetylhydrolase, isoform Ib, alpha subunit 45kDa 
200845_s_at -0.980 PRDX6 peroxiredoxin 6 
200732_s_at -0.725 PTP4A1 protein tyrosine phosphatase type IVA, member 1 
200677_at -0.569 PTTG1IP pituitary tumor-transforming 1 interacting protein 
200749_at -0.283 RAN RAN, member RAS oncogene family 
200060_s_at -0.269 RNPS1 RNA binding protein S1, serine-rich domain 
200872_at -0.580 S100A10 S100 calcium binding protein A10 (annexin II ligand, calpactin I, light polypeptide (p11)) 
200893_at -0.390 SFRS10 splicing factor, arginine/serine-rich 10 (transformer 2 homolog, Drosophila) 
200718_s_at -0.305 SKP1A S-phase kinase-associated protein 1A (p19A) 
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200672_x_at -0.345 SPTBN1 spectrin, beta, non-erythrocytic 1 
200911_s_at -0.643 TACC1 transforming, acidic coiled-coil containing protein 1 
200804_at -0.336 TEGT testis enhanced gene transcript (BAX inhibitor 1) 
200620_at -0.526 TMEM59 transmembrane protein 59 
200662_s_at -0.314 TOMM20 translocase of outer mitochondrial membrane 20 homolog (yeast) 
200973_s_at -0.525 TSPAN3 tetraspanin 3 
200083_at -0.326 USP22 ubiquitin specific protease 22 
200931_s_at -0.389 VCL vinculin 
200867_at -0.304 ZNF313 zinc finger protein 313 
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Table 3.18  Inflamed CD treated with immunosuppressives and non-inflamed CD (Contrast 
4): Top 50 differentially regulated genes from limma analysis 
A. Up-regulated probesets from comparison of CD_IS...CD_NI 
Probe id Log2Ratio Gene symbol Gene name 
213921_at 1.625 --- transcript represented by NM_001048 
200974_at 0.673 ACTA2 actin, alpha 2, smooth muscle, aorta 
202274_at 0.634 ACTG2 actin, gamma 2, smooth muscle, enteric 
228969_at 0.703 AGR2 anterior gradient 2 homolog (Xenopus laevis) 
214953_s_at 0.960 APP amyloid beta (A4) precursor protein (protease nexin-II, Alzheimer disease) 
228241_at 0.537 BCMP11 breast cancer membrane protein 11 
205950_s_at 0.883 CA1 carbonic anhydrase I 
201946_s_at 0.593 CCT2 chaperonin containing TCP1, subunit 2 (beta) 
201735_s_at 0.566 CLCN3 chloride channel 3 
214598_at 0.846 CLDN8 claudin 8 
230360_at 0.911 COLM collomin 
216607_s_at 0.770 CYP51A1 cytochrome P450, family 51, subfamily A, polypeptide 1 
242372_s_at 0.582 DKFZp761N1114 hypothetical protein DKFZp761N1114 
202345_s_at 0.548 FABP5 fatty acid binding protein 5 (psoriasis-associated) 
201889_at 0.547 FAM3C family with sequence similarity 3, member C 
201798_s_at 0.655 FER1L3 fer-1-like 3, myoferlin (C. elegans) 
201540_at 0.550 FHL1 four and a half LIM domains 1 
211719_x_at 1.038 FN1 fibronectin 1 
206422_at 1.211 GCG glucagon 
200648_s_at 0.528 GLUL glutamate-ammonia ligase (glutamine synthase) 
205042_at 0.688 GNE glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase 
202539_s_at 0.553 HMGCR 3-hydroxy-3-methylglutaryl-Coenzyme A reductase 
209844_at 0.639 HOXB13 homeo box B13 
236681_at 0.581 HOXD13 Homeo box D13 
200806_s_at 0.561 HSPD1 heat shock 60kDa protein 1 (chaperonin) 
205403_at 0.713 IL1R2 interleukin 1 receptor, type II 
201627_s_at 0.841 INSIG1 insulin induced gene 1 
221091_at 1.435 INSL5 insulin-like 5 
212192_at 0.619 KCTD12 potassium channel tetramerisation domain containing 12 
206043_s_at 0.546 KIAA0703 KIAA0703 gene product 
213564_x_at 0.582 LDHB lactate dehydrogenase B 
231814_at 0.588 LOC219612 hypothetical gene supported by AK025404 
226654_at 1.145 MUC12 mucin 12 
201497_x_at 0.702 MYH11 myosin, heavy polypeptide 11, smooth muscle 
218189_s_at 0.585 NANS N-acetylneuraminic acid synthase (sialic acid synthase) 
207217_s_at 0.640 NOX1 NADPH oxidase 1 
200845_s_at 0.559 PRDX6 peroxiredoxin 6 
207080_s_at 1.578 PYY peptide YY 
205158_at 0.569 RNASE4 ribonuclease, RNase A family, 4 
209146_at 0.848 SC4MOL sterol-C4-methyl oxidase-like 
205464_at 0.898 SCNN1B sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) 
201742_x_at 0.532 SFRS1 splicing factor, arginine/serine-rich 1 (splicing factor 2, alternate splicing factor) 
205185_at 1.057 SPINK5 serine protease inhibitor, Kazal type 5 
209436_at 0.754 SPON1 spondin 1, extracellular matrix protein 
209218_at 0.783 SQLE squalene epoxidase 
225721_at 0.639 SYNPO2 Synaptopodin 2 
205547_s_at 0.724 TAGLN transgelin 
217979_at 0.558 TM4SF13 Tetraspanin 13 
238846_at 0.661 TNFRSF11A tumor necrosis factor receptor superfamily, member 11a, NFKB activator 
201689_s_at 0.537 TPD52 tumor protein D52 
    
B. Down-regulated probesets from comparison of CD_IS...CD_NI 
211908_x_at -0.376 --- IgM VDJ-region 
214836_x_at -0.390 --- HRV Fab N8-VL 
215176_x_at -0.498 --- HRV Fab 027-VL 
216365_x_at -0.328 --- Clone bsmneg3-t5 nonfunctional immunoglobulin light chain (IGL) mRNA, partial sequence 
234884_x_at -0.522 --- Transcript represented by L21961 
206407_s_at -0.512 CCL13 chemokine (C-C motif) ligand 13 
214038_at -0.486 CCL8 chemokine (C-C motif) ligand 8 
225457_s_at -1.171 DKFZP564I1171 DKFZP564I1171 protein 
212788_x_at -0.344 FTL ferritin, light polypeptide 
217022_s_at -0.394 IGHA1 immunoglobulin heavy constant alpha 1 
211649_x_at -0.326 IGHM Immunoglobulin heavy constant mu 
214677_x_at -0.420 IGL@ immunoglobulin lambda locus 
209138_x_at -0.354 IGLC2 Immunoglobulin lambda variable 3-21 
211798_x_at -0.508 IGLJ3 immunoglobulin lambda joining 3 
229860_x_at -0.428 LOC401115 hypothetical gene supported by BC038466; BC062790 
215946_x_at -0.294 LOC91353 similar to omega protein 
212226_s_at -0.411 PPAP2B phosphatidic acid phosphatase type 2B 
243669_s_at -0.683 PRAP1 proline-rich acidic protein 1 
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Table 3.19  Inflamed CD treated with immunosuppressives and healthy normal controls 
(Contrast 5): Top 50 differentially regulated genes from limma analysis 
A. Up-regulated probesets from comparison of CD_IS...NC 
Probe id Log2Ratio Gene symbol Gene name 
235496_at 0.523 --- Clone DNA49141 LGLL338 (UNQ338) mRNA, complete cds 
227452_at 0.313 --- Hypothetical gene supported by AK000477 
206469_x_at 0.315 AKR7A3 aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase) 
222446_s_at 0.457 BACE2 beta-site APP-cleaving enzyme 2 
229070_at 0.586 C6orf105 chromosome 6 open reading frame 105 
210133_at 1.021 CCL11 chemokine (C-C motif) ligand 11 
206576_s_at 0.594 CEACAM1 carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) 
203757_s_at 0.561 CEACAM6 carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) 
206207_at 0.578 CLC Charcot-Leyden crystal protein 
210107_at 0.630 CLCA1 chloride channel, calcium activated, family member 1 
207529_at 1.107 DEFA5 defensin, alpha 5, Paneth cell-specific 
222847_s_at 0.564 EGLN3 egl nine homolog 3 (C. elegans) 
210950_s_at 0.467 FDFT1 farnesyl-diphosphate farnesyltransferase 1 
218986_s_at 0.529 FLJ20035 hypothetical protein FLJ20035 
233604_at 0.288 FLJ22763 hypothetical gene supported by AK026416 
204875_s_at 0.454 GMDS GDP-mannose 4,6-dehydratase 
202934_at 0.362 HK2 hexokinase 2 
227614_at 0.486 HKDC1 hexokinase domain containing 1 
210619_s_at 0.335 HYAL1 hyaluronoglucosaminidase 1 
202718_at 0.475 IGFBP2 insulin-like growth factor binding protein 2, 36kDa 
209374_s_at 1.161 IGHM immunoglobulin heavy constant mu 
213564_x_at 0.332 LDHB lactate dehydrogenase B 
226702_at 0.333 LOC129607 hypothetical protein LOC129607 
229860_x_at 0.379 LOC401115 hypothetical gene supported by BC038466; BC062790 
223940_x_at 0.556 MALAT1 metastasis associated lung adenocarcinoma transcript 1 (non-coding RNA) 
231736_x_at 0.409 MGST1 microsomal glutathione S-transferase 1 
218698_at 0.480 MMRP19 likely ortholog of mouse monocyte macrophage 19 
211695_x_at 0.322 MUC1 mucin 1, transmembrane 
200632_s_at 0.528 NDRG1 N-myc downstream regulated gene 1 
218888_s_at 0.575 NETO2 neuropilin (NRP) and tolloid (TLL)-like 2 
210519_s_at 0.732 NQO1 NAD(P)H dehydrogenase, quinone 1 
205552_s_at 0.375 OAS1 2',5'-oligoadenylate synthetase 1, 40/46kDa 
212768_s_at 2.225 OLFM4 olfactomedin 4 
230830_at 0.592 OSTbeta organic solute transporter beta 
202619_s_at 0.343 PLOD2 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 
202483_s_at 0.335 RANBP1 RAN binding protein 1 
218353_at 0.267 RGS5 regulator of G-protein signalling 5 
218424_s_at 0.387 STEAP3 STEAP family member 3 
205890_s_at 0.861 UBD ubiquitin D 
217717_s_at 0.514 YWHAB tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta polypeptide 
210996_s_at 0.295 YWHAE tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon polypeptide 
    
B. Down-regulated probesets from comparison of CD_IS...NC 
201752_s_at -0.475 ADD3 adducin 3 (gamma) 
204288_s_at -0.309 ARGBP2 Arg/Abl-interacting protein ArgBP2 
200779_at -0.349 ATF4 activating transcription factor 4 (tax-responsive enhancer element B67) 
202985_s_at -0.296 BAG5 BCL2-associated athanogene 5 
200920_s_at -0.322 BTG1 B-cell translocation gene 1, anti-proliferative 
200953_s_at -0.440 CCND2 cyclin D2 
201743_at -0.371 CD14 CD14 antigen 
202910_s_at -0.314 CD97 CD97 antigen 
203953_s_at -0.323 CLDN3 claudin 3 
201428_at -0.293 CLDN4 claudin 4 
202224_at -0.402 CRK v-crk sarcoma virus CT10 oncogene homolog (avian) 
201220_x_at -0.343 CTBP2 C-terminal binding protein 2 
202157_s_at -0.311 CUGBP2 CUG triplet repeat, RNA binding protein 2 
203917_at -0.552 CXADR coxsackie virus and adenovirus receptor 
200666_s_at -0.357 DNAJB1 DnaJ (Hsp40) homolog, subfamily B, member 1 
201842_s_at -0.348 EFEMP1 EGF-containing fibulin-like extracellular matrix protein 1 
202668_at -0.498 EFNB2 ephrin-B2 
203499_at -0.452 EPHA2 EPH receptor A2 
204131_s_at -0.663 FOXO3A forkhead box O3A 
201738_at -0.339 GC20 translation factor sui1 homolog 
202794_at -0.364 INPP1 inositol polyphosphate-1-phosphatase 
202597_at -0.282 IRF6 interferon regulatory factor 6 
203752_s_at -0.417 JUND jun D proto-oncogene 
203130_s_at -0.317 KIF5C kinesin family member 5C 
203726_s_at -0.540 LAMA3 laminin, alpha 3 
202267_at -0.314 LAMC2 laminin, gamma 2 
201212_at -0.307 LGMN legumain 
202822_at -0.292 LPP LIM domain containing preferred translocation partner in lipoma 
202431_s_at -0.351 MYC v-myc myelocytomatosis viral oncogene homolog (avian) 
202555_s_at -0.349 MYLK myosin, light polypeptide kinase 
201865_x_at -0.300 NR3C1 nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) 
202425_x_at -0.270 PPP3CA protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform (calcineurin A alpha) 
200732_s_at -0.392 PTP4A1 protein tyrosine phosphatase type IVA, member 1 
201164_s_at -0.340 PUM1 pumilio homolog 1 (Drosophila) 
204020_at -0.275 PURA purine-rich element binding protein A 
201785_at -0.463 RNASE1 ribonuclease, RNase A family, 1 (pancreatic) 
203843_at -0.280 RPS6KA3 ribosomal protein S6 kinase, 90kDa, polypeptide 3 
203408_s_at -0.322 SATB1 special AT-rich sequence binding protein 1 (binds to nuclear matrix/scaffold-associating DNA's) 
202071_at -0.306 SDC4 syndecan 4 (amphiglycan, ryudocan) 
202656_s_at -0.295 SERTAD2 SERTA domain containing 2 
203509_at -0.454 SORL1 sortilin-related receptor, L(DLR class) A repeats-containing 
204011_at -0.388 SPRY2 sprouty homolog 2 (Drosophila) 
202021_x_at -0.496 SUI1 putative translation initiation factor 
200911_s_at -0.456 TACC1 transforming, acidic coiled-coil containing protein 1 
201108_s_at -0.662 THBS1 thrombospondin 1 
201986_at -0.351 THRAP1 thyroid hormone receptor associated protein 1 
204094_s_at -0.369 TSC22D2 TSC22 domain family, member 2 
203892_at -0.400 WFDC2 WAP four-disulfide core domain 2 
201367_s_at -0.357 ZFP36L2 zinc finger protein 36, C3H type-like 2 
 
 87
200868_s_at -0.301 ZNF313 zinc finger protein 313 
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Table 3.20  Inflamed CD and inflamed CD treated with immunosuppressives (Contrast 6): 
Top 50 differentially regulated genes from limma analysis 
A. Up-regulated probesets from comparison of CD_I...CD_IS 
Probe id Log2Ratio Gene symbol Gene name 
234884_x_at 0.690 --- Transcript represented by L21961 
214777_at 1.064 --- Anti-HIV-1 gp120 V3 loop antibody DO142-10 light chain variable region 
211643_x_at 0.878 --- Anti-rabies virus immunoglobulin rearranged kappa chain V-region 
211645_x_at 0.823 --- Cationic anti-DNA autoantibody 
216401_x_at 0.699 --- 
Clone plaque 3.4-112 anti-oxidized LDL immunoglobulin light chain variable region mRNA, 
partial cds 
217227_x_at 0.913 --- Hepatitis B surface antigen antibody variable domain 
215176_x_at 0.801 --- HRV Fab 027-VL 
224342_x_at 0.870 --- Ig rearranged lambda-chain gene V-Jl2/l3-region 
217258_x_at 0.901 --- IgG to Puumala virus G2, light chain variable region 
211635_x_at 0.749 --- IgM rheumatoid factor RF-TT1, variable heavy chain 
217281_x_at 0.731 --- IgM rheumatoid factor RF-TT9, variable heavy chain 
211650_x_at 0.792 --- IgM VDJ-region 
211641_x_at 0.769 --- Immunoglobulin heavy chain VH3 (H11) 
211637_x_at 1.000 --- Rearranged Ig mu-chain (V4-59/DIR1-D5'-D21-9/JH4b) 
204705_x_at 0.717 ALDOB aldolase B, fructose-bisphosphate 
209970_x_at 0.706 CASP1 caspase 1, apoptosis-related cysteine protease (interleukin 1, beta, convertase) 
201926_s_at 0.931 DAF decay accelerating factor for complement (CD55, Cromer blood group system) 
207529_at 2.167 DEFA5 defensin, alpha 5, Paneth cell-specific 
207814_at 1.612 DEFA6 defensin, alpha 6, Paneth cell-specific 
225457_s_at 1.242 DKFZP564I1171 DKFZP564I1171 protein 
208250_s_at 1.626 DMBT1 deleted in malignant brain tumors 1 
219017_at 0.789 ETNK1 ethanolamine kinase 1 
227194_at 1.116 FAM3B family with sequence similarity 3, member B 
202269_x_at 0.705 GBP1 guanylate binding protein 1, interferon-inducible, 67kDa 
201601_x_at 0.860 IFITM1 interferon induced transmembrane protein 1 (9-27) 
214916_x_at 0.700 IGH@ immunoglobulin heavy locus 
216557_x_at 0.889 IGHA1 immunoglobulin heavy constant alpha 1 
214973_x_at 1.154 IGHD immunoglobulin heavy constant delta 
211633_x_at 0.811 IGHG1 Immunoglobulin heavy constant gamma 1 (G1m marker) 
216491_x_at 1.030 IGHM immunoglobulin heavy constant mu 
211644_x_at 0.895 IGKC immunoglobulin kappa constant 
214768_x_at 0.898 IGKV1-5 immunoglobulin kappa variable 1-5 
216207_x_at 0.699 IGKV1D-13 immunoglobulin kappa variable 1D-13 
216560_x_at 0.789 IGLC1 Immunoglobulin lambda constant 1 (Mcg marker) 
234764_x_at 1.101 IGLC2 Ig lambda chain V-region (VL-AIG) 
211798_x_at 0.930 IGLJ3 immunoglobulin lambda joining 3 
217148_x_at 0.834 IGLV2-14 immunoglobulin lambda variable 2-14 
217480_x_at 0.713 LOC339562 similar to Ig kappa chain 
217378_x_at 0.688 LOC391427 similar to Ig kappa chain precursor V region (orphon V108) - human  (fragment) 
204580_at 0.991 MMP12 matrix metalloproteinase 12 (macrophage elastase) 
229230_at 0.761 OSTalpha organic solute transporter alpha 
204279_at 0.674 PSMB9 proteasome (prosome, macropain) subunit, beta type, 9 (large multifunctional protease 2) 
209752_at 2.963 REG1A regenerating islet-derived 1 alpha (pancreatic stone protein, pancreatic thread protein) 
205815_at 2.075 REG3A regenerating islet-derived 3 alpha 
201061_s_at 0.736 STOM stomatin 
221253_s_at 0.664 TXNDC5 thioredoxin domain containing 5 
    
B. Down-regulated probesets from comparison of CD_I...CD_IS 
201128_s_at -0.309 ACLY ATP citrate lyase 
201034_at -0.502 ADD3 adducin 3 (gamma) 
200612_s_at -0.615 AP2B1 adaptor-related protein complex 2, beta 1 subunit 
200602_at -0.472 APP amyloid beta (A4) precursor protein (protease nexin-II, Alzheimer disease) 
201176_s_at -0.320 ARCN1 archain 1 
201097_s_at -0.477 ARF4 ADP-ribosylation factor 4 
200950_at -0.404 ARPC1A actin related protein 2/3 complex, subunit 1A, 41kDa 
200818_at -0.311 ATP5O 
ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit (oligomycin sensitivity 
conferring protein) 
200041_s_at -0.293 BAT1 HLA-B associated transcript 1 
201032_at -0.489 BLCAP bladder cancer associated protein 
201005_at -0.356 CD9 CD9 antigen (p24) 
200999_s_at -0.484 CKAP4 cytoskeleton-associated protein 4 
200884_at -1.497 CKB creatine kinase, brain 
200614_at -0.367 CLTC clathrin, heavy polypeptide (Hc) 
201116_s_at -0.308 CPE carboxypeptidase E 
200621_at -0.283 CSRP1 cysteine and glycine-rich protein 1 
200606_at -0.505 DSP desmoplakin 
201016_at -0.350 EIF1AX eukaryotic translation initiation factor 1A, X-linked 
200004_at -0.341 EIF4G2 eukaryotic translation initiation factor 4 gamma, 2 
200043_at -0.292 ERH enhancer of rudimentary homolog (Drosophila) 
200709_at -0.361 FKBP1A FK506 binding protein 1A, 12kDa 
200979_at -0.343 FLJ16518 Mitogen-activated protein kinase kinase kinase 15 
201103_x_at -0.284 FLJ20719 hypothetical protein FLJ20719 
200648_s_at -0.324 GLUL glutamate-ammonia ligase (glutamine synthase) 
200708_at -0.388 GOT2 glutamic-oxaloacetic transaminase 2, mitochondrial (aspartate aminotransferase 2) 
200696_s_at -0.470 GSN gelsolin (amyloidosis, Finnish type) 
201209_at -0.281 HDAC1 histone deacetylase 1 
200955_at -0.299 IMMT inner membrane protein, mitochondrial (mitofilin) 
200698_at -0.388 KDELR2 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 2 
200915_x_at -0.394 KTN1 kinectin 1 (kinesin receptor) 
201030_x_at -0.296 LDHB lactate dehydrogenase B 
200644_at -0.321 MARCKSL1 MARCKS-like 1 
201153_s_at -0.273 MBNL1 muscleblind-like (Drosophila) 
200978_at -0.310 MDH1 malate dehydrogenase 1, NAD (soluble) 
201227_s_at -0.292 NDUFB8 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 8, 19kDa 
200658_s_at -0.265 PHB prohibitin 
200845_s_at -1.039 PRDX6 peroxiredoxin 6 
200677_at -0.411 PTTG1IP pituitary tumor-transforming 1 interacting protein 
201047_x_at -0.273 RAB6A RAB6A, member RAS oncogene family 
200872_at -0.379 S100A10 S100 calcium binding protein A10 (annexin II ligand, calpactin I, light polypeptide (p11)) 
200893_at -0.322 SFRS10 splicing factor, arginine/serine-rich 10 (transformer 2 homolog, Drosophila) 
200718_s_at -0.266 SKP1A S-phase kinase-associated protein 1A (p19A) 
200030_s_at -0.290 SLC25A3 solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 3 
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200672_x_at -0.293 SPTBN1 spectrin, beta, non-erythrocytic 1 
201023_at -0.269 TAF7 TAF7 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 55kDa 
200620_at -0.437 TMEM59 transmembrane protein 59 
201175_at -0.266 TMX2 thioredoxin-related transmembrane protein 2 
201002_s_at -0.277 UBE2V1 ubiquitin-conjugating enzyme E2 variant 1 
200931_s_at -0.466 VCL vinculin 
200609_s_at -0.297 WDR1 WD repeat domain 1 
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3.3.3.2 Functional grouping of differentially regulated transcripts for CD dataset 
 
As previously described for the UC dataset, the Fisher test for a 2X2 contingency table was used to 
check for enrichment of differentially regulated genes in GO classification terms (Table 3.21). A 
total of 11 268 probesets (from chips A and B) and 18 824 GO terms were input into Fisher test 
analysis, resulting in 4614 GO terms being matched to the probesets. 
 
Table 3.21  Frequency of significantly enriched GO terms* in the CD dataset (chips A and B) 
 Without Immunosuppressives Involving Immunosuppressives 
Contrast 1 2 3 4 5 6 
Root GO term CD_NI-NC CD_I-
CD_NI 
CD_I-NC CD_IS-
CD_NI 
CD_IS-
NC 
CD_I-
CD_IS 
Biological 
process 
239 (47)† 135 (55) 248 (51) 199 (79) 168 (70) 198 (34) 
Molecular 
function 
153 (27) 65 (29) 178 (36) 158 (48) 69 (29) 139 (12) 
Cellular 
component 
76 (10) 17 (8) 57 (7) 73 (22) 24 (4) 54 (7) 
* p<0.05, no correction applied; † numbers in parentheses indicate number of GO terms unique for 
that comparison 
 
A sampling of the overall GO profile of the three comparisons without immunosuppressive-treated 
samples (first three contrasts in Table 3.21) indicated that immune-related processes (defense 
response, immune response, antigen binding, apoptotic protease activator activity, caspase 
activator activity), signaling (signal transducer activity, cell-cell signaling), detoxification (xenobiotic 
metabolism), and transport (calcium ion transport) were represented by differentially regulated 
genes in all three comparisons. 
 
Considering all GO terms significant in both CD to normal control comparisons (CD_NI-NC and 
CD_I-NC), cell junction was extremely well represented, including 75% of all ‘cellular component’ 
GO terms relating to cell junction from all present genes: intercellular junction, adherens junction, 
cell-cell adherens junction, tight junction, cell-substrate adherens junction, cell-matrix junction, 
apical junction complex, zonula adherens. To a lesser extent, terms relating to apoptosis 
(regulation of apoptosis, anti-apoptosis, negative regulation of apoptosis) and transport (calcium-
transporting ATPase activity, ion transport, phosphatidylinositol transporter activity, channel or pore 
class transporter activity) were also identified. 
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Analysis of GO terms that were significant between non-inflamed CD and normal controls only (ie. 
the effect of disease without inflammation effects) revealed a significant number of differentially 
regulated genes related to RNA (RNA binding, helicase activity, processing, metabolism and 
splicing), localization to diverse cellular locations (for example, nuclear membrane, mitochondrial 
outer membrane, endosome, coated vesicle), and transport (intracellular, protein, hexose, and 
cation transport), to name but a few select GO groups. Among the more specific terms revealed by 
GO analysis, Notch signaling pathway, low-density lipoprotein receptor activity, peptide hormone 
processing, regulation of cell migration, and regulation of neurotransmitter levels were identified. 
 
The comparison of inflamed CD to non-inflamed CD has the potential to reveal inflammation effects 
specifically within the context of CD. GO analysis yielded terms with implications in the 
inflammatory/immune response (prostaglandin-D synthase activity, cytokine activity), lipid 
metabolism (fatty acid biosynthesis, lipid biosynthesis), protein degradation (proteasome complex 
(sensu Eukaryota), proteolysis and peptidolysis), apoptosis (regulation of I-kappaB kinase/NF-
kappaB cascade, caspase activity) and reactive oxygen species (response to oxidative stress). 
 
A wide variety of significant GO terms were identified from the comparison between normal controls  
and inflamed CD. As expected, many inflammatory or immune-related terms were identified, for 
example (coagulation, immune cell activation, MHC class I receptor activity). Other significant 
terms, which were not directly related to inflammation or immune response, included terms related 
to wound healing (vasculature development, growth factor activity, platelet activation, homophilic 
cell adhesion), binding (cation binding, growth factor binding, ligand-dependent nuclear receptor 
activity, enzyme linked receptor protein signaling pathway), and other terms, such as reproduction, 
transcription regulator activity, and regulation of cell activation, to name but a few. 
 
It is possible to observe the effect of immunosuppressive treatment in the comparisons only 
involving CD samples treated with immunosuppressives (Table 3.21). Uniquely significant GO 
terms in comparisons between CD_IS and CD_NI samples include steroid metabolism, 
ribonucleotide metabolism, purine nucleotide metabolism, purine ribonucleotide metabolism, 
ribonucleoside monophosphate metabolism, and purine ribonucleoside monophosphate 
metabolism—all of these terms play a role in the metabolism of steroids or the response to 
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azathioprine treatment. Notably absent from the above contrast involving CD_IS and CD_NI was 
an abundance of terms related to immune response or inflammation. The comparison between 
CD_IS and normal controls shows that GO terms related to nucleotide metabolism (regulation of 
nucleobase, nucleoside, nucleotide and nucleic acid metabolism), apoptosis (induction of 
apoptosis, positive regulation of apoptosis), immune response (chemokine receptor binding, 
leukocyte adhesion) and cell cycle (regulation of cell cycle, G0 to G1 transition) were noted. In the 
last of the three contrasts involving samples treated with immunosuppressives (CD_I vs. CD_IS), 
unique GO terms for this contrast included terms relating to immune response (regulation of T-cell 
differentiation, cell-mediated immune response, antibacterial humoral response, natural killer cell 
activation), detoxification (carboxypeptidase activity, metallocarboxypeptidase activity, aromatic 
compound metabolism), and other groups (negative regulation of Wnt receptor signaling pathway, 
hormone binding, intercellular junction assembly and/or maintenance), just to name a few. 
 
Analysis of the GO terms represented by differentially regulated genes between inflamed/non-
inflamed CD and UC or normal controls shows that biological processes and molecular functions 
(such as inflammation/immune response and apoptosis) were observed, as expected. Additionally, 
known processes related to immunosuppressive treatment in CD were noted. Though many of the 
identified GO groups (and genes) could have been the basis of further investigation, only two 
subject areas were chosen for further study, based on the fact that they were not directly related to 
immune function. The themes chosen for further real-time analysis include WNT signaling pathway 
and epithelial barrier function. 
3.3.4 Functional themes supported by microarray analysis in IBD 
 
The results from cDNA (Costello et al., 2005) and Affymetrix microarrays used in this thesis cannot 
be directly combined in terms of expression values; however, the results should be complementary 
in terms of the broad functional groups represented by the differentially expressed genes from both 
platforms. The findings of all 11 group comparisons from all microarray datasets are summarized in 
Table 3.22. The differentially regulated genes in each of the group comparisons were categorized 
into three major functional groups: immune and inflammatory response; oncogenesis, cell 
proliferation and growth; and structure and permeability. 
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Table 3.22  Log2 ratios of differentially regulated genes from comparisons in the cDNA and Affymetrix microarray cohorts*. 
 
  cDNA arrays Affymetrix arrays 
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Immune and Inflammatory Response 
             
--- Transcribed sequence with strong similarity to protein pir:I38067 (H.sapiens) I38067 
nitric-oxide synthase 
6.34 6.89          
ADORA3 adenosine A3 receptor -0.57           
ALDH2 aldehyde dehydrogenase 2 family (mitochondrial)  0.36       0.33 -0.31  
ALOX5 arachidonate 5-lipoxygenase -0.66         0.54 0.31 
ALOX5AP arachidonate 5-lipoxygenase-activating protein -0.60           
APOL2 apolipoprotein L, 2     0.36     0.32 0.45 
ASS argininosuccinate synthetase 1.50 1.54   0.67    0.33 0.64 0.97 
BIRC4 baculoviral IAP repeat-containing 4 -0.50 -0.44 -0.31  -0.34  -0.34     
BST1 bone marrow stromal cell antigen 1  -0.42          
BST2 bone marrow stromal cell antigen 2   0.32 0.41 0.73   0.56  0.59 0.61 
C2 complement component 2   0.28 0.29 0.57   0.39  0.55 0.59 
C5 complement component 5 -0.51 -0.36          
CASP1 caspase 1, apoptosis-related cysteine protease (interleukin 1, beta, convertase)   0.54 0.47 1.02   0.71 0.53 0.78 1.32 
CCL11 chemokine (C-C motif) ligand 11   1.13  1.63  1.02  1.17 1.17 2.33 
CCL13 chemokine (C-C motif) ligand 13   0.63  0.65 -0.51  0.54 0.46  0.49 
CCL28 chemokine (C-C motif) ligand 28 -0.54           
CCL8 chemokine (C-C motif) ligand 8   0.61  0.43 -0.49   0.67  0.56 
CD164 CD164 antigen, sialomucin   -0.50  -0.54   -0.38   -0.35 
CD58 CD58 antigen, (lymphocyte function-associated antigen 3)   -0.42  -0.42 0.30  -0.30 -0.40  -0.28 
CD79A CD79A antigen (immunoglobulin-associated alpha)     0.34   0.32  0.98 0.88 
CD9 CD9 antigen (p24)   -0.34  -0.37   -0.36  -0.50 -0.49 
CD97 CD97 antigen   -0.42  -0.41  -0.31  -0.48 0.30  
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) -0.55           
CEACAM1§ carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) 
(Affymetrix probe: 211883_x_at) 
 1.01   0.43  0.47  0.66  0.60 
CEACAM1§ carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) 
(Affymetrix probe: 209498_at) 
 1.01       0.77 -0.80  
CFB complement factor B   0.48 0.38 0.85   0.50 0.48 0.95 1.44 
CFI complement factor I   0.41  0.68   0.59 0.44 0.50 0.94 
CHUK conserved helix-loop-helix ubiquitous kinase  0.59          
CLC Charcot-Leyden crystal protein   0.88  1.13  0.58 0.56 0.96  0.95 
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  cDNA arrays Affymetrix arrays 
    CD UC 
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CRIP1 cysteine-rich protein 1 (intestinal)   -1.31  -1.56  -1.37  -1.65 0.57 -1.09 
CTSC cathepsin C    0.30 0.54   0.39 0.32 0.34 0.67 
CTSE cathepsin E   -0.78  -0.77 0.51 -0.27 -0.50 -0.74 0.94  
CXCL12 chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1)   -0.36  -0.31    -0.64  -0.38 
CXCL2 chemokine (C-X-C motif) ligand 2     0.47   0.43  1.64 1.84 
CYLD†† cylindromatosis (turban tumor syndrome) -0.61         0.39  
DAF decay accelerating factor for complement (CD55, Cromer blood group system) 0.87 1.66   0.61   0.93  1.51 1.78 
DEFA5 defensin, alpha 5, Paneth cell-specific   1.81 1.47 3.27  1.11 2.17 2.22  2.42 
DEFA6 defensin, alpha 6, Paneth cell-specific   1.01 1.03 2.03   1.61 1.34  1.51 
DMBT1† deleted in malignant brain tumors 1   1.23  1.82   1.63 1.64 1.35 2.99 
ECGF1 endothelial cell growth factor 1 (platelet-derived)    0.28 0.51   0.37  0.39 0.56 
EGLN3 egl nine homolog 3 (C. elegans) (Affymetrix probe: 222847_s_at)  0.51 0.41  0.59  0.56     
EGLN3 egl nine homolog 3 (C. elegans) (Affymetrix probe: 219232_s_at)  0.51       0.29  0.45 
ELF4 E74-like factor 4 (ets domain transcription factor)   -0.36  -0.45     -0.28 -0.53 
F2RL1 coagulation factor II (thrombin) receptor-like 1   -0.65  -0.65     -0.54 -0.80 
FAM3C family with sequence similarity 3, member C   -0.70  -0.77 0.55  -0.61 -1.07 0.74 -0.34 
FAS Fas (TNF receptor superfamily, member 6)   -0.50  -0.40 0.34   -0.51  -0.29 
FCGR3A Fc fragment of IgG, low affinity IIIa, receptor (CD16a)   0.29  0.45   0.38 0.30 0.64 0.94 
FCGR3B Fc fragment of IgG, low affinity IIIb, receptor (CD16b)   0.38  0.43     0.78 1.02 
FN1 fibronectin 1   -1.57  -1.58 1.04 -0.53 -1.05 -2.13 1.03 -1.10 
FTH1 ferritin, heavy polypeptide 1     -0.59   -0.73 -0.36 -0.29 -0.65 
GBP1 guanylate binding protein 1, interferon-inducible, 67kDa   0.48 0.53 1.01   0.70 0.47 0.93 1.40 
GBP2 guanylate binding protein 2, interferon-inducible    0.33 0.56   0.36  0.61 0.75 
GMDS GDP-mannose 4,6-dehydratase   0.39 0.32 0.72  0.45  0.82  0.78 
GNAQ Guanine nucleotide binding protein (G protein), q polypeptide   -0.46  -0.41      -0.30 
HAMP hepcidin antimicrobial peptide -0.59 -0.58          
HLA-A major histocompatibility complex, class I, A 1.12  0.29  0.36       
HLA-B major histocompatibility complex, class I, B 0.97 1.13   0.43   0.36  0.27 0.36 
HLA-DMB major histocompatibility complex, class II, DM beta    0.35 0.51   0.41  0.53 0.49 
HLA-DQA1 major histocompatibility complex, class II, DQ alpha 1 -0.56        -0.43 0.85 0.41 
HLA-DRA major histocompatibility complex, class II, DR alpha    0.65 0.80    -0.37 1.14 0.78 
HLA-E major histocompatibility complex, class I, E   0.32 0.33 0.65   0.48  0.51 0.77 
IER3 immediate early response 3 0.96 1.21          
IFITM1 interferon induced transmembrane protein 1 (9-27)  0.72 0.55 0.69 1.24   0.86 0.79 0.49 1.28 
IFITM2 interferon induced transmembrane protein 2 (1-8D)   0.33 0.50 0.83   0.59  0.87 1.11 
IFITM3 interferon induced transmembrane protein 3 (1-8U)   0.33 0.49 0.82   0.56  0.84 1.06 
IGH@ immunoglobulin heavy locus 2.46 3.32 0.64 0.47 1.11   0.70 0.47 0.60 1.07 
IGHA1 immunoglobulin heavy constant alpha 1   0.62 0.43 1.06   0.89  0.71 1.04 
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IGHD immunoglobulin heavy constant delta   0.46 0.75 1.21   1.15  1.01 1.35 
IGHG1 Immunoglobulin heavy constant gamma 1 (G1m marker) 3.32 3.32  0.50 0.73   0.81  1.15 1.37 
IGHM immunoglobulin heavy constant mu    0.96 1.61  1.16  0.90  1.12 
IGKC immunoglobulin kappa constant  1.77 0.59 0.49 1.08   0.89  0.91 0.99 
IGKV1-5 immunoglobulin kappa variable 1-5   0.58 0.83 1.41   0.90 0.44 0.86 1.29 
IGL@ immunoglobulin lambda locus   0.34  0.54 -0.42  0.62  0.36 0.33 
IGLC2 Immunoglobulin lambda variable 3-21   0.57 0.61 1.18   0.88 0.39 0.65 1.04 
IGLL1 immunoglobulin lambda-like polypeptide 1  0.96          
IL1R1 interleukin 1 receptor, type I 0.40           
IL1R2 interleukin 1 receptor, type II   -0.96  -1.41 0.71  -1.16 -0.86 -0.70 -1.56 
IL2RG interleukin 2 receptor, gamma (severe combined immunodeficiency)   -0.43  -0.66 0.39  -0.61 -0.34  -0.30 
ITGB2 integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; 
macrophage antigen 1 (mac-1) beta subunit) 
1.40 1.20   0.47     0.58 0.55 
LEFTY1 left-right determination factor 1   -0.89  -1.20   -0.79 -1.04  -0.79 
LTB4R2 leukotriene B4 receptor 2 -0.67           
MASP1 mannan-binding lectin serine protease 1 (C4/C2 activating component of Ra-reactive 
factor) 
-0.44           
MICA MHC class I polypeptide-related sequence A -0.49           
MYBL2 v-myb myeloblastosis viral oncogene homolog (avian)-like 2  0.43          
NMI N-myc (and STAT) interactor    0.29 0.46   0.27  0.31 0.55 
NOS2A nitric oxide synthase 2A (inducible, hepatocytes)  1.02  0.43 0.71   0.52  0.95 1.15 
OAS1 2',5'-oligoadenylate synthetase 1, 40/46kDa     0.29  0.38  0.68 -0.34 0.35 
P4HB procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), beta 
polypeptide (protein disulfide isomerase-associated 1) 
 1.24          
PDGFA platelet-derived growth factor alpha polypeptide   -0.61  -0.67  -0.74  -0.29  -0.44 
PLA2G2A phospholipase A2, group IIA (platelets, synovial fluid) 0.78 1.24       -1.21 1.88  
PROS1 protein S (alpha)   -0.32  -0.50 0.36  -0.53 -0.58  -0.33 
PSMB10 proteasome (prosome, macropain) subunit, beta type, 10    0.31 0.47     0.31 0.50 
PSMB8 proteasome (prosome, macropain) subunit, beta type, 8 (large multifunctional protease 
7) 
   0.36 0.59    0.29 0.51 0.80 
PSMB9 proteasome (prosome, macropain) subunit, beta type, 9 (large multifunctional protease 
2) 
  0.55 0.50 1.05   0.67 0.54 0.92 1.45 
PTGDS prostaglandin D2 synthase 21kDa (brain)    0.65 0.77    0.32 1.09 1.41 
PTGER4 prostaglandin E receptor 4 (subtype EP4)   -0.40  -0.47  -0.36  -0.49  -0.28 
PTN pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1)     -0.28    -0.68  -0.61 
REG3A regenerating islet-derived 3 alpha   1.33 1.52 2.84   2.07 1.67 0.98 2.65 
RNPEP arginyl aminopeptidase (aminopeptidase B) -0.45           
S100A8 S100 calcium binding protein A8 (calgranulin A)   0.91  1.49    0.78 1.92 2.70 
S100A9 S100 calcium binding protein A9 (calgranulin B)   0.34  0.56   0.44  0.80 1.07 
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SPINK5‡ serine protease inhibitor, Kazal type 5   -0.99  -1.49 1.06  -1.55 -1.59 1.43  
SPRED2 sprouty-related, EVH1 domain containing 2   -0.47  -0.51  -0.28  -0.41 -0.30 -0.71 
ST6GAL1 ST6 beta-galactosamide alpha-2,6-sialyltranferase 1   -0.37  -0.42   -0.27 -0.70 0.75  
TFF1 trefoil factor 1 (breast cancer, estrogen-inducible sequence expressed in)  1.61 -0.80  -0.89    -1.07 1.71 0.65 
THBS1 thrombospondin 1   -0.75  -1.02  -0.66  -0.79  -0.70 
TNFRSF11A tumor necrosis factor receptor superfamily, member 11a, NFKB activator   -0.33  -0.43 0.40  -0.50 -0.50  -0.32 
TNFRSF6B tumor necrosis factor receptor superfamily, member 6b, decoy 0.90 1.23        0.98 1.09 
TRBV21-1 T cell receptor beta variable 21-1    0.43 0.41   0.52  0.80 0.75 
UBD ubiquitin D    0.67 0.99  0.86   2.18 2.23 
VWF von Willebrand factor     0.40     0.67 0.90 
             
Oncogenesis, Cell Proliferation and Growth 
             
ADRA2A adrenergic, alpha-2A-, receptor   0.31  0.55   0.51 1.36 -0.98 0.38 
BHLHB3 basic helix-loop-helix domain containing, class B, 3   -0.49  -0.61  -0.35  -0.89 0.41 -0.48 
BST2 bone marrow stromal cell antigen 2   0.32 0.41 0.73   0.56  0.59 0.61 
BTG3 BTG family, member 3   -0.57  -0.70 0.36  -0.49 -0.88 0.35 -0.53 
CAPN1 calpain 1, (mu/I) large subunit  0.45          
CAPNS1 calpain, small subunit 1 0.31 0.44          
CCND2 cyclin D2   -0.56  -0.49  -0.44  -0.76  -0.55 
CCT2 chaperonin containing TCP1, subunit 2 (beta)   -0.38   0.43   -0.40  -0.31 
CD164 CD164 antigen, sialomucin   -0.50  -0.54   -0.38   -0.35 
CDK2AP1 CDK2-associated protein 1   -0.31   0.37  -0.27 -0.29 0.35  
CDK5RAP1 CDK5 regulatory subunit associated protein 1 -0.45           
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) -0.55           
CENPE centromere protein E, 312kDa  3.32          
CISH cytokine inducible SH2-containing protein -0.58           
CRIP1 cysteine-rich protein 1 (intestinal)   -1.31  -1.56  -1.37  -1.65 0.57 -1.09 
CSNK1D casein kinase 1, delta 0.62  -0.28  -0.29      -0.39 
CYLD cylindromatosis (turban tumor syndrome) -0.61         0.39  
DAB2 disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila) -0.41 -0.28 -0.27  -0.36 0.44  -0.53 -0.51  -0.41 
DKC1 dyskeratosis congenita 1, dyskerin   -0.38  -0.28 0.37   -0.40  -0.31 
DMBT1† deleted in malignant brain tumors 1   1.23  1.82   1.63 1.64 1.35 2.99 
DNAJB5 DnaJ (Hsp40) homolog, subfamily B, member 5 0.71           
DST dystonin   -0.41  -0.49 0.34  -0.42 -0.41  -0.38 
EIF4G2 eukaryotic translation initiation factor 4 gamma, 2   -0.40  -0.37 0.37  -0.34    
ELF4 E74-like factor 4 (ets domain transcription factor)   -0.36  -0.45     -0.28 -0.53 
FGFBP1 fibroblast growth factor binding protein 1   -0.34   0.49  -0.40    
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FGFR2 fibroblast growth factor receptor 2 (bacteria-expressed kinase, keratinocyte growth 
factor receptor, craniofacial dysostosis 1, Crouzon syndrome, Pfeiffer syndrome, 
Jackson-Weiss syndrome) 
  0.35  0.44    1.01 -1.23  
FGFR3 fibroblast growth factor receptor 3 (achondroplasia, thanatophoric dwarfism)   -0.27  -0.47  -0.27   -0.64 -0.70 
FHL1 four and a half LIM domains 1   -0.72  -0.58 0.55  -0.41 -0.57   
FTH1 ferritin, heavy polypeptide 1     -0.59   -0.73 -0.36 -0.29 -0.65 
GAS2 growth arrest-specific 2 -0.62 -0.54          
GCG glucagon   -1.64  -2.06 1.21  -1.63 -2.63 0.74 -1.89 
GMNN geminin, DNA replication inhibitor   -0.30  -0.32 0.34  -0.35  -0.37 -0.59 
GSPT1 G1 to S phase transition 1   -0.28   0.36   -0.41  -0.27 
HRASLS3 HRAS-like suppressor 3     0.37      0.44 
HSPA2 heat shock 70kDa protein 2   -0.33  -0.46   -0.47 -0.48  -0.35 
IFITM1 interferon induced transmembrane protein 1 (9-27)  0.72 0.55 0.69 1.24   0.86 0.79 0.49 1.28 
IGFBP2 insulin-like growth factor binding protein 2, 36kDa   0.84  1.12  0.47 0.64 1.82 -0.88 0.93 
IGFBP3 insulin-like growth factor binding protein 3   -0.66  -0.85   -0.54 -1.17  -0.95 
IL2RG interleukin 2 receptor, gamma (severe combined immunodeficiency)   -0.43  -0.66 0.39  -0.61 -0.34  -0.30 
INSIG1 insulin induced gene 1   -0.51  -0.39 0.84  -0.72 -0.43   
KLF4 Kruppel-like factor 4 (gut)   -0.55  -0.42 0.38    -0.32 -0.51 
KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog   -0.46  -0.55   -0.41 -0.46  -0.55 
LEFTY1 left-right determination factor 1   -0.89  -1.20   -0.79 -1.04  -0.79 
MACF1 microtubule-actin crosslinking factor 1   -0.32  -0.30    -0.42 0.34  
MYBL2 v-myb myeloblastosis viral oncogene homolog (avian)-like 2  0.43          
NDRG3 NDRG family member 3  -0.31          
NEDD9 neural precursor cell expressed, developmentally down-regulated 9 -0.71    -0.30   -0.40    
NME2 non-metastatic cells 2, protein (NM23B) expressed in 0.36           
PDGFA platelet-derived growth factor alpha polypeptide   -0.61  -0.67  -0.74  -0.29  -0.44 
PICALM phosphatidylinositol binding clathrin assembly protein -0.55           
PIM2 pim-2 oncogene     0.45   0.49  0.68 0.86 
PLA2G2A phospholipase A2, group IIA (platelets, synovial fluid) 0.78 1.24       -1.21 1.88  
PMP22 peripheral myelin protein 22   -0.58  -0.43  -0.54  -0.75 0.61  
PPP2CA protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform -0.57  -0.39  -0.28 0.28   -0.36   
PPP6C protein phosphatase 6, catalytic subunit     -0.35   -0.33   -0.40 
PRDX1 peroxiredoxin 1     0.45    0.43  0.38 
PRKD3 protein kinase D3  0.75          
PTN pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1)     -0.28    -0.68  -0.61 
PTP4A1 protein tyrosine phosphatase type IVA, member 1   -0.66  -0.73  -0.39  -0.33 -0.62 -0.95 
PYY peptide YY   -1.72  -2.49 1.58  -2.35 -3.09 0.54 -2.56 
QSCN6 quiescin Q6   -0.28  -0.47   -0.38 -0.50 0.65  
RABGAP1 RAB GTPase activating protein 1   -0.46  -0.59 0.33  -0.45 -0.55  -0.45 
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RAD1 RAD1 homolog (S. pombe) -0.41           
RASA1 RAS p21 protein activator (GTPase activating protein) 1 -0.48  -0.27  -0.28       
REG1A regenerating islet-derived 1 alpha (pancreatic stone protein, pancreatic thread protein)   1.72 1.58 3.30   2.96 3.62  4.35 
REG3A regenerating islet-derived 3 alpha   1.33 1.52 2.84   2.07 1.67 0.98 2.65 
ROCK1 Rho-associated, coiled-coil containing protein kinase 1 -0.57           
S100A11 S100 calcium binding protein A11 (calgizzarin)  0.64        0.75 0.48 
S100A6 S100 calcium binding protein A6 (calcyclin)  0.88          
S100P S100 calcium binding protein P  1.38       -1.05 2.07 1.02 
SFN stratifin   -0.72  -0.89  -0.51  -0.50 -0.37 -0.87 
SH3BP4 SH3-domain binding protein 4   -0.41  -0.42  -0.28  -0.39  -0.36 
STAG1 stromal antigen 1 -0.55 -0.39          
STAT1 signal transducer and activator of transcription 1, 91kDa    0.32 0.53   0.38  0.88 1.07 
TACC1 transforming, acidic coiled-coil containing protein 1   -0.61  -0.64  -0.46  -0.67  -0.46 
TFF1 trefoil factor 1 (breast cancer, estrogen-inducible sequence expressed in)  1.61 -0.80  -0.89    -1.07 1.71 0.65 
TIMP1 tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase 
inhibitor) 
1.23 2.04       -0.40 1.85 1.45 
TNFRSF11A tumor necrosis factor receptor superfamily, member 11a, NFKB activator   -0.33  -0.43 0.40  -0.50 -0.50  -0.32 
TSSC1 tumor suppressing subtransferable candidate 1 -0.59           
TXN thioredoxin   -0.37  -0.50   -0.48 -0.59  -0.40 
WARS tryptophanyl-tRNA synthetase    0.65 0.79   0.54  1.03 1.09 
WIT-1 Wilms tumor associated protein -0.54           
             
Structure and Permeability 
             
--- Transcribed sequences (N48794) -0.55           
ACTA2 actin, alpha 2, smooth muscle, aorta   -0.82  -0.50 0.67   -0.68 0.70  
ACTG2 actin, gamma 2, smooth muscle, enteric   -0.87  -0.64 0.63   -0.89 0.61  
ADD3 adducin 3 (gamma)   -0.66  -0.67  -0.48  -0.29 -0.40 -0.69 
ASPH aspartate beta-hydroxylase     -0.27 0.34  -0.38 -0.32 0.47  
C5 complement component 5 -0.51 -0.36          
CD58 CD58 antigen, (lymphocyte function-associated antigen 3)   -0.42  -0.42 0.30  -0.30 -0.40  -0.28 
CDH1 cadherin 1, type 1, E-cadherin (epithelial)   -0.37  -0.42      -0.38 
CEACAM1§ carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) 
(Affymetrix probe: 211883_x_at) 
 1.01   0.43  0.47  0.66  0.60 
CEACAM1§ carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) 
(Affymetrix probe: 209498_at) 
 1.01       0.77 -0.80  
CRYBA2 crystallin, beta A2   -0.28  -0.33    -0.45  -0.46 
DES desmin   -0.42  -0.33 0.32   -0.54 0.39  
DKFZp547A023 hypothetical protein DKFZp547A023 -0.72 -0.56          
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EPB41L4B 
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FAT 
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FMOD fibromodulin 
GJB3 
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KRT19 keratin 
MAP7 
MMP12 
MMP2 
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MUC1 
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MYL9 
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OCLN occludin 
PCDH21 protocadhe
PDLIM5 
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REG3A 
RPL22 
SPINK5
SPON1 
SPTBN1 
SYNE2 
THBS1 thrombospondin 
TIMP1 
TPM1 
TPM2 
TRAPPC4 
TUBB6 
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aining fibulin-like extracellular matrix protein 1   -0.70  -0.63 0.35 -0.35 -0.28 -1.02 0.72 -0.31 
erythrocyte membrane protein band 4.1 like 4B   -0.41  -0.69   -0.60  -0.71 -0.89 
epithelial V-like antigen 1   -0.37  -0.28 0.27   -0.31  -0.37 
FAT tumor suppressor homolog 1 (Drosophila)   -0.33  -0.40 0.35  -0.42 -0.29   
hypothetical protein FLJ25778 -0.41           
hypothetical protein FLJ36812 -0.51 -0.39          
  -0.31  -0.35 0.31  -0.35 -0.70 0.41 -0.29 
gap junction protein, beta 3, 31kDa (connexin 31)   -0.53  -0.64  -0.40  -0.84 0.35 -0.49 
GDP-mannose 4,6-dehydratase   0.39 0.32 0.72  0.45  0.82  0.78 
integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; 
macrophage antigen 1 (mac-1) beta subunit) 
1.40 1.20   0.47     0.58 0.55 
19   -0.60  -0.78   -0.51 -0.73 0.41 -0.32 
microtubule-associated protein 7   -0.30  -0.30 0.40  -0.40 -0.31  -0.42 
matrix metalloproteinase 12 (macrophage elastase)    0.94 1.14   0.99 0.78 1.36 2.14 
matrix metalloproteinase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) 0.99 0.85   0.33     0.71 0.80 
mitochondrial ribosomal protein S18A   -0.36  -0.41   -0.29 -0.43  -0.40 
mucin 1, transmembrane 0.75 0.80     0.32  -0.29 0.57 0.28 
mucin 13, epithelial transmembrane 0.43 0.71 -0.42  -0.29 0.37   -0.48 0.32  
mucin 2, intestinal/tracheal   -0.50  -0.69    -1.08 0.74 -0.34 
mucin 5, subtype B, tracheobronchial     -0.37 0.48  -0.58 -0.47   
myosin, light polypeptide 9, regulatory   -0.48  -0.34 0.44   -0.62 0.61  
  -0.33  -0.36    -0.55 0.44  
-0.42  -0.30  -0.33   -0.27 -0.27  -0.46 
rin 21   -0.36 -0.43 -0.79   -0.60 -0.73  -0.79 
PDZ and LIM domain 5 -0.57  -0.29         
protein kinase C, beta 1 -0.58          0.35 
regenerating islet-derived 3 alpha   1.33 1.52 2.84   2.07 1.67 0.98 2.65 
ribosomal protein L22     -0.32   -0.34   -0.45 
‡ serine protease inhibitor, Kazal type 5   -0.99  -1.49 1.06  -1.55 -1.59 1.43  
spondin 1, extracellular matrix protein   -0.88  -1.23 0.75  -1.10 -1.25 0.39 -0.86 
spectrin, beta, non-erythrocytic 1   -0.27  -0.39   -0.33 -0.34  -0.33 
spectrin repeat containing, nuclear envelope 2   -0.40  -0.55   -0.38  -0.43 -0.67 
1   -0.75  -1.02  -0.66  -0.79  -0.70 
tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase 
inhibitor) 
1.23 2.04       -0.40 1.85 1.45 
tropomyosin 1 (alpha)   -0.33  -0.34 0.36  -0.36 -0.38  -0.42 
tropomyosin 2 (beta)   -0.43   0.36   -0.68 0.68  
trafficking protein particle complex 4   -0.32  -0.35   -0.27 -0.44  -0.37 
tubulin, beta 6   -0.29      -0.52 0.66  
100
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villin 2 (ezrin)   -0.66  -0.53  -0.52  -0.42  -0.50 
von Willebrand factor     0.40     0.67 0.90 
           
re log2 ratios for all microarray comparisons; all displayed values are log2 ratio > 0.268 (greater than 1.2 fold change). Baseline group is always the second 
group listed in the column heading. For example, values in the column “CD_I-NC” are expressed as the log2 ratio value of CD_I with respect to NC group. A minus 
sign before the log2 ratio value indicates down-regulation with respect to baseline group. 
§ Log2 ratios for CEACAM1 from real-time PCR on extended cohort: CD_NI-NC (0.68); CD_I-CD_NI (no regulation); CD_I-NC (0.59); UC_NI-NC (0.62); UC_I-UC_NI 
(-0.74); UC_I-NC (no regulation); DC_NI-NC (no regulation); DC_I-DC_NI (no regulation); DC_I-NC (no regulation). 
†† Log2 ratios for CYLD from real-time PCR on extended cohort: CD_NI-NC (-0.66); CD_I-CD_NI (no regulation); CD_I-NC (-0.71); UC_NI-NC (-1.06); UC_I-UC_NI 
(no regulation); UC_I-NC (-1.07); DC_NI-NC (no regulation); DC_I-DC_NI (-0.76); DC_I-NC (-0.92). 
† Log2 ratios for DMBT1 from real-time PCR on extended cohort: CD_NI-NC (0.78); CD_I-CD_NI (2.88); CD_I-NC (3.66); UC_NI-NC (0.65); UC_I-UC_NI (2.76); 
UC_I-NC (3.41); DC_NI-NC (0.79); DC_I-DC_NI (2.94); DC_I-NC (3.73). 
‡ Log2 ratios for SPINK5 from real-time PCR on extended cohort: CD_NI-NC (no regulation); CD_I-CD_NI (no regulation); CD_I-NC (no regulation); UC_NI-NC (-
1.01); UC_I-UC_NI (1.25); UC_I-NC (no regulation); DC_NI-NC (no regulation); DC_I-DC_NI (no regulation); DC_I-NC (no regulation).  
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3.3.5 mRNA expression of genes involved in Wnt signaling in IBD 
 
To further investigate the role of the Wnt pathway in IBD, a comprehensive list of genes directly or 
indirectly involved in the Wnt signaling pathway was compiled using the Affymetrix pathway 
annotations and complemented by literature searching. Genes involved in the Wnt pathway may be 
divided into the following groups: A) upstream of Wnt (processing of wnt ligands or co-receptors); 
B) initiation of Wnt signaling (extracellular and integral membrane Wnt components); C) 
cytoplasmic Wnt signaling transduction; D) nuclear transcription of TCF/LEF; E) transcriptional 
targets of Wnt. The relative expression values of these genes on both the cDNA and Affymetrix 
microarrays are summarized in Table 3.23. 
Table 3.23  Microarray expression of genes associated with Wnt signaling* 
  CD log2ratio  UC log2ratio 
Gene symbol CD Probe id CD_NI-
NC 
CD_I-
CD_NI 
CD_I-
NC 
UC Probe id UC_NI-
NC 
UC_I-
UC_NI 
UC_I-
NC 
A. upstream of Wnt (processing of wnt ligands or co-receptors) 
ADAM12 204943_at - - - 204943_at - - - 
 28B08† NA NA - 28B08 NA NA 1.49 
FOXL1 216572_at - - - 216572_at - - - 
GPR177 221958_s_at -0.40 - -0.47 221958_s_at -0.32 -0.18 -0.50 
HS3ST1 205466_s_at - - - 205466_s_at - 0.17 - 
HS3ST4 228206_at - - - 228206_at - - - 
XYLT2 219401_at -0.16 - -0.15 219401_at -0.23 0.11 -0.12 
 231550_at -0.21 - -0.21 231550_at - - - 
         
B. initiation of Wnt signaling (extracellular and integral membrane Wnt components) 
CDH1 201130_s_at -0.49 - -0.37 201130_s_at - - -0.38 
CDH11 207173_x_at - - - 207173_x_at - 1.05 0.86 
 54E05† NA NA 0.67 54E05 NA NA 0.57 
DKK3 214247_s_at - - - 214247_s_at - 0.52 0.32 
FRZB 203697_at -0.24 -0.30 -0.54 203697_at -0.75 - -0.81 
 62O09† NA NA 0.61 62O09 NA NA 0.85 
FZD1 204451_at - - - 204451_at - - - 
FZD2 210220_at - - - 210220_at - - - 
FZD4 218665_at - - - 218665_at - - - 
 92H05 NA NA -0.45 92H05 NA NA - 
FZD6 203987_at - - - 203987_at - - - 
 18M23† NA NA -0.53 18M23 NA NA -0.40 
FZD7 203706_s_at - - - 203706_s_at -0.37 - -0.28 
FZD8 227405_s_at -0.26 - -0.32 216587_s_at - - - 
GPC3 209220_at - - - 209220_at 0.52 -0.40 - 
LDLR 202068_s_at -0.92 - -0.79 202068_s_at -1.07 0.61 -0.46 
LRP6 225745_at -0.14 - -0.23 205606_at - - - 
SDC1 201287_s_at - - - 201287_s_at - - - 
SFRP1 202037_s_at - - - 202037_s_at -0.40 - -0.27 
WNT4 230751_at - - - 208606_s_at - 0.20 0.20 
WNT5A 205990_s_at - - - 205990_s_at - 0.44 0.61 
         
C. cytoplasmic WNT signaling transduction 
APC 203527_s_at - - - 203527_s_at - - - 
ARHGEF10 216620_s_at - - - 216620_s_at - - - 
 47I05† NA NA 0.38 47I05 NA NA - 
AXIN1 212849_at - - - 212849_at - - - 
C2orf31 221245_s_at - - -0.47 221245_s_at - -0.74 -0.79 
CEACAM1 206576_s_at - - 0.48 206576_s_at 0.79 - - 
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  CD log2ratio  UC log2ratio 
Gene symbol CD Probe id CD_NI-
NC 
CD_I-
CD_NI 
CD_I-
NC 
UC Probe id UC_NI-
NC 
UC_I-
UC_NI 
UC_I-
NC 
 209498_at - - - 209498_at 0.77 -0.80 - 
 211883_x_at - - 0.43 211883_x_at 0.66 - 0.60 
 211889_x_at - - 0.44 211889_x_at 0.80 - - 
 71D13† NA NA - 71D13 NA NA 1.01 
CSNK1D 207945_s_at - - - 207945_s_at - - - 
CSNK1D 208774_at -0.28 - -0.29 208774_at -0.21 -0.18 -0.39 
 59L04† NA NA 0.62 59L04† NA NA - 
CSNK1E 226858_at - - - 222015_at - - - 
CTNNA1 200764_s_at - - - 200764_s_at - - - 
 200765_x_at - - - 200765_x_at - - - 
 210844_x_at -0.27 - -0.22 210844_x_at - - - 
CTNNB1 201533_at - - - 201533_at - - - 
 223679_at -0.19 - -0.17     
DAAM1 216060_s_at -0.33 - -0.34 216060_s_at -0.26 - -0.35 
DVL1 203230_at -0.19 - -0.21 203230_at - - - 
DVL2 57532_at - - - 57532_at - - - 
 18E06† NA NA -0.60 18E06† NA NA - 
DVL3 201908_at -0.25 - -0.30 201908_at -0.21 - -0.27 
FBXW2 209630_s_at -0.34 - -0.29 209630_s_at -0.30 - -0.28 
 91B05† NA NA - 91B05† NA NA 0.57 
FRAT2 209864_at - - - 209864_at - -0.27 -0.28 
GSK3B 226183_at - - -0.12 209945_s_at - - - 
 226191_at -0.19 - -0.23     
MAPK9 225781_at - - -0.21     
 203218_at -0.21 - -0.21 203218_at - - - 
MUC1 207847_s_at - - - 207847_s_at -0.56 0.88 - 
 211695_x_at - - - 211695_x_at -0.29 0.57 0.28 
 213693_s_at - - - 213693_s_at -0.52 0.92 - 
 22E24† NA NA 0.75 22E24† NA NA 0.80 
PAFAH1B1 200816_s_at -0.30 - -0.29 200816_s_at -0.15 -0.15 -0.30 
PLAU 205479_s_at - - - 205479_s_at - 0.73 0.64 
PPP2R5C 201877_s_at -0.27 - - 201877_s_at -0.20 - - 
PPP2R5E 203338_at -0.35 - -0.37 203338_at -0.49 - -0.38 
PRKCA 213093_at - - - 213093_at - -0.29 -0.20 
PRKCB1 209685_s_at 0.17 - 0.17 209685_s_at - 0.24 0.35 
 01M08† NA NA -0.59 01M08† NA NA - 
PRKCD 202545_at - - - 202545_at - -0.20 -0.17 
PRKCE 226101_at - - -0.10     
PRKCH 218764_at - - - 218764_at - 0.33 0.28 
 18L05† NA NA -0.39 18L05† NA NA - 
PRKCI 209678_s_at - - - 209678_s_at -0.21 - -0.32 
PRKCZ 202178_at - - - 202178_at - -0.31 -0.32 
RHOA 200059_s_at -0.24 - - 200059_s_at - - - 
VCL 200931_s_at -0.38 - -0.39 200931_s_at -0.38 - -0.27 
         
D. nuclear transcription of TCF/LEF 
CREBBP 202160_at - - - 202160_at -0.26 - -0.25 
CTBP1 203392_s_at -0.29 - -0.28 203392_s_at -0.42 - -0.47 
CTBP2 210835_s_at -0.36 - -0.38 210835_s_at -0.30 - -0.37 
HDAC1 201209_at -0.25 - - 201209_at - - - 
HDAC2 201833_at -0.19 - -0.14 201833_at - - - 
HDAC7A 217937_s_at - - 0.18 217937_s_at - - - 
LEF1 221558_s_at - - - 221558_s_at - 0.54 0.54 
TCF7L2 212759_s_at - - - 212759_s_at - -0.20 -0.23 
 212762_s_at - - - 212762_s_at - -0.28 -0.34 
 216035_x_at - - - 216035_x_at - -0.20 -0.23 
 216037_x_at - - - 216037_x_at - -0.19 -0.26 
 216511_s_at - - - 216511_s_at - - -0.27 
TLE1 203221_at -0.39 - -0.28 203221_at -0.34 - -0.23 
TLE2 40837_at -0.17 - -0.30 40837_at -0.26 -0.18 -0.44 
TLE3 212770_at - - -0.16 212770_at - - - 
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  CD log2ratio  UC log2ratio 
Gene symbol CD Probe id CD_NI-
NC 
CD_I-
CD_NI 
CD_I-
NC 
UC Probe id UC_NI-
NC 
UC_I-
UC_NI 
UC_I-
NC 
E. transcriptional targets of WNT 
CCND1 208712_at -0.30 - -0.26 208712_at -0.42 - -0.35 
CCND2 200951_s_at - - - 200951_s_at -0.28 0.34 - 
 200952_s_at -0.33 - -0.28 200952_s_at -0.23 - -0.15 
 200953_s_at -0.56 - -0.49 200953_s_at -0.76 0.21 -0.55 
CCND3 201700_at - - -0.20 201700_at - - - 
EMP3 203729_at - - - 203729_at -0.30 0.62 0.32 
EPHB2 209589_s_at -0.19 - -0.25 209589_s_at -0.23 - -0.23 
EPHB3 1438_at -0.29 - -0.30 1438_at -0.45 0.15 -0.30 
FOSL1 204420_at - - - 204420_at -0.21 0.19 - 
JUN 201465_s_at - - - 201465_s_at 0.16 - 0.14 
JUNB 201473_at - - - 201473_at - 0.37 - 
 22G16† NA NA 0.60 22G16† NA NA 0.69 
MYC 202431_s_at -0.39 - - 202431_s_at -0.35 - -0.22 
PPARD 37152_at - - - 37152_at - -0.27 -0.28 
VANGL2 226029_at -0.20 - -0.34     
         
* Significant log2 ratio values are shown from both the cDNA and Affymetrix microarrays. Baseline group is 
always the second group listed in the column heading. For example, values in the column “CD_NI-NC” are 
expressed as the log2 ratio value of CD_NI with respect to NC group. A minus sign before the log2 ratio value 
indicates down-regulation with respect to baseline group. All probes listed are from the Affymetrix arrays, 
unless indicated with a “†”—these probes originated from the cDNA arrays. A lone minus sign within a cell 
indicates that the probe was not significantly regulated. “NA” indicates that the comparison was not applicable 
for that probe id. 
 
Genes involved in processes preceding the initiation of Wnt signaling include those involved in 
ligand processing (proteases), heparin sulfate proteoglycan (HSPG) synthesis (sulfotransferase, 
xylosyltransferase), and transcription factors involved in modulating heparin sulfate proteoglycan 
levels (FOXL1). A recently characterized gene involved in intracellular processing of Wnt ligands, G 
protein-coupled receptor 177 (GPR177), was suggested to promote secretion of Wnt ligands by 
either directing proper secretion of Wnt or by post-translational modification of the Wnt ligand 
(Banziger et al., 2006; Bartscherer et al., 2006). Microarray analysis indicated that this gene was 
down-regulated in IBD (inflamed or non-inflamed) compared to normal controls, possibly indicating 
that Wnt ligand processing, and thus Wnt pathway activation, is reduced in CD and UC. Differential 
regulation of HS3ST1 and XYLT2, genes involved in HSPG synthesis, may indicate that different 
HSPG modifications are made in IBD mucosa, which could modulate Wnt signaling in a different 
manner compared to normal or non-inflamed mucosa. 
 
In contrast to events preceding Wnt signaling, many genes involved in signal transduction process 
have been well-characterized in the literature. Wnt signaling is initiated by binding of Wnt ligands to 
the Frizzled or LRP receptors. Wnt ligand binding can be inhibited by specific proteins (secreted 
frizzled-related proteins, Wnt inhibitory factor, dickkopf) and the presence of co-receptors (HSPG, 
KREMEN) may promote/inhibit Wnt ligand binding. The number and variety of Wnt ligands and 
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receptors and co-receptors for Wnt ligands is extensive. Over half of the 20 Wnt family ligand 
genes were detected as being ‘present’ on the microarrays, and interestingly, two Wnt genes 
involved in the non-canonical Wnt pathway, WNT4 and WNT5A were only differentially regulated in 
UC. In terms of colon maintenance, WNT4 and 5A inhibit proliferation and promote differentiation 
(Gregorieff et al., 2005). WNT5A up-regulation may be particularly relevant to IBD in light of the 
recent finding that WNT5A/FZD5 signaling is able to regulate anti-microbial response in human 
antigen presenting cells and macrophages (Blumenthal et al., 2006). 
 
At least 70% of the ten frizzled family of receptors (FRZ1-10) were detected on the arrays, and two 
genes were differentially regulated, FZD7 in UC and FZD8 in CD. Of the frizzled-related genes, 
which include 5 family members (SFRP1,2,4,5 and FRZB), 60% were detected and differential 
expression was monitored in FRZB (both CD and UC) and SFRP1 (only UC). The dickkopf (DKK1-
4) and dickkopf-like (DKKL1-2) family of genes, of which there are six members, is represented by 
the expression of three members on the arrays (DKK3, DKK4 and DKKL1), and DKK3 showed 
differential expression in UC. Known co-receptors of the Wnt pathway (KREMEN1 and 2, LRP5 
and 6) and potential modulators, including the heparin sulfate proteoglycan proteins (syndecan, 
perlecan and glypican), were detected. Of these, GPC3 was differentially regulated in UC. 
 
Nuclear members of the canonical Wnt signaling pathway (Groucho, CtBP, HDAC, CBP, TCF) 
were also generally down-regulated with respect to non-inflamed tissue (normal or IBD). In the 
inactive state, Groucho (official name: TLE1-4; transducin-like enhancer of split), CtBP (official 
name: CTBP1-2; C-terminal binding protein) and histone deacetylases (HDAC) repress 
transcription activation by TCF (Chinnadurai, 2002). Upon Wnt pathway activation, β-catenin 
translocates to the nucleus, and along with the co-activator CBP (official name: CREBBP; CREB-
binding protein), β-catenin displaces the repressor Groucho, and converts the repressor complex 
into a transcription activation complex (Logan and Nusse, 2004). As observed on the microarrays, 
down-regulation of the repressors CTBP1-2, TLE1-3, HDAC1,2,7A in IBD compared to normal 
controls favored activation of the Wnt pathway in IBD. 
 
In the comparisons between inflamed IBD and normal controls, it was also possible to incorporate 
microarray data from the cDNA microarray dataset, which consisted of a similar comparison 
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between inflamed IBD and hospitalized normal controls. Results from both array platforms were 
available for 14 of the Wnt signaling genes. For six genes (ADAM12, ARHGEF10, DVL2, JUNB, 
FZD6, FZD4), differential regulation was detected in the cDNA microarray only. In five cases, 
(PRKCH, FBXW2, CSNK1D, FRZB, PRKCB1), the regulation from the cDNA or the Affymetrix 
platform was in the opposite direction in one or both IBD subtypes. In the remaining three cases 
(CEACAM1, MUC1, CDH11) either or both IBD subtypes showed differential regulation in the same 
direction (up- or down-regulation) as the other microarray platform. 
 
The mRNA expression of Wnt pathway associated genes in an expanded real-time PCR cohort 
was further investigated in 27 genes from the microarray results in Table 3.24. In general, 
differentially regulated Wnt genes were heavily influenced by inflammation state—about 80% of 
Wnt genes quantitated in the extended cohort were differentially expressed in inflamed CD or UC 
compared to normal controls. As for comparisons between inflammation states of a particular 
disease group, most regulated genes were down-regulated in all diseases, and the UC group 
contained the most up-regulated genes (seven genes in total). Eight genes (ADAM12, CDH11, 
SFRP2, LEF1, TCF7L2, EMP3, JUNB and TCF4), representing 30% of the transcripts quantitated 
by real-time PCR, were specifically regulated in IBD, as no differential regulation was detected in 
the disease control group. 
 
Table 3.24  Relative mRNA transcript levels of Wnt pathway associated genes as determined 
by real-time PCR†
  CD log2ratio UC log2ratio DC log2ratio 
Gene symbol Assay ID CD_NI
-NC 
CD_I-
CD_NI 
CD_I-
NC 
UC_NI
-NC 
UC_I-
UC_NI 
UC_I-
NC 
DC_N
I-NC 
DC_I-
DC_NI 
DC_I-
NC 
A. upstream of WNT (processing of wnt ligands or co-receptors) 
ADAM12 Hs00291596_s1 - 0.28 0.39* - 1.16* 0.99* - - - 
FOXL1 Hs00534264_s1 -0.62* - -0.71* -0.78* - -0.74* - - -0.53 
 
B. initiation of WNT signaling (extracellular and integral membrane WNT components) 
CDH1 Hs00170423_m1 - -0.80* -0.89* -0.21 -0.72 -0.93* - -0.54 -0.63* 
CDH11 92E24_CDH11 - - 0.48 - 0.72 1.13* - - - 
FRZB AAX00559008s1 - -0.52* -0.33 - -0.49 -0.55* - -0.62* -0.59 
FRZB Hs00173503_m1 -1.11* -0.55 -1.66 -0.47 -1.35* -1.82* -1.44* - -2.08* 
FZD1 Hs00268943_s1 -0.27 -0.45 -0.72* -0.45 -0.79 -1.23* -0.35 - -1.17 
FZD2 Hs00361432_s1 - - - -0.23 0.42 - - - -0.81 
FZD7 Hs00275833_s1 - - -0.78 - -0.39 -0.98* -0.74 - -1.25 
SDC1 Hs00174579_m1 - -0.36 -0.38 -0.25 - -0.20 - -0.44 -0.52 
SFRP2 SERP2.1M1 - - 1.41 - 2.32 2.68* - - - 
 
C. cytoplasmic WNT signaling transduction 
APC Hs00181051_m1 - - -0.32 -0.27 -0.23 -0.50* -0.20 - -0.51 
ARHGEF10 Hs00206020_m1 -0.67* 0.32 -0.35 -0.78* 0.50* -0.28 -0.53* - - 
AXIN1 Hs00394718_m1 - -0.60* -0.76* - -0.57* -0.77* - -0.64 -0.83 
CSNK1D AAX00503624m1 - -0.15 -0.16* -0.23 -0.14 -0.36* - -0.56 -0.43 
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  CD log2ratio UC log2ratio DC log2ratio 
Gene symbol Assay ID CD_NI
-NC 
CD_I-
CD_NI 
CD_I-
NC 
UC_NI
-NC 
UC_I-
UC_NI 
UC_I-
NC 
DC_N
I-NC 
DC_I-
DC_NI 
DC_I-
NC 
CSNK1E Hs00266431_m1 -0.77* - -0.81* -0.72* - -0.51 -0.75* - -1.00 
CTNNA1 Hs00426996_m1 -0.43 - -0.59* -0.23 -0.51* -0.74* -0.24 - -0.39 
CTNNB1 Hs00170025_m1 -0.37* - -0.44* -0.42* - -0.41* - - -0.44 
DVL1 Hs00182896_m1 -0.60* - -0.62* -0.37 - -0.48* -0.40* - -0.59 
GSK3B Hs00275656_m1 -0.85* -0.21 -1.06* -0.55* -0.48* -1.03* -0.52* -0.45 -0.97* 
VCL Hs00243320_m1 -0.73* -0.31 -1.03* -0.71* - -0.85* -0.37 - - 
 
D. nuclear transcription of TCF/LEF 
LEF1 Hs00212390_m1 - 0.95 - - 0.88* 0.43 - - - 
TCF7 Hs00175273_m1 - - 0.57 - - - 0.58 - - 
TCF7L2 Hs00181036_m1 0.26 -0.89* -0.64* - - -0.38 - - - 
 
E. transcriptional targets of WNT 
EMP3 Hs00171319_m1 - - - - 0.40 0.56 - - - 
IL8 IL-8_ - 3.25 2.66 - 3.57 3.48 NA NA NA 
JUNB Hs00357891_s1 - - - - 0.72 - - - - 
TCF4 Hs00162613_m1 - - 0.49 - 0.47 0.78 - - - 
           
† Significant log2 ratio values (p<0.05) are shown from both the cDNA and Affymetrix microarrays. Baseline 
group is always the second group listed in the column heading. For example, values in the column “CD_NI-
NC” are expressed as the log2 ratio value of CD_NI with respect to NC group. A minus sign before the log2 
ratio value indicates down-regulation with respect to baseline group. A lone minus sign within a cell indicates 
that the probe was not significantly regulated. An asterisk indicates p<0.001 for that ratio.  The number of 
samples in each group range as follows: NC (12-25), inflamed CD (17-36), non-inflamed CD (16-32), inflamed 
UC (27-47), non-inflamed UC (8-30), inflamed DC (6-13), non-inflamed DC (17-27).  
 
3.3.6 mRNA expression of genes involved in barrier function 
 
Genes related to cellular junction were extracted from the GO annotations of the Affymetrix 
probesets and additional genes associated to known cell junction proteins were complemented by 
literature search. The genes were categorized into five categories: A) intercellular junction; B) tight 
junction; C) cell-cell adherens junction; D) cell-matrix junction; and E) other genes associated with 
barrier function. In cases where a gene was associated to multiple categories, the gene was 
classified by its most specific description, i.e. GO term furthest from the root term. The mRNA 
expression, as detected by cDNA and Aftfymetrix arrays, is depicted in Table 3.25.  
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Table 3.25  Microarray expression of genes associated with barrier function* 
  CD log2ratio  UC log2ratio 
Gene 
sym.bol 
CD Probe id CD_NI-
NC 
CD_I-
CD_NI 
CD_I-
NC 
UC Probe id UC_NI-
NC 
UC_I-
UC_NI 
UC_I-
NC 
A. intercellular junction 
CNN2 201605_x_at - - - 201605_x_at -0.10 0.28 0.17 
DLG1 202514_at -0.23 - -0.26 202514_at -0.21 - -0.23 
DLG5 201681_s_at -0.14 - -0.15 201681_s_at - - - 
DSC2 204750_s_at - - - 204750_s_at -0.23 - -0.40 
 204751_x_at -0.40 - -0.32 204751_x_at -0.23 -0.20 -0.43 
DSG2 217901_at -0.26 - -0.26 217901_at - - -0.25 
GJA1 201667_at - - - 201667_at -0.70 0.89 - 
GJB1 204973_at - - - 204973_at 0.25 -0.50 -0.25 
GJB3 205490_x_at -0.53 - -0.64 205490_x_at -0.84 0.35 -0.49 
 215243_s_at -0.40 - -0.44 215243_s_at -0.69 0.32 -0.37 
PDZK2 220303_at - - - 220303_at - -0.25 -0.15 
PECAM1 208982_at - - - 208982_at - 0.87 0.93 
 208983_s_at - - 0.37 208983_s_at - 0.77 0.90 
PKP2 207717_s_at -0.28 - - 207717_s_at - -0.38 -0.51 
PNN 212036_s_at -0.28 - -0.18 212036_s_at -0.21 - - 
 212037_at -0.32 - -0.29 212037_at -0.35 - -0.35 
STEAP1 205542_at - - - 205542_at 0.50 - 0.34 
VCL 200931_s_at -0.38 - -0.39 200931_s_at -0.38 - -0.27 
         
B. tight junction 
ALS2CR19 228411_at -0.16 - -0.23     
ARHGEF10 216620_s_at - - - 216620_s_at - - - 
ASH1L 226447_at - - -0.22     
C3orf4 208925_at -0.25 - -0.20 208925_at -0.23 0.19 - 
CASK 207620_s_at -0.25 - -0.21 207620_s_at -0.21 - -0.17 
CASK 211208_s_at -0.27 - -0.25 211208_s_at -0.20 - -0.27 
 60L19† NA NA -0.37 60L19† NA NA -0.46 
CDC42 208727_s_at - - - 208727_s_at - - - 
CLDN1 218182_s_at - - - 218182_s_at - - - 
CLDN15 219640_at - - - 219640_at - -0.32 -0.30 
CLDN3 203953_s_at -0.75 - -0.82 203953_s_at -0.47 -0.36 -0.83 
CLDN3 203954_x_at -0.52 - -0.67 203954_x_at -0.57 -0.28 -0.85 
 53N07† NA NA 0.56 53N07† NA NA - 
CLDN4 201428_at -0.55 - -0.72 201428_at -0.49 - -0.63 
 59O01† NA NA 0.77 59O01† NA NA - 
CLDN5 204482_at - - - 204482_at - 0.20 0.21 
CLDN7 202790_at -0.29 - -0.30 202790_at - -0.40 -0.35 
CLDN8 214598_at -1.57 - -2.09 214598_at -2.62 - -2.62 
CRB3 236279_at -0.24 - -0.36     
CSDA 201160_s_at -0.32 - -0.23 201160_s_at -0.33 0.26 - 
 201161_s_at - - - 201161_s_at -0.32 0.31 - 
CXADR 203917_at -0.79 - -0.85 203917_at -0.38 -0.17 -0.55 
 239155_at -0.22 - -0.29     
F11R 221664_s_at -0.33 - -0.19 221664_s_at - - - 
INADL 223681_s_at -0.23 - -0.30     
LIN7C 219399_at -0.22 - -0.17 219399_at - - - 
 221568_s_at -0.16 - -0.15 221568_s_at -0.13 -0.15 -0.28 
MAGI1 225465_at - - -0.22     
OCLN 209925_at -0.30 - -0.33 209925_at -0.27 -0.19 -0.46 
 38K23† NA NA -0.42 38K23 NA NA - 
PARD3 221526_x_at -0.27 - -0.30 221526_x_at -0.23 - -0.29 
PPP2CA 208652_at -0.39 - -0.28 208652_at -0.36 - -0.24 
 238719_at -0.11 - -0.11     
 33E15† NA NA -0.56 33E15† NA NA - 
PPP2CB 201375_s_at -0.39 - -0.35 201375_s_at -0.19 - -0.30 
PPP2R1B 202883_s_at -0.28 - -0.29 202883_s_at -0.15 -0.17 -0.32 
 202886_s_at -0.26 - -0.17 202886_s_at - - - 
 47O03† NA NA 1.11 47O03 NA NA - 
PPP2R2A 202313_at -0.24 - - 202313_at - - - 
 228013_at -0.16 - -0.13     
PPP2R3A 209633_at - - - 209633_at - -0.36 -0.28 
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  CD log2ratio  UC log2ratio 
Gene 
sym.bol 
CD Probe id CD_NI-
NC 
CD_I-
CD_NI 
CD_I-
NC 
UC Probe id UC_NI-
NC 
UC_I-
UC_NI 
UC_I-
NC 
PRKCA 213093_at - - - 213093_at - -0.29 -0.20 
PRKCD 202545_at - - - 202545_at - -0.20 -0.17 
PRKCH 218764_at - - - 218764_at - 0.33 0.28 
 18L05† NA NA -0.39 18L05 NA NA - 
PRKCZ 202178_at - - - 202178_at - -0.31 -0.32 
PTEN 228006_at - - -0.21     
RAB13 202252_at -0.25 - -0.22 202252_at -0.19 0.32 0.13 
ROCK1 230239_at - - -0.10     
 18N21† NA NA -0.57 18N21 NA NA - 
ROCK2 202762_at - - -0.22 202762_at -0.18 -0.14 -0.31 
TJP2 202085_at -0.36 - -0.27 202085_at - - -0.28 
TJP3 213412_at - - - 213412_at 0.31 -0.42 - 
 35148_at - - - 35148_at 0.20 -0.47 -0.27 
VAPA 208780_x_at -0.18 - -0.19 208780_x_at - - - 
WNK4 229158_at -0.25 - -0.37     
         
C. cell-cell adherens junction 
CDH1 201130_s_at -0.49 - -0.37 201130_s_at - - -0.38 
 201131_s_at -0.37 - -0.42 201131_s_at -0.14 -0.24 -0.38 
CDH11 207173_x_at - - - 207173_x_at - 1.05 0.86 
 54E05† NA NA 0.67 54E05 NA NA 0.57 
CDH17 209847_at - - - 209847_at - -0.30 -0.21 
CDH3 203256_at - - - 203256_at - 0.65 0.66 
CDH5 204677_at - - - 204677_at - 0.36 0.43 
CTNNB1 223679_at -0.19 - -0.17     
 201533_at - - - 201533_at - - - 
CTNND1 208407_s_at -0.38 - -0.48 208407_s_at -0.22 -0.40 -0.62 
DSP 200606_at -0.42 - -0.48 200606_at -0.27 -0.33 -0.60 
MLLT4 214939_x_at -0.20 - -0.13 214939_x_at - - - 
 224685_at -0.23 -0.24 -0.47     
PGM5 226303_at -0.21 - -0.24     
SDCBP 200958_s_at - - - 200958_s_at - 0.30 - 
TJP1 202011_at -0.47 - -0.52 202011_at -0.47 - -0.59 
 214168_s_at -0.23 - -0.15 214168_s_at - - - 
         
D. cell-matrix junction 
DST 212254_s_at -0.41 - -0.49 212254_s_at -0.41 - -0.38 
ERBB2IP 217941_s_at - - - 217941_s_at 0.35 -0.46 - 
SORBS1 218087_s_at -0.53 - -0.60 218087_s_at -0.80 - -0.63 
         
E. Other genes associated with barrier function 
CLTA 216295_s_at -0.18 - -0.15 216295_s_at - - - 
CLTC 200614_at -0.39 - -0.42 200614_at -0.26 - -0.35 
 22P10† NA NA -  NA NA 1.54 
FLNA 200859_x_at -0.27 - - 200859_x_at -0.45 0.40 - 
 213746_s_at - - - 213746_s_at -0.36 0.38 - 
 214752_x_at - - - 214752_x_at -0.49 0.43 - 
 67G22† NA NA -  NA NA 0.51 
ITM2C 221004_s_at -0.26 - -0.51 221004_s_at -0.54 - -0.59 
 55I12† NA NA 0.71 55I12 NA NA - 
MUC1 207847_s_at - - - 207847_s_at -0.56 0.88 - 
 211695_x_at - - - 211695_x_at -0.29 0.57 0.28 
PICALM 212506_at -0.23 - - 212506_at - - - 
 01A04† NA NA -0.55 01A04 NA NA - 
         
* Significant log2 ratio values are shown from both the cDNA and Affymetrix microarrays. Baseline group is 
always the second group listed in the column heading. For example, values in the column “CD_NI-NC” are 
expressed as the log2 ratio value of CD_NI with respect to NC group. A minus sign before the log2 ratio value 
indicates down-regulation with respect to baseline group. All probes listed are from the Affymetrix arrays, 
unless indicated with a “†”—these probes originated from the cDNA arrays. A lone minus sign within a cell 
indicates that the probe was not significantly regulated. “NA” indicates that the comparison was not applicable 
for that probe id. 
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The GO term intercellular junction (Table 3.25) is a broad category that includes genes involved in 
specialized regions that connect two cells. The gap junction family of genes form hemichannels, or 
connexons, which allow cell-cell communication in adjacent cells. Of 17 gap junction family 
members represented on the array, 14 were detected (CX36, CX40.1, GJA1, GJA3, GJA4, GJA5, 
GJA7, GJA8, GJB1, GJB2, GJB3, GJB4, GJB5, GJC1), and three genes (GJA1, GJB1, GJB3) 
were differentially regulated, mostly down-regulated in inflamed CD or UC samples compared to 
healthy controls. The desmoglein subfamily (DSG1-3) and plakophilins (PKP1 and 2) are involved 
in cell-cell junctions (desmosomes). DSG2 is represented by three probes on the Affymetrix 
microarray, each of which indicates different pattern of regulation in the six comparisons, probably 
due to different gene transcripts; however, in general, DSG2 was down-regulated in inflamed IBD 
compared to normal controls. Both plakophilins were detected by the arrays, but only PKP2 was 
differentially down-regulated in disease compared to normal controls. Other genes associated with 
cell adhesion and/or cell matrix interactions (Table 3.25) were also generally down-regulated in 
inflamed samples compared to normal controls. These include MAGUK family members DLG1 and 
DLG5, regulator of E-cadherin PNN, and cell matrix components VCL, DST and SORBS1. Within 
the intercellular junction group, the few genes that displayed a general up-regulation in inflamed CD 
and/or UC compared to non-inflamed samples include cell-adhesion receptor PECAM1, cell 
adhesion associated CNN2, and the cell-cell junction gene STEAP1. 
 
The tight junction complex is the most apical cell-cell barrier in the epithelial layer. Transmembrane 
proteins, such as the junctional adhesion molecule (JAM) and claudin (CLDN) families and occludin 
(OCLN), form contacts to adjacent cells. On the microarrays, 16/18 claudin family members were 
detected as being present on the array, and six claudin genes were differentially expressed in at 
least one IBD subtype. CLDN3,4,7,8 were down-regulated in inflamed compared to non-inflamed 
samples on the Affymetrix arrays, while CLDN5 was up-regulated. In contrast, the cDNA 
microarrays showed that CLDN 3 and 4 were up-regulated in inflamed CD compared to 
hospitalized normal controls. All three JAM genes were detected (F11R, JAM2, JAM3), and only 
F11R was differentially down-regulated in CD compared to normal controls. OCLN was down-
regulated in inflamed IBD compared to normal controls, a result which was replicated in the cDNA 
microarrays. Adaptor proteins, such as the tight junction (TJP) and membrane associated 
guanylate kinase (MAGI) families, interact between the transmembrane and cytoplasmic proteins 
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and serve to transmit signals to and from the tight junction. Tight junction genes TJP1-3 were all 
down-regulated in inflamed IBD compared to normals, while TJP3 was up-regulated in non-
inflamed UC compared to normal controls. Membrane associated guanylate kinases MAGI1-3 were 
only detected in CD, and MAGI1 was down-regulated in inflamed CD compared to normals. Finally, 
genes regulating tight junction assembly or paracellular permeability, including the protein 
phosphatase 2 (PPP2C and PPP2R), protein kinase C (PRKCD and PRKCZ) and the Rho-
associated, coiled-coil containing protein kinase genes (ROCK1 and 2), were down-regulated in at 
least one inflamed IBD subtype compared to normal controls or non-inflamed samples. RAS 
oncogene family member 13 (RAB13) and PRKCH were the only two genes with up-regulation in 
inflamed UC compared to non-inflamed samples. 
 
Many of the genes involved in cell-cell adhesion are represented by the cadherin and catenin 
families. From 17 cadherin family members on the Affymetrix arrays, 15 were present. CDH1 and 
17 were down-regulated in inflamed IBD compared to normal or non-inflamed samples. CDH 3, 5 
and 11 were up-regulated only in inflamed UC compared to non-inflamed UC or normal controls. 
The up-regulation of CDH11 in inflamed UC compared to hospitalized normal controls was 
replicated in the cDNA array, but additional gene regulation was observed for CD as well. Two 
forms of the catenin (cadherin-associated protein) family (CTNNB1, CTNND1) were down-
regulated (inflamed or diseased compared to non-inflamed or normal control) in the Affymetrix 
microarrays. 
 
Other genes associated with barrier function, either by endocytosis or association with known 
components of cell junction, include the clathrins or clathrin binding proteins (CLTA, CLTC, 
PICALM; generally down-regulated in disease compared to normal controls) and MUC1 and FLNA, 
which were both down-regulated in non-inflamed UC compared to normal controls but up-regulated 
in inflamed UC compared to non-inflamed UC. 
 
A select number of genes (23 genes) involved in barrier function were further investigated using 
real-time PCR in an expanded number of IBD samples, as well as in a cohort of inflamed and non-
inflamed disease controls (DC). Overall, 18 genes were down-regulated in either or both inflamed 
IBD subtypes compared to normal controls (Table 3.26). In four genes, up-regulation was observed 
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in either or both inflamed IBD subtypes compared to normal controls: CLDN1, CLDN2, CDH11 and 
MUC1. For TJP2 and CDH11, the observed up-regulation appeared to be specific to IBD, since no 
regulation was observed in any of the comparisons involving disease controls. Furthermore, the 
down-regulation in VCL, ARHGEF10, and ITM2C were observed in inflamed IBD but not in 
inflamed disease controls, possibly indicating that regulation of these genes is influenced by 
disease rather than general inflammation. On the other hand, all other genes (DLG5, CLDN1, 
CLDN2, CLDN3, CLDN4, CLDN7, OCLN, TJP1, TJP3, CHD1, CTNNA1, CTNNB1, ERBB2IP, 
CLTC, FNLA, MUC1, NRG1, SORBS3) were regulated in all inflamed disease (CD, UC, DC) 
samples compared to normal controls. 
 
Table 3.26  Relative mRNA transcript levels of gene associated with barrier function, as 
determined by real-time PCR†
  CD log2ratio UC log2ratio DC log2ratio 
Gene symbol Assay ID CD_NI
-NC 
CD_I-
CD_NI 
CD_I-
NC 
UC_NI
-NC 
UC_I-
UC_NI 
UC_I-
NC 
DC_NI-
NC 
DC_I-
DC_NI 
DC_I-
NC 
A. Intercellular junction 
DLG5 DLG5_A -0.50* - -0.53* -0.58* - -0.41* -0.68* - -0.75* 
VCL Hs00243320_m1 -0.73* -0.31 -1.03* -0.71* - -0.85* -0.37 - - 
 
B. Tight junction 
ARHGEF10 Hs00206020_m1 -0.67* 0.32 -0.35 -0.78* 0.5 * -0.28 -0.53* - - 
CLDN1 Hs00221623_m1 - 1.47* 1.27* - 2.00* 1.85* 0.62 - 1.62 
CLDN2 Claudin2.2s1 - 3.1* 3.52* - 4.86* 5.30* - 2.94 4.01* 
CLDN3 Hs00265816_s1 -0.51 -0.43 -0.94* -0.47* -0.64 -1.11* -0.56* - -0.54* 
CLDN4 Hs00533616_s1 -1.03* - -1.23* -1.15* -0.63 -1.78* -0.59 - -0.82* 
CLDN7 Hs00600772_m1 - -0.46* -0.63* - -0.85* -0.73* - -0.47 -0.46 
OCLN Hs00170162_m1 -0.48* -0.47 -0.95* -0.68* -0.72 -1.40* -0.54* -0.36 -0.90* 
TJP1 Hs00268480_m1 -0.91* -0.36 -1.28* -0.94* -0.46 -1.40* -0.70* - -0.96* 
TJP2 Hs00178081_m1 - 0.48 - - 0.58 0.56 - - - 
TJP3 Hs00274276_m1 - -0.21 -0.44 - -0.81* -0.82* - -0.56 -0.43 
 
C. Cell-cell adherens junction 
CDH1 Hs00170423_m1 - -0.80* -0.89* -0.21 -0.72 -0.93* - -0.54 -0.63* 
CDH11 92E24_CDH11 - - 0.48 - 0.88* 1.13* - - - 
CTNNA1 Hs00426996_m1 -0.43 - -0.59* -0.23 -0.51* -0.74* -0.24 - -0.39 
CTNNB1 Hs00170025_m1 -0.37* - -0.44* -0.42* - -0.41* - - -0.44 
 
D. Cell-matrix junction 
ERBB2IP Hs00180965_m1 - -0.34 -0.52 -0.38 -0.63 -1.01* - -0.76 -0.73 
 
E. Other genes associated with barrier function 
CLTC Hs00191535_m1 -0.52* -0.34 -0.86* -0.71* -0.37 -1.08* -0.38 - -0.41 
FLNA Hs00155065_m1 -1.64* - -1.62* -1.32* - -1.50* -1.31* - -1.33 
ITM2C ITM2C_1s_ -0.66 - -0.79* -0.61* -0.47 -1.08* -0.79* - - 
MUC1 Mucin(22E24) - 0.82 0.77 - 1.40* 0.94* - 1.11 0.65 
NRG1 Hs00247620_m1 -0.65 - -0.78* -1.04 - -0.49 -0.57 - -1.14 
SORBS3 Hs00195059_m1 - -0.94* -1.10* -0.39* -1.22 -1.61* -0.35 -0.81 -1.16* 
           
† Significant log2 ratio values (p<0.05) are shown from both the cDNA and Affymetrix microarrays. Baseline 
group is always the second group listed in the column heading. For example, values in the column “CD_NI-
NC” are expressed as the log2 ratio value of CD_NI with respect to NC group. A minus sign before the log2 
ratio value indicates down-regulation with respect to baseline group. A lone minus sign within a cell indicates 
that the probe was not significantly regulated. An asterisk indicates p<0.001 for that ratio. The number of 
samples in each group range as follows: NC (16-25), inflamed CD (29-36), non-inflamed CD (15-21), inflamed 
UC (16-25), non-inflamed UC (10-16), inflamed DC (4-9), non-inflamed DC (15-24). 
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4 Discussion 
 
The objective of this study was to identify novel genes involved in the pathogenesis of IBD. To this 
end, genome-wide microarray expression screening was employed to identify mRNA transcript 
differences between normal controls and different IBD disease states. In a first step, the two major 
types of microarray platforms, namely cDNA clone-based and oligonucleotide-based arrays, were 
compared using the same starting material. This initial experiment determined the extent of 
compatibility between results received from different platforms. Having established that quantitative 
results from different microarray platforms could not be directly combined, results from different 
experimental approaches were analysed separately. Comparing expression profiles from normal 
controls and inflamed/non-inflamed CD or UC yielded thousands of differentially expressed genes. 
To place these differentially regulated genes in a tangible context, Gene Ontology (GO) categories 
that were over-represented by the transcripts were elucidated, leading to the identification of the 
following three broad functional themes in IBD: immune and inflammatory response; oncogenesis, 
cell proliferation and growth; and structure and permeability. Additionally, two specific themes, 
namely Wnt signaling pathway and cell-cell adhesion, were also highlighted by GO analysis. Over 
50 transcripts involved in the specific themes and 15 transcripts involved in the broad themes were 
subject to real-time PCR quantitation in an extended cohort of IBD, disease controls and normal 
controls. 
4.1 Microarray comparison 
 
Microarray technology has rapidly evolved from high-density cDNA clone-based arrays to 
oligonucleotide-based arrays. In this study, these two main microarray platforms were compared 
using the same starting target RNA from human colonic mucosa biopsies. This study is the first to 
compare fluorescent and radioactively labeled platforms, probed with complex tissue, rather than 
homogenous cell lines (Mah et al., 2004). 
 
Using full-length clone sequences and publicly released Affymetrix probe sequences, an in-depth 
analysis of the probe sequences and their corresponding expression levels was carried out. The 
results clearly showed that there was no rank order correlation of either 1) mean expression values 
from matched probes between both arrays, irrespective of the probe-matching methods (through 
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UniGene or BLAST search of the Affymetrix probe database); or 2) individual expression values for 
each patient within a platform. Moreover, the overlap in detection of the same genes on both 
platforms, in terms of concordant present/absent calls, was only 60-68%. Less than 8% of the 
discordant calls could be attributed to clone sequencing errors or differences in probe design for 
the same gene, suggesting that other factors influenced the discordant call rate. 
 
All stages of the microarray experiment, from platform design, experimental conditions, spot 
quantitation, and further data processing, to the final gene expression values, may contribute to 
differences in expression results. The Affymetrix design bases its quantitation value on the 
difference in fluorescence between the 16 match and mismatch probe sets, whereas the clone-
based system uses the hybridization signal from a single clone spotted in duplicate. Each method 
has its disadvantages. The use of a difference between match and mismatch as a quantitative 
measure is potentially vulnerable to single base changes due to polymorphism or sequencing 
errors in the original sequence used for oligonucleotide design. As it is possible for a mismatched 
oligonucleotide to produce 5–54% signal of a perfect match (Okamoto et al., 2000), cross-
hybridization to mismatch oligonucleotides may result in an underestimation of gene expression. 
On the other hand, cDNA arrays are less sensitive to single base pair changes in the probe 
sequence because the spotted probe is longer (200–1500 bp), but they are more open to cross-
hybridization (i.e. gene families) and may contain latent non-specific sequence (i.e., repetitive 
elements) since the cDNA clones are not completely sequenced. Compared with the Affymetrix 
arrays, which are directly synthesized on glass under controlled reaction conditions (McGall et al., 
1996), cDNA probes may be subject to concentration variations due to printing effects and PCR 
amplification efficiency. The region of the gene represented by the probe may affect detected 
expression levels if the probes matched solely by UniGene cluster association detect different parts 
of the gene that are absent or poorly represented in target DNA, possibly due to alternative splicing 
or 3' bias in target labeling. Taken together, there are many opportunities for platform-specific 
biases to render cross-platform data incomparable. 
 
The microarray comparison was limited to the analysis of baseline quantitation of biological 
replicates and did not attempt to compare the arrays’ ability to detect changes in gene transcript 
levels. However, comprehensive analysis of the basic technique of hybridization alone shows that 
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there are many factors influencing microarray compatibility at a basal level, some of which may 
also influence differential gene analysis. Typically, microarrays are used to identify differentially 
expressed genes in an experimental setup that includes a group of arrays from two conditions 
(control and test condition), with the test and control samples being processed on the same array 
(in the case of two-color hybridization) or copies of the same array (as in the case of single-channel 
hybridizations). Usually, the differences are expressed as fold changes or log ratios for a single 
gene, rather than differences between different genes. Differences in a gene’s expression, not 
explicit levels of gene expression, are the final values reported. In theory, ratios should be a more 
reliable output than baseline expression signals, because the ratio of test to control samples 
reduces the effect of systematic platform variables such as spotted probe concentration, printing 
effects, and probe sequence and length. 
 
It should be noted that the aim of the microarray comparison was not to conclusively determine 
which platform outperformed the other. Such an endeavour would only be possible if microarray 
results could be compared to a "gold standard" on a large scale. As a cursory inquiry, absolute 
signal intensities from each array were compared to independent real-time PCR quantitation of 13 
selected genes. The rank order of the expression levels from the cDNA and oligonucleotide 
platforms showed a strong positive correlation (rs = 0.75 - 0.90) with the real-time PCR quantities in 
genes that were called "present" on the arrays. However, one cannot extrapolate these results, 
which were based on a small number of real-time assays, to conclude that this correlation is true 
for larger data sets. Contrary to other published comparisons, which matched cross-platform 
probes by gene name or homology to expressed sequence tags (ESTs), this study eliminated such 
variables as sequence ambiguity by basing the analysis on sequence-verified clones and fully 
sequenced clones, an important detail that was not adequately addressed in previous studies. No 
other microarray comparison has matched cross-platform microarray probes using the complete 
and exact probe sequence printed on the array. Additionally, this study did not restrict the analysis 
to a few selected genes of interest (i.e., highly up-regulated genes or those known to be involved in 
a specific process), but rather chose arbitrary genes in a non-hypothesis-driven fashion. Since 
large-scale analysis may involved whole gene sets, it is imperative to know whether cross-platform 
microarray data correlates as a whole, not just on a few select genes. 
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The results of the microarray comparison indicate that oligonucleotide-based arrays, such as those 
produced by Affymetrix, and full-length clone-based arrays may be too different in experimental 
design to give directly correlating results for the same genes. This suggests that microarray 
technologies should not be used as an absolute quantitation method and that pooling of global 
expression profiles from different microarray platforms for the purposes of large-scale data mining 
should be undertaken with caution. The observation that there is only moderate overlap in genes 
that are called "present" and no correlation in the expression levels from each platform 
necessitates complementary approaches to confirm findings solely based on microarray data (Mah 
et al., 2004). 
4.2 Expression profiling in inflammatory bowel disease 
 
The pathology of IBD is influenced by various factors, including genetic and environmental factors, 
which contribute to an inappropriate immune response in the lower gastrointestinal tract. To date, 
genetic linkage and association studies have identified sequence variants that confer disease 
susceptibility, with the strongest association being found in CARD15 for CD and lesser associations 
in SLC22A4 and SLC22A5 for CD, AGR2 and MUC3 for UC, and DLG5 and NR1I2 for IBD (Dring 
et al., 2006; Hugot et al., 2001; Kyo et al., 1999; Peltekova et al., 2004; Stoll et al., 2004; Waller et 
al., 2006; Zheng et al., 2006). At the mRNA level, genome-wide expression screening has the 
potential to reveal disease-relevant genes by comparing expression profile snapshots of different 
disease states. Previous microarray expression studies in IBD have highlighted the dysregulation of 
the REG gene family (Dieckgraefe et al., 2000; Lawrance et al., 2001) and detoxification genes 
(Langmann et al., 2004). 
 
In this thesis, two experimental approaches were used to investigate differential transcription 
profiles in IBD. In the first setup, cDNA microarrays were used to differentiate mRNA transcript 
expression between patients with active IBD and hospitalized normal controls. A particular 
advantage of this cohort was that all individuals in the cohort were accustomed to the hospital 
environment. In contrast, the second experimental setup compared active and non-active IBD 
hospitalized patients to healthy normal controls who were not currently hospitalized. However, it 
should be noted that both hospitalized normal controls and healthy normal controls were treated in 
the same manner throughout the colonoscopy procedure, except that the healthy normal controls 
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were given an enema if required. The patient cohort of the second experimental setup was 
advantageous due to the fact that macroscopically non-inflamed IBD samples compared to healthy 
normal controls could reveal IBD-specific effects independent of inflammation (CD_NI-NC or 
UC_NI-NC comparisons). Additionally, IBD-specific inflammation effects could be revealed by the 
comparison between inflamed and non-inflamed IBD (CD_I-CD_NI or UC_I-UC_NI), and 
cumulative effects between active IBD and healthy normal controls could be observed (CD_I-NC or 
UC_I-NC). Finally, the second experimental setup contained a number of inflamed and non-
inflamed samples from the same patient, thereby eliminating noise due to inter-individual 
differences such as bacterial flora or genetic background. 
 
The comparison between active IBD and hospitalized normal controls on cDNA microarrays 
identified 650 differentially regulated genes, with 500 and 272 regulated transcripts from the 
comparison between hospitalized normal controls and CD or UC, respectively. Interestingly, there 
was an imbalance in the proportion of genes that were dysregulated—approximately 84% of the 
differentially regulated genes were down-regulated in CD, compared to 42% down-regulated in UC. 
However, this result cannot be interpreted to infer that a broad up-regulation in UC and broad 
down-regulation in CD are distinguishing features of the two subtypes, since the genes found are 
highly influenced by the types and numbers of genes present on the particular microarray platform 
that was used. Of the overlapping 122 genes that were dysregulated in both CD and UC, none 
were found to be regulated in opposite direction. 
 
Using Affymetrix-based arrays, the comparison of inflamed or non-inflamed IBD and healthy normal 
controls identified thousands of differentially regulated transcripts. The greater number of 
differentially regulated transcripts in this experimental setup is partly due to the fact that the 
oligonucleotide probes did not have to be verified by cDNA clone sequencing, which was a 
necessary and limiting step in the cDNA microarray protocol. There was also a markedly greater 
number of differentially regulated transcripts for the CD comparison than the UC comparison, since 
the CD dataset derived from two Affymetrix chips (U133A and B), while results were only available 
from chip U133A in the UC dataset. In all comparisons where IBD was compared to healthy normal 
controls, 63%-92% of the regulated transcripts were down-regulated compared to normal controls. 
However, in the comparisons between inflamed and non-inflamed within an IBD subtype, 58% of 
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the differentially regulated transcripts were up-regulated (with respect to non-inflamed) in both CD 
and UC, which suggests that disease-specific inflammation results in a broad up-regulation of 
genes, at least on these Affymetrix arrays (HG-U133). Of transcripts that were differentially 
regulated in both CD and UC for the three analogous comparisons (non-inflamed IBD vs. healthy 
normal controls, inflamed IBD vs. non-inflamed IBD, and inflamed IBD vs. healthy normal controls), 
only a handful of transcripts were regulated in the opposite direction. Of 1487 transcripts 
differentially regulated in both the non-inflamed IBD subtypes vs. healthy normal controls (CD_NI-
NC and UC_NI-NC), only six genes were oppositely regulated (C14orf43, ATP5F1, DLD, RAB5C, 
RRAS2, SRRM2), but the fold changes were lower than 1.2-fold in at least one of the comparisons. 
With respect to disease-specific inflammation, there were 122 overlapping transcripts in the 
inflamed IBD vs. non-inflamed IBD comparison (CD_I-CD_NI and UC_I-UC_NI), and very 
interestingly, eight transcripts were oppositely regulated. CHST5, HOXB13, LGALS2, WFDC2, and 
HOXB6 were differentially regulated with changes greater than 1.2-fold in their respective IBD 
subtype, while S100A10, SPON1, and CDK2AP2 experienced changes lower than 1.2-fold. In the 
last comparison between inflamed IBD and healthy normal controls (CD_I-NC and UC_I-NC), 11 
genes were oppositely regulated (ASPN, GSN, PARP8, QSCN6, RAB13, RAB27A, RAB5C, 
RDH11, TFF1, FGFR2, PAPSS2). However, these opposing microarray results should not be taken 
at face value, as one of these genes, TFF1, though it was regulated greater than 1.2 fold, was 
shown not to be oppositely regulated in CD and UC in real-time PCR experiments. Together with 
the cDNA microarray results, these results show that although there are genes that are differentially 
regulated in one subtype but not the other, diametrically opposite regulation of the same genes in 
CD and UC was quite rare, and in one case, not verifiable by real-time PCR in an extended cohort 
of samples. This observation supports the notion of a shared general inflammation profile 
underlying two clinically divergent forms of IBD. 
4.2.1 Broad functional themes in the pathology of IBD 
 
Interpreting the functional consequences of changes in gene expression observed in microarray 
expression screening is one of the major goals of exploratory microarray data analysis. One 
method used to attempt functional interpretation of microarray data is the use of annotation-based 
pathway databases such as Gene Ontology (GO). The use of GO does have its limitations, in 
particular the amount and quality of annotation (Fraser and Marcotte, 2004), but it does allow a 
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broad overview of terms to decipher gene pathways. In the present study, GO terms were 
supplemented with literature references to yield the classification of differential expression of genes 
from all microarray results. Differentially regulated genes were classified into three major groups: 
immune and inflammatory response; oncogenesis, cell proliferation and growth; and structure and 
permeability. 
4.2.1.1 Immune and inflammatory response 
 
The intestinal mucosa represents a key barrier between the hostile environment of pathogenic 
luminal antigens and internal tissues. It is no surprise that the IBD mucosa, compared to normal 
controls (healthy or hospitalized normal controls), exhibits differential regulation of many immune-
related genes. In both subtypes, many genes which code for proteins with immunoglobulin receptor 
function, including (BST2, IGH@, IGHG1, IGKC, IGLL1, IGKV1-5, IGLC2, IGHA1, IGHD, IGL@, 
IGHM, FCGR3B and CD79A), were up-regulated in inflamed IBD compared to normal controls or 
non-inflamed IBD. Similarly, genes involved in antigen presentation (HLA-A, HLA-B, HLA-E, HLA-
DMB, HLA-DRA, PSMB10) or anti-bacterial peptides (DEFA5, DEFA6) were largely up-regulated in 
inflamed IBD compared to non-inflamed IBD or normal controls. The acute phase response genes 
C5 and FTH1 were down-regulated, while CFB and C2 were up-regulated in inflamed compared to 
non-inflamed samples. However, some of the aforementioned genes (IGLC2, IGH@, IGHG1, 
DEFA5, DEFA6, HLA-A, HLA-E, HLA-DRA, CFB, C2) did demonstrate up-regulation between non-
inflamed IBD and normal controls, which may indicate that macroscopically non-inflamed mucosa 
maintained residual molecular traces of an immune response. 
 
Of particular interest in this group, cylindromatosis (turban tumor syndrome) (CYLD) is a tumour 
suppressor and negative regulator of nuclear factor-kappa B (NF-kB) (Neurath et al., 1996; Rogler 
et al., 1998; Schreiber et al., 1998), a key transcription factor which regulates adaptive and innate 
immune responses. In vitro investigations into the regulation of CYLD have revealed that CYLD is 
part of an autoregulatory control mechanism for TNFR-induced NFkB activation. In this pathway, 
TNF up-regulates CYLD, which in turn leads to down-regulation of NF-kB signaling (Jono et al., 
2004; Yoshida et al., 2005). Recent in vivo studies have demonstrated that CYLD is a deubiqitation 
enzyme with different effects. In one study, CYLD regulates cell growth and proliferation by 
deubiquitinating Bcl-3 in keratinocytes, leading to degradation of Bcl-3 and preventing its co-
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activation with NFkB (Massoumi et al., 2006). Another study showed that CYLD participates in T-
cell development by regulating T-cell receptor signaling in T-cell clonal selection (Reiley et al., 
2006). Despite its involvement with NFkB regulation, CYLD has not yet been examined in IBD. In 
the present study, microarray analysis showed that the tumour suppressor CYLD was down-
regulated in CD compared to hospitalized normal controls and up-regulated in inflamed UC 
compared to non-inflamed UC. Real-time PCR analysis showed that CYLD was in fact down-
regulated in both inflamed CD and UC compared to normal controls. Down-regulation was also 
observed in non-inflamed CD and UC compared to normal controls, showing that its regulation was 
dependent on disease but not on inflammation. Potentially, deficient amounts of CYLD transcript 
precede active inflammation and perpetuate inflammation by insufficient down-regulation of NFkB 
in IBD. 
 
Another gene with a dual immune/tumour function is deleted in malignant brain tumors 1 (DMBT1). 
DMBT1 was originally identified as a scavenger receptor with tumour suppressor properties, since 
its absence or reduction in expression was observed in different cancers (Braidotti et al., 2004; Wu 
et al., 1999). Two main functions for DMBT1 have been suggested, including mucosal defence and 
epithelial differentiation (Kang and Reid, 2003); however, to date, no role for DMBT1 has been 
suggested in the pathogenesis of IBD. Real-time PCR shows that DMBT1 transcript is strongly up-
regulated (log2 ratio ≥ 2.76) in inflamed mucosa of any disease state (CD, UC or DC) compared to 
any non-inflamed mucosa (IBD or normal control). DMBT1 is also up-regulated to a lesser extent 
(log2 ratio ranges from 0.65 to 0.79) in non-inflamed IBD or disease controls compared to normal 
controls (Table 3.22, footnote), indicating that the up-regulation is evident in all disease states. On 
the microarrays, immunosuppressive treatment appears to reduce DMBT1 expression to normal 
levels, as no significant regulation is detected between immunosuppressive treated CD patients 
and non-inflamed CD or normal controls. Though there is no clear function for DMBT1, a peptide 
from a splice variant of DMBT1 was found to have the ability to bind various bacterial species 
(Bikker et al., 2002), suggesting its function as an innate immunity receptor. Alternatively, DMBT1 
up-regulation in IBD may reflect an increase in epithelial restitution in response to damage, since a 
porcine splice variant of DMBT1, CRP-ductin, has been suggested as a receptor for trefoil factor 
(Thim and Mortz, 2000), which is highly expressed in the intestine and promotes healing (Taupin 
and Podolsky, 2003). 
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Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) has roles including 
negative regulation of epithelial cell growth, differentiation, neutrophil activation and most 
interestingly, negative regulation of Th-1 mediated inflammation in a mouse colitis model (Chen et 
al., 2004; Iijima et al., 2004; Izzi et al., 1999; Rubel et al., 2001). The microarrays detected up-
regulation of CEACAM1 in inflamed CD or UC compared to normal controls and in non-inflamed 
UC compared to normal controls (Table 3.22). Real-time PCR detected significant up-regulation of 
CEACAM1 transcript in inflamed CD, but interestingly, not in inflamed UC compared to normal 
controls (Table 3.22, footnote). Up-regulation of CEACAM1 was also detected in non-inflamed 
CD/UC compared to healthy controls (Table 3.22, footnote). Conversely, one microarray probeset 
(209498_at) and real-time PCR showed down-regulation in inflamed UC compared to non-inflamed 
UC. Consistent detection of CEACAM1 transcript was complicated by the fact that multiple splice 
variants of CEACAM1 were detected by the microarray and real-time probes; however, there was 
consistent up-regulation in CD (inflamed or non-inflamed) compared to normal controls, thus 
pointing to unique up-regulation due to the CD condition. In addition, immunohistochemical staining 
of mucosal sections (Figure 3.12, Panel A) showed that infiltrating immune cells in the lamina 
propria were stained by anti-CEACAM antibody in CD, but not in UC, further suggesting the 
importance of CEACAM1 in the pathology of CD. As the mechanism by which CEACAM1 regulates 
T-cells does not occur at the transcript level, but rather involves phosphorylation of the protein 
and/or interaction with other CEACAM molecules (Chen et al., 2004; Iijima et al., 2004), increased 
transcript levels could result in an over-expression of the short form of CEACAM1 protein, which is 
a co-stimulatory receptor in T-cell regulation, over the long form of CEACAM1, which is an 
inhibitory receptor. As a consequence, the short form could dominate over the long form of 
CEACAM1, resulting in a Th-1 cell driven response in CD. 
 
4.2.1.2 Oncogenesis, cell proliferation and growth 
 
The intestinal epithelium is one of the most rapidly self-renewing tissues in the body, making it 
more susceptible to malignant transformation. Inflammation is characterized by expression of 
chemotactic factors, growth factors, and proteases which facilitate leukocyte migration and healing 
at the site of injury. The normal intestinal epithelium is under a state of controlled inflammation, 
such that an immune response is invoked by pathogenic antigens, yet commensal bacteria are 
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tolerated. Within the context of IBD, abnormal processes in tissue renewal, either through normal 
epithelial maintentance or tissue injury, and chronic inflammation, increase the potential for cancer 
to develop. Dysregulation of genes, which either promote tumour progression or ultimately fail to 
suppress tumours, is of particular interest in IBD, as there is an increased risk of developing 
colorectal carcinoma in UC (Brostrom et al., 1987; Ekbom et al., 1990). Tumour progression genes 
in this group include TIMP1 and members of the S100 calcium binding protein family (S100A6, 
S100A11 and S100P), whose expression promotes cell proliferation and survival and are 
associated with tumor progression in pancreatic and colon cancers (Arumugam et al., 2004; 
Bronckart et al., 2001; Holten-Andersen et al., 2004; Komatsu et al., 2002; Melle et al., 2005). 
These genes show an up-regulation on the microarrays, primarily in inflamed UC compared to non-
inflamed controls. The up-regulation of TIMP1 expression in inflamed IBD compared to normal 
controls was confirmed by real-time PCR (Figure 3.10). 
 
Trefoil factor 1 (TFF1) has both tumour suppressor and tumour progression properties (Emami et 
al., 2004), in addition to a regenerative role in the gut, which specifically promotes epithelial cell 
migration without apoptosis in response to injury (Vieten et al., 2005). Microarray expression results 
from both cDNA and Affymetrix arrays show up-regulation in TFF1 in inflamed UC compared to the 
respective control group, while in CD, significant down-regulation was detected in CD compared to 
healthy normal controls on the Affymetrix arrays but not on the cDNA arrays (Table 3.22). In the 
real-time PCR cohort comparing active IBD to hospitalized normal controls, the up-regulation in 
active UC was confirmed (Figure 3.10), while no regulation was observed in the CD or disease 
controls. This may suggest that TFF1 expression in inflamed UC mucosa may play a specific role in 
TFF1 tumour progression, in accordance to a previous report showing that TFF1 protein expression 
is significantly over expressed in UC-associated colorectal adenocarcinoma compared to normal 
mucosa (Hirota et al., 2000). 
 
Finally, within this category, the Wnt pathway is of interest since inappropriate activation is a 
common signaling abnormality in human cancers (Ergun et al., 2000; Hauck, 2002). As members of 
the casein kinase I gene family (CSNK1) have been implicated in the regulation of Wnt-targeted 
gene expression (Amit et al., 2002; Liu et al., 2002), both transcript levels and 
immunohistochemical protein localization were examined in IBD biopsies. Real-time PCR results 
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indicate that CSNK1D was down-regulated in all UC comparisons, while in CD, down-regulation 
was only observed for comparisons involving inflamed CD (Table 3.24). Immunohistochemistry 
staining of the mucosa (Figure 3.12, Panel C) showing basolateral staining of CSNK1D in normal 
and active UC epithelial cells, but only faint staining in the crypts of CD, may imply a role for Wnt 
signaling, especially in UC pathogenesis. 
4.2.1.3 Structure and permeability 
 
The intestinal epithelial barrier, in terms of a physical barrier of surface glycocalyx and a layer of 
epithelial cells, prevents luminal contents, such as bacteria and viruses from transversing the 
epithelial layer. Impaired barrier function makes the gut vulnerable to microbial invasion and 
invokes an immune response. In some respects, IBD can be thought of as being caused by chronic 
inflammation produced by a vicious circle of barrier breach and immune response, perpetuated by 
inefficient healing and re-infection by luminal contents (Clayburgh et al., 2004; Korzenik, 2005). 
Several genes in this category were ubiquitously regulated in both IBD and non-IBD samples, 
reflecting known gene dysregulation in disease where inflammation and wound healing are 
recurrent events. These include paracellular permeability (down-regulation of OCLN, Figure 3.10) 
(Kucharzik et al., 2001), degradation of extracellular matrix (up-regulation of TIMP1 and MMP2, 
Figure 3.10 and Table 3.3, respectively) (Massova et al., 1998; von Lampe et al., 2000) and barrier 
protection against bacterial invasion of the epithelial surface (up-regulation of MUC1, Figure 3.10) 
(Carraway et al., 2003). 
 
Furthermore, the present study identified several genes (CDH11, transcripts represented by 
N48794 and AF087994, SPINK5, PDLIM5 and ROCK1) that were novel within the context of IBD. 
Members of the cadherin superfamily, integral membrane proteins that mediate calcium-dependent 
cell-cell adhesion, have been shown to be involved in epithelial cell migration and resealing the site 
of tissue damage in the intestinal mucosa (Wilson and Gibson, 1997). Up-regulation of cadherin 11 
(CDH11) in both IBD subtypes, but not in inflamed non-IBD tissue (Table 3.26), furthers speculation 
that this member of the cadherin family could also be involved in IBD-specific restructuring 
processes in the intestinal mucosa. Continuing with the structure theme, two uncharacterized 
transcripts (GenBank accession numbers N48794 and AF087994), which were assigned a role in 
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cell-cell adhesion (one of them containing cadherin repeats), were also found to be differentially 
regulated (Table 3.4). 
 
Genes which are involved in extracellular matrix maintenance or cell-cell adhesion have the 
potential to impair barrier function when dysregulated. One such gene is serine peptidase inhibitor, 
Kazal type 5 (SPINK5), which borders the IBD5 locus on 5q31. IBD5 contains many susceptibility 
genes, including clusters of cytokines and transporters, and an association to CD was shown 
(Rioux et al., 2001), though no one causal gene has been identified. SPINK5 has been postulated 
to provide anti-microbial protection of the mucosal epithelia (Magert et al., 1999), regulate 
differentiation of T-lymphocytes, or regulate extracellular matrix remodeling (Chavanas et al., 
2000). Already implicated in Netherton Syndrome (NS), the lack of SPINK5 allows unrestricted 
serine protease activation and eventual degradation of the stratum corneum, resulting in impaired 
barrier function (Hachem et al., 2006). In the present study, the microarrays showed that 
transcription of this gene was down-regulated in both non-inflamed IBD subtypes compared to 
normal controls; however, real-time PCR on an extended patient cohort confirmed differential 
regulation in UC, but not in CD or disease controls (Table 3.22, footnote). There was no difference 
detected between inflamed UC and normal controls, but SPINK5 transcript was down-regulated in 
non-inflamed UC compared to normal controls. A down-regulation in SPINK5 could possibly allow 
unlimited digestion of the extracellular matrix, thereby compromising the epithelial barrier and 
allowing bacteria to induce prolonged inflammation responses. 
 
Cell migration in response to wound healing is regulated in part by cell adhesion processes, such 
as Rho-ROCK-mediated cytoskeletal reorganization (Kuroda et al., 1996; Nakagawa et al., 2000). 
Interestingly, members of this pathway, ROCK1 and PDLIM5, were down-regulated in both IBD 
subtypes (but not in inflamed DC) in the real-time PCR experiments using hospitalized normal 
controls, which might indicate a potential decline in cell migration and an impaired ability to 
maintain epithelial integrity in IBD. Furthermore, immunohistochemistry staining of PRKCB1, which 
has been shown to interact with PDLIM5 (Kuroda et al., 1996), showed that lamina propria cells 
were preferentially stained in UC, but not CD or normal controls, possibly indicating a unique role 
for this protein in UC. Interestingly, a genetic variant in DLG5, which was recently associated with 
IBD (Stoll et al., 2004), is a PDZ-containing scaffolding protein that associates with beta-catenin 
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and is a binding partner of vinexin at cell-cell contacts (Wakabayashi et al., 2003). PDLIM5, in 
addition to its signaling function by interacting with PRKCB1 through its LIM domain (Kuroda et al., 
1996), also contains PDZ domains, which may be used as sites for interaction of scaffolding 
proteins. These findings might represent interesting targets for further functional characterization in 
the context of wound healing and regeneration. 
4.2.2 Specific themes in the pathology of IBD 
 
From exploratory data analysis of GO terms represented by differentially regulated genes between 
inflamed/ non-inflamed CD and UC or normal controls, many GO terms were found to be over-
represented by the differentially regulated genes. Of particular interest were GO terms that were 
not directly related to immune function. Two such specific themes, namely Wnt pathway and cell-
cell adhesion, were chosen for further analysis by real-time PCR. 
 
4.2.2.1 Wnt pathway 
 
The role of the Wnt pathway in the context of IBD is interesting in two respects. Firstly, the Wnt 
pathway controls intestinal epithelial cell proliferation, which is essential for development and 
renewal processes in the colon (Batlle et al., 2002; van de Wetering et al., 2002). Secondly, 
aberrations in the Wnt pathway have been shown to cause cancer (Moon et al., 2004), and as 
there is an elevated risk for colorectal cancer in UC, there is the possibility that the Wnt pathway 
could be involved. To date, one publication has used cDNA macroarrays to identify up-regulation of 
five Wnt transcripts (FRZB, FRZ5, FZD3, DVL3, SFRP2) in a single UC sample compared to one 
CD sample (Uthoff et al., 2001). In contrast, the present study is the first to report differential 
expression of 28 Wnt pathway transcripts, as measured by real-time PCR, in a larger number of 
CD and UC samples, as well as disease and normal controls. Since the anomalous expression of 
gene transcripts at any stage of Wnt signaling have the potential to influence Wnt activation, the 
potential contributions of each gene are discussed in the following groups: 1) Wnt ligand modifiers 
or co-receptors; 2) Wnt receptors and ligands; 3) cytoplasmic components of Wnt signaling; 4) 
nuclear components of Wnt signaling; and 5) Wnt target genes. 
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Genes involved in processes preceding the initiation of Wnt signaling include those involved in 
ligand processing of Wnt ligands, heparin sulfate proteoglycan (HSPG) synthesis, and transcription 
factors involved in modulating heparin sulfate proteoglycan levels. Heparin sulfate proteoglycans 
may participate in Wnt signaling by acting as low-affinity co-receptors for Wnt ligands, facilitating 
transport or stabilizing Wnt ligands (Hacker et al., 2005; Logan and Nusse, 2004; Wodarz and 
Nusse, 1998). Wnt activation can be promoted by the heparin sulfate proteoglycan protein 
syndecan (Alexander et al., 2000; Munoz et al., 2006), which binds ADAM12. Although ADAM12 
has primarily been characterized in its role for ADAM12/syndecan-4-mediated cell adhesion in 
mesenchymal cell lines (Iba et al., 2000; Thodeti et al., 2003), its specific up-regulation in IBD (but 
not disease controls) compared to non-inflamed groups (normal control or non-inflamed IBD) in 
real-time PCR (Table 3.24) has the potential to affect Wnt pathway activation by engaging more 
syndecan molecules for ADAM12/syndecan signaling and leaving less syndecan available to act a 
co-receptor for Wnt activation. The transcription factor FOXL1 has been shown to be involved in 
gastrointestinal cell proliferation and negative regulation of the Wnt pathway by suppressing the 
expression of HSPGs, which act as co-receptors for Wnt ligand binding (Perreault et al., 2001). 
Real-time PCR noted a down-regulation of FOXL1 in IBD (inflamed or non-inflamed) or inflamed 
DC compared to normal controls (Table 3.24). This may suggest that in IBD, regardless of 
inflammation status, FOXL1 fails to negatively regulate HSPG expression, which may lead to a 
increased HSPG expression and higher efficiency for Wnt activation. However, the expression of 
the HSPG transcript syndecan-1 (SDC1) was confirmed by real-time PCR to be down-regulated in 
inflamed IBD or DC compared to normal controls (Table 3.24). Considering the fact that the 
mechanism of FOXL1 regulation of proteoglycan expression has not been fully elucidated but is 
thought to occur at the post-transcriptional level (Perreault et al., 2001), it is possible that the 
observed down-regulation of SDC1 cannot directly be associated with diminished FOXL1 transcript 
levels. 
 
Initiation of Wnt signaling, be it in the canonical or non-canonical Wnt pathway, requires binding of 
Wnt ligands to the transmembrane receptor complex (LRP5/6 and Frizzled family members). Once 
secreted from the initiating cell into the extracellular space, Wnt ligands can be modulated by the 
secreted frizzled related protein family (sFRPs), which have been shown to either promote or inhibit 
Wnt activation, depending on the Wnt ligands present, the tissue specificity, and the concentration 
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of sFRPs (Kawano and Kypta, 2003). Down-regulation of SFRP1 or deletion of chromosomal 
regions (2q) containing FRZB have been observed in many cancers (Ko et al., 2002; Schmitt et al., 
2002; Ugolini et al., 2001; Zhou et al., 1998), potentially because SFRP proteins can promote 
apoptosis (Kawano and Kypta, 2003). Frizzled related protein (FRZB) was shown to be down-
regulated in inflamed IBD compared to normal or non-inflamed IBD by real-time PCR (Table 3.24), 
while on the microarrays, SFRP1 was down-regulated in UC (inflamed or non-inflamed) but not in 
CD compared to normal controls (Table 3.23). In contrast, real-time PCR indicated that SFRP2 was 
specifically up-regulated in inflamed IBD, but not inflamed DC compared to normal controls (Table 
3.24). This result is compatible with the observation that SFRP2 has been shown to inhibit Wnt 
(Kawano and Kypta, 2003), as well as SFRP1 (Yoshino et al., 2001). 
 
The diversity of Wnt functions in various tissues is achieved through the binding various 
combinations of Wnt ligands to Frizzled-LRP4/5 transmembrane receptor complex (Miller, 2002). 
Though many studies have examined ligand-receptor associations in developing Drosophila and C. 
elegans cells, there is a paucity of information on the function and specificity of the intact Wnt-
receptor interactions in mammalian cells (Dale, 1998; Takada et al., 2005) and especially in adult 
colon, partly due to the functional redundancy of the ligand-receptor interactions and the 
requirement for conditional activation methods to single out specific interactions (Kuhnert et al., 
2004). Nevertheless, real-time PCR detected a down-regulation of transcripts for FZD1, FZD2, and 
FZD7 in normal controls compared to inflamed IBD or disease controls (Table 3.24), suggesting 
that down-regulation of these receptor transcripts is likely influenced by inflammation and not by 
IBD alone. 
 
Cytoplasmic members of the canonical Wnt signaling pathway were primarily down-regulated in 
inflamed IBD compared to normal controls or even non-inflamed IBD, as shown by real-time PCR 
experiments. However, the overwhelming down-regulation does not uneqivocally support a 
decrease or increase in Wnt activation, since many of the involved genes affect the pathway by 
different means. For example, members of the destruction complex, casein kinase I and GSK3, 
phosphorylate β-catenin, thereby targeting it for protein degradation. The observed down-regulation 
of two casein kinase I family members (CSNK1D, CSNK1E), in inflamed IBD compared to normal 
controls (Table 3.24), may indicate that inflammation has the potential to transduce (i.e., positively 
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regulate) Wnt signaling by reducing the amount of free casein kinase I and decreasing the 
phosphorylation of β-catenin that targets it for degradation. The observed down-regulation of AXIN1 
in inflamed tissue only (both IBD and disease controls) in real-time PCR (Table 3.24) may be 
interpreted as positive regulation of the Wnt pathway, since axin forms the scaffolding structure for 
the destruction complex. As a reduction in axin transcript could reduce its availability to the 
destruction complex, the functionality of the destruction complex could be impaired, leading to an 
increase of β-catenin, translocation of β-catenin to the nucleus and transcription of Wnt target 
genes. APC, along with axin, forms the protein scaffolding to which other elements of the 
destruction complex bind, and also functions to chaperone nuclear β-catenin to the destruction 
complex (Giles et al., 2003). Down-regulation of APC in inflamed IBD and DC compared to normal 
controls (Table 3.24) could be interpreted as a positive effect on the Wnt pathway, since a 
reduction in APC could impair effective degradation of β-catenin. On the other hand, a decrease in 
disheveled 1 (DVL1) in all disease states compared to non-inflamed tissue (normal, IBD, or DC; 
Table 3.24) may lead to negative regulation of Wnt signaling, since dishevelled is required to 
transduce Wnt ligand activation between the Frizzled receptor and the destruction complex through 
axin (Moon et al., 2004). Moreover, the observed decrease in β-catenin in all IBD states compared 
to normals in real-time PCR (Table 3.24) could suggest that the concentration of the co-
transcriptional activator is reduced, thus limiting transcription of Wnt targets. 
 
The expression of the TCF/LEF transcription factors, as measured by real-time PCR, did not reach 
a clear consensus on Wnt pathway activation or repression. Transcription factor TCF7L2 
(commonly known by unofficial name Tcf-4), the most prominently expressed TCF transcription 
family member in colon epithelium (Korinek et al., 1997), was seen to be down-regulated in 
inflamed IBD compared to normals, while its co-transcription factor LEF1 was up-regulated in 
inflamed IBD compared to non-inflamed IBD tissue (Table 3.24). Both TCF7L2 and LEF1 were 
specifically regulated in IBD, as no regulation was observed in the disease control group. TCF7, 
which can act as an antagonist of TCF7L2 (Giles et al., 2003), was up-regulated in inflamed CD 
compared to normals (Table 3.24), thus supporting repression of Wnt activation. Interestingly, the 
differential expression of the antagonist TCF7 (commonly known by unofficial name Tcf-1) in CD 
but not in UC, may protect the CD colon by inhibiting Wnt target gene transcription to a greater 
extent than in the UC colon, where TCF7 expression is not elevated. Overall, the pattern of TCF 
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family expression supports repression of Wnt target genes, while LEF1 expression supports 
transcription of Wnt target genes. 
 
All of the previously described gene transcript regulations, from upstream of Wnt processing to 
nuclear transcription of TCF/LEF, culminate in the transcription initiation of Wnt target genes. Many 
target genes of canonical Wnt pathway transcription have been identified from studies investigating 
β-catenin/TCF signaling in colorectal and other cancers (Giles et al., 2003). Some of these target 
genes have clear roles in intestinal epithelial homeostasis and renewal, such as cell proliferation 
mediated by MYC and PPARD (He et al., 1999; van de Wetering et al., 2002) and cell migration 
and proliferation mediated by ephrin receptors EPHB2 and EPHB3 (Holmberg et al., 2006). 
Microarray results showed that transcripts of these aforementioned genes were down-regulated in 
inflamed IBD compared to normals (Table 3.23), which could imply that the inflamed IBD colon has 
impaired ability to regenerate, resulting in barrier breach by bacteria and subsequent chronic 
inflammation.  
 
Interestingly, a recent study showed that bone marrow transplant lead to a reduction in disease 
severity in an IL10 knockout colitic mouse model (Bamba et al., 2006). The improvement was 
attributed to the localization and differentiation of bone-marrow derived cells to colonic subepithelial 
myoblasts (SEMFs), which are located in the mesenchyme surrounding inflamed colon crypts. The 
authors suggested that the improvement was due to the cytokine-mediated effector function of the 
colonic SEMFs. In the same vein, it is also possible that the SEMFs could improve colon 
regeneration by providing proper Wnt signals to the proliferating colon crypts, as Wnt signaling to 
the colon crypts originate from the mesenchyme (Gregorieff et al., 2005). 
 
However, it is difficult to discern whether or not other genes involved in Wnt-related cancer 
progression also have a specific role in IBD, since many of the differentially regulated Wnt targets 
are also transcription regulators (e.g. JUN, MYC, TCF4, TLE, VANGL2, FOSL1, PPARD) and affect 
genes further downstream of Wnt, or are cross-regulated by other pathways. For example, MYC 
induces the expression of EMP3, which is thought to be involved in cell proliferation and cell-cell 
interactions (Ben-Porath et al., 1998), and JUN may be cross-regulated by its interaction with TJP2 
(Betanzos et al., 2004). In at least two instances, immune responses are likely to represent 
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dominant control of two Wnt targets. IL8 was shown to be inducible by Wnt/ β-catenin pathway and 
is up-regulated in many cancers, including colorectal cancer (Levy et al., 2002). As an inflammation 
marker, IL8 is also regulated by inflammatory response mediated by Toll-like receptor signaling 
(Yoshida et al., 2005). In another example, TCF4 (also known as immunoglobulin transcription 
factor-2) was also shown to be induced by the β-catenin /TCF to promote cell growth in neoplastic 
transformation (Kolligs et al., 2002), but since TCF4 binds to an immunoglobulin enhancer 
(Gstaiger et al., 1996; Henthorn et al., 1990) it is likely to be strongly involved in antibody 
expression. Therefore, the observed up-regulation of IL8 and TCF4 in inflamed IBD compared to 
normal controls from real-time PCR (Table 3.24) may be primarily due to immune response rather 
than Wnt activation. Interestingly, three of the downstream targets of Wnt were shown to be 
exclusively regulated in IBD and not in disease controls (real-time PCR result): TCF4 was specific 
for IBD; EMP3 and JUNB were specific for UC only (Table 3.24). These results may implicate a 
specific role for these transcripts in IBD pathogenesis. However, within the context of IBD, the 
complexity of pathway interactions indicates that more research is needed to elucidate the 
downstream roles of other Wnt targets, many of which are transcription regulators themselves. 
 
To date, it is not conclusive whether disruption of the Wnt pathway can lead to a higher rate of 
colorectal cancer in IBD patients, and in particular UC patients, since APC and CTNNB1 mutation 
detection studies have not conclusively demonstrated the involvement of the Wnt pathway in UC-
related colorectal carcinomas (Aust et al., 2002). Overall, of the 28 Wnt pathway transcripts 
monitored in real-time PCR analysis (Table 3.24), 64% of the genes were differentially regulated in 
inflamed UC compared to non-inflamed tissue (UC or normal control). In contrast to UC, only 46% 
of the Wnt transcripts were differentially regulated in inflamed CD compared to non-inflamed tissue. 
Despite the lack of mutation detection results in two key genes of the Wnt pathway, differential 
transcript regulation of many different Wnt pathway genes may indicate that overall, the UC 
condition has a predisposition towards cancer, since more Wnt transcripts are dysregulated in UC 
than in the CD condition. 
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4.2.2.2 Cell-cell adhesion 
 
An increase in intestinal permeability—be it the result of stress, genetic predisposition, or bacterial 
environment—has been suggested as an exacerbating factor to the pathology of IBD (Nazli et al., 
2004; Soderholm et al., 1999; Soderholm et al., 2002; Yang et al., 2006). Broadly speaking, 
permeability in the intestinal epithelium may refer to surface barrier protection (glycocalyx), 
permeability between cells (paracellular) or permeability through cells (transcellular). Here, 
discussions relating to barrier function will be focused on junctions between cells, particularly on 
genes involved in cell-cell adhesion interactions. 
 
The coordinated interaction of proteins involved in cell-cell junctional complexes, which include the 
tight junction, adherens junction and desmosome, maintain the integrity of the intestinal epithelium, 
while selectively regulating paracellullar traffic (Sawada et al., 2003). The tight junction (TJ) is 
located most apically in the polarized intestinal epithelial cell and forms a semi-permeable ring that 
seals the gap between neighbouring cells and further serves to separate basolateral from apical 
membrane components. Three transmembrane proteins, including claudin (CLDN), occludin 
(OCLN) and junctional adhesion molecule (JAM), form the tight junction. Within the claudin family, 
different dysregulation patterns were observed, which would suggest that claudin members are 
regulated by different mechanisms. CLDN3, 4, and 7 were confirmed in real-time PCR to be 
consistently down-regulated in inflamed IBD compared to normal controls, while CLDN1 and 2 
were strikingly up-regulated (ranging from a log2 ratio of 1.27 to 5.30) in the same comparison 
(Table 3.26). The differential expression of the claudins was dependent on inflammation, as 
inflamed disease controls mirrored the results seen in inflamed IBD. These results are consistent 
with a recent study, which showed that CLDN2 protein expression was significantly increased in the 
colonic epithelium of active UC and CD, whereas CLDN3 and 4 were sporadically reduced or 
redistributed compared to normal controls, a difference which the authors suggest may be due to 
differential responses to IL13 and TNF/IFNG, respectively (Prasad et al., 2005). The study further 
demonstrated that both the up-regulation of CLDN2 and down-regulation of CLDN3 and 4 were 
associated with increased permeability in a model system (Prasad et al., 2005), indicating that the 
net effect of CLDN dysregulation lead to barrier dysfunction. 
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Another tight junction transmembrane component, occludin (OCLN), was down-regulated in real-
time PCR in all disease states compared to non-inflamed samples (Table 3.26), suggesting that 
dysregulation of this gene was wholly dependent on disease condition (either IBD or disease 
control), rather than inflammation. The effect of inflammation on OCLN expression is supported by 
a study showing that immunofluorescence labeling of OCLN was reduced in the colon epithelium of 
active CD and UC patients (Kucharzik et al., 2001); however, the same study reported no 
differences in immunofluorescence labeling between normal controls and inactive IBD. As OCLN 
transcript expression can be negatively regulated by TNF or IFNG (Mankertz et al., 2000) and TNF 
is up-regulated in IBD (Breese et al., 1994), these results may suggest that in the inactive IBD 
mucosa, underlying events at the transcriptional level have not yet translated into an effect 
detectable by immunofluorescence microscopy. 
 
The third major component of tight junctions, the JAM proteins, are single-transmembrane proteins 
which recruit other proteins (claudins, occludin, tight junction protein family and partitioning 
defective family members) to the tight junction through its PDZ domains (Ebnet et al., 2004; 
Mandell and Parkos, 2005). One JAM family member, F11R, was observed to be down-regulated 
on the microarrays in inflamed or non-inflamed CD compared to normal controls, and no regulation 
was observed in UC (Table 3.25). The CD-specific dysregulation may implicate a role for F11R in 
the pathogenesis of CD, through TJ disruption and additionally through leukocyte migration events, 
since F11R is also expressed on leukocytes and participates in transendothelial migration (Ebnet et 
al., 2004). The specificity of this interaction, however, remains to be confirmed by additional 
studies. 
 
While the transmembrane claudins, occludin and JAM proteins seal the extracellular space 
between epithelial cells, a network of cytoplasmic proteins provide scaffolding for the 
transmembrane proteins and transmit signals between the tight junction and actin cytoskeleton 
(Matter and Balda, 2003; Mitic et al., 2000). In particular, the tight junction protein family (TJP or 
commonly known as zonula occludens (ZO)), which is a member of the membrane associated 
guanylate kinase family (MAGUK), contains PDZ domains and a guanylate kinase-like (GUK) 
domain, which interact with cytoplasmic domains of claudin and occludin, respectively (Itoh et al., 
1999). In real-time PCR, TJP1 and TJP3 exhibited consistent down-regulation in inflamed IBD and 
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disease controls when compared to normal controls (Table 3.26). In contrast, TJP2 was exclusively 
up-regulated in IBD. TJP2 was up-regulated in inflamed UC compared to normal controls and up-
regulated in inflamed IBD compared to non-inflamed IBD (Table 3.26). The up-regulation of TJP2 in 
inflamed IBD tissue may represent a functional redundancy to attempt to compensate for the 
reduction in TJP1, as it has been shown that TJP2 is recruited to tight junctions in TJP1-deficient 
cells (Umeda et al., 2004). Alternatively, TJP2 may function in inflamed IBD as a regulator of cell 
proliferation. TJP2 has been shown to act as a messenger molecule between the TJ and the 
nucleus, since TJP2 has been associated with transcription factors in the nucleus upon loss of cell-
cell contact (Betanzos et al., 2004; Islas et al., 2002). 
 
Formation of the tight junction is thought to be preceded by the formation of the adherens junction, 
which is initiated by CDH1 (E-cadherin) binding to extracellular domains of other CDH1 molecules 
in adjacent cells in a Ca2+ dependent manner (Sawada et al., 2003). Through its cytoplasmic 
domains, CDH1 interacts directly with members of the catenin family (beta, gamma and delta 
cateinin (p120)), while vinculin (VCL) and α-catenin link the cadherin-catenin complex to the actin 
cytoskeleton (Gumbiner, 2005; Zbar et al., 2004). Other cytoplasmic proteins, such as TJP1 and 
JAM, are also recruited to the developing adherens junction, and subsequent recruitment of 
occludin, claudin, partitioning defective family members (PAR3 and PAR6) and atypical protein 
kinase C (PRKCI; common name: aPKC) lead to maturation of the intercellular junction and 
segregation of the apical junction complex into adherens and tight junctions (Sawada et al., 2003). 
Within the context of IBD, cadherins CDH1 and CDH11 demonstrate opposite behaviours in real-
time PCR. CDH1 is down-regulated in all inflamed disease conditions (CD, UC and DC) compared 
to normal controls, while CDH11 is specifically up-regulated in inflamed IBD but not in inflamed 
disease controls (Table 3.26). Similar to CDH1, the actin linking proteins α- /β-catenin (CTNNA1, 
CTNNB1) and vinculin (VCL) are down-regulated in inflamed disease conditions compared to 
normal controls in real-time PCR, an effect which is also evident when non-inflamed IBD is 
compared to normal controls (Table 3.26). The down-regulation of CDH1, CTNNA1 and CTNNB1 in 
inflamed mucosa may be indicative of cell adhesion disruption resulting from cell migration, since 
epithelial restitution is the primary repair mechanism induced in response to ulcerations in the 
gastrointestinal mucosa (Zbar et al., 2004). Furthermore, the down-regulation of these genes in 
non-inflamed CD or UC mucosa compared to normal controls may point towards a general defect 
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in the IBD mucosa to produce sufficient amounts of these proteins in the absence of inflammation. 
Interestingly, in stark contrast to CDH1, CDH11 is specifically up-regulated in inflamed IBD 
compared to normal controls. Though there are no studies specifically addressing the role of 
CDH11 in the gut mucosa, a recent study in a murine fibroblast cell line has shown that CDH11 is a 
cellular motility factor that regulates remodeling of cell-cell contacts and the actin cytoskeleton 
(Kiener et al., 2006). It is therefore conceivable that the up-regulation of CDH11 and the down-
regulation of CDH1, CTNNB1 and CTNNA1 work together to promote epithelial cell restitution in 
the inflamed IBD mucosa. 
 
The fact that components of the cell-cell adhesion interaction are also associated with the Wnt 
pathway suggests that there could be cross-talk between cell-cell adhesion mechanism and the 
Wnt pathway. β-catenin and APC are both multifunctional proteins that interact with both the Wnt 
pathway and cell-cell adhesion. In the Wnt pathway, APC forms part of the degradation complex 
that inactivates the Wnt pathway by targeting cytoplasmic β-catenin for proteomic degradation. In 
the role of cell-cell adhesion, β-catenin links the adherens junction to the actin cytoskeleton through 
E-cadherin and α-catenin. APC has been shown act as a shuttling chaperone for β-catenin in and 
out of the nucleus (Henderson and Fagotto, 2002). APC has also been localized to various parts of 
the cell (cytoplasm, microtubule tips, plasma membrane, nuclei) (Bienz, 2002). Experiments in a 
human colon cancer cell line have also shown that restoration of APC expression in a APC-
mutated cell line improved cell-cell adhesion. Based on these results, it has been proposed that 
APC interacts with β-catenin to promote translocation of E-cadherin (CDH1) and β-catenin to the 
cell membrane (Faux et al., 2004). Though APC and β-catenin transcripts are regulated in the 
inflamed IBD and DC (Table 3.24 and Table 3.26), it is currently not clear whether inappropriate 
cross-talk between the Wnt pathway and cell-cell adhesion processes contribute to IBD 
pathogenesis. 
 
Overall, many genes involved in tight junction and adherens junction were shown to be 
dysregulated at the transcriptional level in inflamed or diseased colonic mucosa biopsies compared 
to normal controls. Tight junction genes, including CLDN1,2, and 7, displayed inflammation-
dependent dysregulation, whereas occludin showed disease-dependent down-regulation. 
Cytoplasmic proteins associated with the tight junction, including TJP1, 2, and 3, were dysregulated 
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in inflamed IBD compared to non-inflamed conditions. Collectively, these results support the notion 
that inflammation and disease dysregulate the expression of tight junction components, which can 
disrupt the function of the tight junction. Finally, the differential expression of adherens junction 
components, CDH1, CDH11, VCL, CTNNA1, and CTNNB1 suggest that adherens junction 
disruption may be part of the epithelial cell restitution process at work in IBD. 
4.3 Conclusions 
 
Genome-wide microarray expression profiling is increasingly being used as a screening tool for 
hypothesis generation. Examples of the two main types of microarray platforms, mainly the cDNA 
and oligonucleotide platforms, were compared by hybridizing the same RNA samples on each 
platform. Contrary to previously published microarray comparisons, the present study was the first 
to match like-probes from different microarray platforms using sequence-verified probes. 
 
The present study demonstrates for the first time that oligonucleotide-based arrays and full-length 
clone-based arrays may be too different in experimental design to give directly correlating results 
for the same genes. Pooling of global expression profiles for different platforms for the purpose of 
meta-analysis should be undertaken with caution, and results obtained from microarrays should be 
confirmed by complementary approaches. 
 
A thorough analysis of the microarray comparison data showed that there was no rank order 
correlation of mean expression values from matched probes between both arrays, and that 
individual expression values for each patient within a platform showed no rank order correlation. 
Furthermore, the overlap in detection of the same genes on both platforms, in terms of concordant 
present/absent calls, was only 60-68%. Detailed analysis moreover showed that less than 8% of 
the discordant calls were caused by clone sequencing errors or differences in probe design for the 
same gene. Comparison of microarray expression levels with that of real-time PCR indicated that 
the data from both microarray platforms did display a strong positive rank order correlation, 
however, this was based on a small number of genes (13 genes) and was not a reliable indicator 
for larger datasets. 
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The present study also provided a whole genome snapshot of molecular processes taking place at 
the transcriptional level in the active and inactive IBD colonic mucosa. The transcription profiles of 
colonic mucosal biopsies from CD, UC and control individuals were obtained using two different 
microarray platforms. Keeping the results of the microarray comparison in mind, the data from each 
microarray experiment was analysed separately, and many of the key results were subject to real-
time PCR quantitation in an extended cohort of over 300 individuals. 
 
The main findings of these microarray analyses point to genes involved in immune and 
inflammatory response (CYLD, DMBT1, CEACAM1); oncogenesis, cell proliferation and growth 
(TIMP1, CSNKD1); and structure and permeability (PDLIM5, ROCK1, CDH11, SPINK5, PRKCB1). 
All of these genes have some known functions but have not been previously described in the 
context of inflammatory bowel disease. Based on microarray results and references in the 
literature, further verification was carried out in over 50 genes in two more specific subject areas: 
Wnt pathway and cell-cell adhesion. The differential regulation (detected by real-time PCR) of 
almost all of the cell-cell adhesion genes and 85% of the Wnt pathway members was influenced by 
inflammation. Of particular note were members of the TCF family of transcription factors in the Wnt 
pathway, namely TCF7 and TCF7L2, which exhibited distinctly different patterns of expression 
between CD and UC, with the end result favoring Wnt transcription factor transcription in UC over 
CD. Additionally, three Wnt target genes (TCF4, EMP3, JUNB), all of which are involved in cell 
growth or proliferation, exhibited specific regulation in IBD, with EMP3 and JUNB regulation 
exclusive for UC. UC-specific regulation of genes in the Wnt pathway could suggest that 
dysregulation of Wnt pathway may be more commonplace in UC than in CD, consequently leading 
to a higher predisposition for UC-related cancer via Wnt pathway. 
 
Within the cell-cell adhesion theme, the differential regulation of CDH11, CDH1, VCL, CTNNB1, 
and CTNNA1 may be working in an concerted effort to promote epithelial cell restitution in the 
inflamed IBD mucosa. The role of cell migration in restitution process is additionally supported by 
Rho-ROCK-mediated cytoskeletal reorganization mediated by regulation of ROCK1 and PDLIM5. 
Also, TJP2 is of particular interest since its up-regulation is specific to inflamed IBD, and it could be 
an important signaling messenger between the tight junction and the nucleus, with possible cross-
talk with Wnt pathway target genes. 
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A wealth of transcript information can be obtained by microarray expression profiling, which can be 
used to identify processes or pathways for further study. In the present study, microarray data 
analysis provided a number of potential leads. As it was not possible to follow all leads, gene 
transcripts from five focused functional themes were subject to verification using quantitative real-
time PCR. However, the true fruits of microarray analysis will not be realized until further specific 
investigations are pursued. 
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5 Summary 
 
The etiology of the two main forms of inflammatory bowel disease (IBD), Crohn's disease (CD) and 
ulcerative colitis (UC) remains unknown; however, a combination of environmental and genetic 
factors participate in the etiopathogenesis of IBD, including microbial, dietary, immune, 
inflammatory, and intestinal permeability factors. The advent of microarray expression screening 
facilitates the investigation of complex, polygenic diseases by enabling the scientist to monitor the 
gene transcript levels of the whole genome. As a first step, a comparison was made between two 
such methods, namely cDNA-based and oligonucleotide-based microarray platforms. For a given 
set of genes known to be present on both platforms, there was moderate overlap in 'present' or 
'absent' gene calls and weak correlation in the expression levels of transcripts detected. Keeping 
these results in mind, both cDNA- and oligo-based microarrays were used to perform whole-
genome expression profiling in colonic mucosa biopsies obtained from IBD patients and normal 
controls (> 80 individuals), and the resulting microarray datasets were analysed separately. This 
study identified many functional groups of gene transcripts that were differentially expressed 
between inflamed/non-inflamed IBD and normal controls. Though many different lines of 
investigation could have been pursued, specific focus was placed on immune and inflammatory 
response, oncogenesis, and structure and permeability. Particular attention was further limited to 
the role of genes involved in Wnt pathway and cell-cell adhesion in IBD. Selected genes of interest 
were further verified using an independent technique (quantitative real-time PCR) in a larger cohort 
of IBD patients, disease-specificity controls and normal controls (>300 individuals). Taken together, 
a comprehensive whole-genome expression analysis revealed novel genes (CYLD, DMBT1, 
CEACAM1, CSNKD1, PDLIM5, ROCK1, CDH11, SPINK5, PRKCB1, TJP2, VCL, ADAM12, 
FOXL1, TCF7, TCF7L2, TCF4, EMP3, JUNB) that are associated with the pathogenesis of IBD and 
serve to provide fresh insight into the mechanisms of this complex disease. 
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6 Zusammenfassung 
 
Die Ursachen von Morbus Crohn (MC) und Colitis Ulcerosa (CU), den beiden Hauptformen der 
chronisch entzündlichen Darmerkrankungen (CED), sind noch weitestgehend unbekannt. Derzeit 
geht man davon aus, dass eine Reihe von Faktoren wie genetischer Hintergrund, pathogene 
Keime, Ernährung, verschiedene Umweltfaktoren, Immunsystem sowie Entzündung und intestinale 
Permeabilität einen Einfluss auf CED ausüben. Die systematische Expressionsanalyse mittels 
Microarrays bietet die Möglichkeit, mRNA-Transkriptmengen des gesamten Genoms zu 
quantifizieren und stellt somit ein geeignetes Werkzeug dar, komplexe polygene Erkrankungen zu 
untersuchen. 
 
In einem ersten Schritt wurden cDNA- und Oligonucleotid-basierte Microarrays systematisch 
verglichen. Dabei zeigten Transkripte, die mit beiden Systemen nachgewiesen werden konnten, 
eine mäßige Übereinstimmung in der Detektionsrate (Transkript detektiert / nicht detektiert) und 
eine schwache Korrelation zwischen den quantitativen Expressionswerten beider Systeme. Vor 
dem Hintergrund dieser Ergebnisse wurden in einem zweiten Schritt genomweite 
Expressionsprofile aus Darmbiopsien von CED Patienten und gesunden Individuen gewonnen (ca. 
80 Probanden). Im Rahmen dieser Untersuchungen wurden verschiedene funktionelle Gruppen 
von Transkripten identifiziert, deren differentielle Expression zwischen entzündeten / nicht-
entzündeten CED Patientengeweben und Normalgeweben deutliche Unterschiede aufwies. Im 
weiteren Verlauf wurde biologischen Prozessen, die mit Immun -und Entzündungsantworten, der 
Oncogenese sowie Struktur und Permeabilität assoziiert sind, besondere Aufmerksamkeit 
gewidmet. Dabei wurde im Speziellen der Einfluss von Genen, welche Funktionen im Wnt-
Signaltranduktionsweg ausüben und an der Zell-Zell Adhäsion beteiligt sind, auf die 
Pathophysiologie von CED untersucht. Die Ergebnisse für ausgewählte Gene wurden mittels einer 
unabhängigen Technologie (Real-Time PCR) in einer größeren Stichprobe bestehend aus CED-
Patienten, erkrankten Kontrollindividuen und gesunden Individuen (>300 Probanden) verifiziert. 
 
Die vorliegende umfassende Studie konnte mittels genomweiter Expressionanalyse eine Reihe von 
neuen Genen (CYLD, DMBT1, CEACAM1, CSNKD1, PDLIM5, ROCK1, CDH11, SPINK5, 
PRKCB1, TJP2, VCL, ADAM12, FOXL1, TCF7, TCF7L2, TCF4, EMP3, JUNB) identifizieren, die 
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mit der Pathophysiologie von CED assoziiert sind. Sie liefert damit neue Erkenntnisse zu 
molekularen Mechanismen dieser komplexen Erkrankungen. 
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8 Appendix 
8.1 Materials 
 
Table 8.1. Materials and Sources 
Material Manufacturer / Supplier 
100 bp DNA ladder Invitrogen; Karlsruhe, Germany 
[33P]dCTP (≥2,500 Ci/mmol) AmershamBiosciences/GE Healthcare UK Ltd, Little 
Chalfont, UK 
10 X MOPS Sigma; München, Germany 
20 X SSC Sigma; München, Germany 
2-Mercaptoethanol Sigma; München, Germany 
37% Formaldehyde Sigma; München, Germany 
384-deep-well storage plate ABgene, Epsom, UK 
ABI PRISM® 96-Well Optical Reaction Plate Applied Biosystems; Weiterstadt, Germany 
Agarose Eurogentec; Köln, Germany 
Ampicillin Sigma; München, Germany 
AmpliTaq® DNA Polymerase Applied Biosystems; Weiterstadt, Germany 
AmpliTaq® Gold DNA Polymerase Applied Biosystems; Weiterstadt, Germany 
Anti-CSNK1D antibody Santa Cruz Biotechnology, Santa Cruz, CA, USA 
Anti-PRKCB1 antibody Pharmingen, San Diego, CA, USA 
Aquatek Merck, Hawthorne, NY, USA 
Bacto-Tryptone BD Biosciences, Heidelberg 
Bacto-Yeast Extract BD Biosciences, Heidelberg 
BigDye Terminator Ready reaction kit Applied Biosystems; Weiterstadt, Germany 
Bovine serum albumin (albumin fraction V) Merck; Darmstadt, Germany 
Bromophenol blue Sigma; München, Germany 
Cryotubes (2ml) Greiner Bio-One GmbH; Frickenhausen, Germany 
Diethyl pyrocarbonate (DEPC) Sigma; München, Germany 
di-Sodium hydrogen phosphate Merck; Darmstadt, Germany 
dNTP set (100mM solutions 100µM each ) Amersham Biosciences; Freiburg, Germany 
Easy peel heat seal foil ABgene, Epsom, UK 
EDTA Sigma; München, Germany 
Enzo Bioarray High Yield RNA transcript labeling kit Affymetrix, USA  
Ethanol p. a. Merck; Darmstadt, Germany 
Ethidium bromide solution (10mg/ml) Invitrogen; Karlsruhe, Germany 
Formamide Sigma; München, Germany 
GeneAmp PCR buffer system (10x buffer w/o 
MgCl2; 25mM MgCl2 solution) 
Applied Biosystems; Weiterstadt, Germany 
Goat anti-rabbit IgG Sigma; München, Germany 
Glycerol Sigma; München, Germany 
HG-U133A GeneChips Affymetrix, Santa Clara, USA 
HG-U95Av2 GeneChips Affymetrix, Santa Clara, USA 
Hybridization blocking reagent Roche Diagnostics, Mannheim, Germany 
Isopropanol Merck; Darmstadt, Germany 
MgCl2 Merck; Darmstadt, Germany 
MicroAmp® optical 96 well reaction plate Applied Biosystems; Weiterstadt, Germany 
MicroAmp® single strips Applied Biosystems; Weiterstadt, Germany 
Microtiter 384 well plates Sarstedt; Nürnberg, Germany 
Microtiter 96 well plates Costar Corning Incorporated; Cambridge, MA, USA 
Montage Plasmid Miniprep96 Kit Millipore, Billerica, MA 
Multiscreen column loader Amersham Biosciences; Freiburg, Germany 
MultiScribe Reverse Transcriptase Applied Biosystems; Weiterstadt, Germany 
Oligotex mRNA Mini Kit Qiagen, Hilden, Germany 
Peroxidase-conjugated rabbit anti-mouse 
secondary antibody 
Sigma, Deisenhofen, Germany 
Phosphate buffered saline (PBS) Invitrogen/Gibco; Karlsruhe, Germany  
Pipette (serological, sterile with filter 5 / 10 / 25 ml) Sarstedt; Nümbrecht, Germany 
Pipette tips with filter (10 / 200 / 1000 µl) Sarstedt; Nürnberg, Germany 
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Material Manufacturer / Supplier 
Primers and Probes Eurogentec, Seraing, Belgium 
QIAshredder homogenizer kit Qiagen; Hilden, Germany 
RNA Ladder Invitrogen/Gibco; Karlsruhe, Germany 
RNase-Free DNase Set Qiagen, Hilden, Germany 
RNaseZap wipes Ambion; Austin, TX, USA 
RNeasy mini RNA extraction kit Qiagen, Hilden, Germany 
Salmon sperm DNA Sigma; München, Germany 
SAP shrimp alkaline phosphatase Amersham Biosciences; Freiburg, Germany 
Sephadex powder (G50 superfine) Amersham Biosciences; Freiburg, Germany 
Sephadex spin column plates MAHVN 4550 Amersham Biosciences; Freiburg, Germany 
SmartLadder DNA marker Eurogentec; Köln, Germany 
Sodium acetate Sigma; München, Germany 
Sodium carbonate Sigma; München, Germany 
Sodium chloride Merck; Darmstadt, Germany 
Sodium citrate Sigma; München, Germany 
Sodium dodecyl sulfate Sigma; München, Germany 
Sodium hydrogen carbonate Sigma; München, Germany 
Sodium hydroxide Merck; Darmstadt, Germany 
Sodium phosphate Sigma; München, Germany 
SuperScript reverse transcriptase Invitrogen/Life Technologies, Carlsbad, USA 
TAE Buffer 25 × Ready Pack Amresco; Solon, OH, USA 
TAE Buffer 25x ready pack Amresco; Solon, OH, USA 
TaqMan® Universal PCR Master Mix Applied Biosystems; Weiterstadt, Germany 
Tris Merck; Darmstadt, Germany 
Tubes (0.5 / 1.5 / 2.0 mL) Eppendorf; Köln, Germany 
Tubes, sterile (15 mL) Sarstedt; Nümbrecht, Germany 
Tubes, sterile (50 mL) BD Biosciences; Heidelberg, Germany 
Universal TaqMan Master Mix Applied Biosystems; Weiterstadt, Germany 
 
8.2 Equipment 
 
Table 8.2. Equipment and Sources 
Item Manufacturer/ Supplier 
ABI 9700 Sequencer Applied Biosystems, Foster City, USA 
ABI Prism 7900HT Sequence Detection System Applied Biosystems, Foster City, USA 
Agilent 2100 Bioanalyzer  Agilent Technologies, Palo Alto, USA 
GeneAmp PCR system 9700 Applied Biosystems, Foster City, USA 
General purpose centrifuge (Labofuge 400R) Heraeus Instruments, Osterode, Germany 
Homogenizer for microfuge tubes, Teflon head Omnilab, Bremen, Germany  
Microfuge (Biofuge fresco) Heraeus Instruments, Osterode, Germany 
Phosphorimaging plate (BAS-MS 2325) Fujifilm, Kanagawa, Japan 
Phosphorimaging scanner (FLA-3000G) Fujifilm, Kanagawa, Japan 
Shaking incubator (GFL 3033) Gesellschaft für Labortechnik mbH, Burgwedel, 
Germany 
Thermomixer compact Eppendorf, Hamburg, Germany  
Ultrospec 3100 pro spectrophotometer Amersham Pharmacia Biotech, Uppsala, Sweden 
Vortex-genie 2 Scientific Industries, Bohemia, USA 
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8.3 Solutions and media 
 
Solution Composition 
10 X DNA gel loading 
buffer 
 50% v/v glycerol, 0.1% bromophenol blue (w/v) 
RNA gel loading buffer 40 % (v/v) formaldehyde, 40% (v/v) formamide, 0.9 X MOPS, 0.3 
µg/µL ethidium bromide, 1 mM EDTA (pH 7.5), 1 X DNA gel loading 
buffer 
TE (pH 7.5, 8.0)   10 mM Tris-HCl, 1 mM EDTA 
DEPC treated water 1 mL DEPC in 1 L DDW, shake vigorously and autoclave 
LB media 10g/L Tryptone, 5g/L Yeast Extract, 5 g/L NaCl 
 
8.4 Primer and probe sequences 
Primers and probes are listed according to the section in which they were mentioned. For Assays-
On-Demand Gene expression assays from Applied Biosystems, only a context sequence is 
provided by the manufacturer. All fluorogenic probes are labeled with 5’FAM and 3’TAMRA. 
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Table 8.3 Primer and probe sequences for real-time PCR or regular PCR 
 
Section Gene Name or Primer Pair Gene 
Symbol 
Forward Primer Sequence 
5' to 3' 
Reverse Primer Sequence 
5' to 3' 
Probe Sequence/ Context 
sequence 
2.1 M13F/ M13R n/a CGTTGTAAAACGACGGCCAGT TTTCACACAGGAAACAGCTATGAC  
2.1 M13for23/ M13rev30 n/a GACGTTGTAAAACGACGGCCAGT ATAACAATTTCACACAGGAAACAGC
TATGA 
 
2.1 T7/ T3 n/a TAATACGACTCACTATAGGG AATTAACCCTCACTAAAGGG  
2.1, 2.2 actin, beta ACTB AGCCTCGCCTTTGCCGA CTGGTGCCTGGGGCG CCGCCGCCCGTCCACACCCGCC 
2.1 glyceraldehyde-3-phosphate 
dehydrogenase 
GAPDH ACCCACTCCTCCACCTTTGAC CTGTTGCTGTAGCCAAATTCGT N/A 
2.1 cadherin 11 CDH11 ACCAACACCCTCACCATCAAA GGCCGGCGTTCAGAA TGCGGGTGCGACGTGAACG 
2.1 claudin 4 CLDN4 GTGTACCAACTGCCTGGAGGAT ACCCCGGCACTATCACCATA CCAAGACCATGATCGTGGCGGTC 
2.1 carcinoembryonic antigen-related cell 
adhesion molecule 1 (biliary glycoprotein) 
CEACAM1 TTCTGCTCACAGCCTCACTTCTA AACCTCCTTCCCCTCTGCAA CCTTCTGGAACCCGCCCACC 
2.1 N-methylpurine-DNA glycosylase MPG AGCATCTATTTCTCAAGCCCAAA GGAGTTCTGTGCCATTAGGAAGTC CCAGCCGGCAGTCCCCCTG 
2.1 protein kinase C binding protein 1 PRKCBP1 AAGCGCCAGATTCGTAGCA CTTCCGAGATTTCATTTATGCCTAA TTGACAAGACCATAGAGAGTTGCAAAGCAC
A 
2.1 matrix metalloproteinase 3 MMP3 TGTAGAAGGCACAATATGGGCAC AGTCACTTGTCTGTTGCACACGA ATGTTCGTTTTCTCCTGCCTGTGCTGTGA 
2.1 aldolase B, fructose-bisphosphate ALDOB GGAGGCTTTTATGAAGCGGG TGAAGAGCGACTGGGTGGAA TAACTGCCAGGCGGCCAAAGGAC 
2.1 mucin 1, transmembrane MUC1 GTGCCCCCTAGCAGTACCG GAAGTGGCTGCCACTGCTG TGAGAAGGTTTCTGCAGGTAATGGTGGCA 
2.1 translocase of inner mitochondrial 
membrane 17 homolog B (yeast) 
TIMM17B CAAGGGTTTCCGCAATGC TGCGAAGCTACCTCCAATCTG CCGGTTGAGAGGTAGTGCCAATGCTGT 
2.1 matrix metalloproteinase 1 MMP1 ATGCGCACAAATCCCTTCTACC TCCTCAGAAAGAGCAGCATCGATA  ACGAATTTGCCGACAGAGATGAAGTCCGGT 
2.1 pro-platelet basic protein PPBP ACACTGAAGGATGGGAGGAAAATC GCAGATTCATCACCTGCCAATTT CAGATGCTCCCAGAATC 
2.1 apolipoprotein A-I APOA1 ACAGCGTGACCTCCACCTTC CTGCCTCAGGCCCTCTGTCT TCGGCCCTGTGACCCAGGAGTTCTG 
2.2 interleukin 8 IL8 GGAATTGAATGGGTTTGCTAGAA TGTGGATCCTGGCTAGCAGAC TGGAAATCCTGGATTTTTTTCTGTTAAATCTG
GCAA 
2.2 tumor necrosis factor (TNF superfamily, 
member 2) 
TNF AGGCGGTGCTTGTTCCTCA GTTCGAGAAGATGATCTGACTGCC CCAGAGGGAAGAGTTCCCCAGGGAC 
2.2 cadherin 11, type 2, OB-cadherin 
(osteoblast) 
CDH11 ACCAACACCCTCACCATCAAA GGCCGGCGTTCAGAATG TGCGGGTGCGACGTGAACG 
2.2 decay accelerating factor for complement 
(CD55, Cromer blood group system) 
DAF CGAGGTGCCAACAAGGCTAA CCTGGACGGCACTCATATTCC TTCTGCATCCCTCAAACAGCCTTATATCACT
CT 
2.2 immunoglobulin heavy constant gamma 1 
(G1m marker) 
IGHG1 GCCCCAGTTGCTGGC AGCTGGGTCCCGCTGC TTTCAATCCAAGCATAACTCAGTGACGCAT 
2.2 mucin 1, transmembrane MUC1 GTGCCCCCTAGCAGTACCG GAAGTGGCTGCCACTGCTG TGAGAAGGTTTCTGCAGGTAATGGTGGCA 
2.2 trefoil factor 1 (breast cancer, estrogen-
inducible sequence expressed in) 
TFF1 GACACCTCAGACACGCTTCT GAGTAGTCAAAGTCAGAGCAGTCAA CCTCGGCTCACAACAC 
2.2 TIMP metallopeptidase inhibitor 1 TIMP1 TTCTGGCATCCTGTTGTTGCT TGACGAGGTCGGAATTGCA CCCCCAGCAGGGCCTGCACC 
2.2 cylindromatosis (turban tumor syndrome) CYLD   TCGGGATGGTGGTCAGAATGGCTTC 
2.2 CTTNBP2 N-terminal like DKFZp547A0
23 
  AGGCTGACTCAACAGTTGGAATTTG 
2.2 PDZ and LIM domain 5 PDLIM5   AAAATGGCCCACCAAGAAAACACAT 
2.2 occludin OCLN   CCACGCCGGTTCCTGAAGTGGTTCA 
2.2 phospholipase A2, group IIA (platelets, PLA2G2A   AGCAGAATCACCTGTGCAAAACAGG 
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Section Gene Name or Primer Pair Gene 
Symbol 
Forward Primer Sequence 
5' to 3' 
Reverse Primer Sequence 
5' to 3' 
Probe Sequence/ Context 
sequence 
synovial fluid) 
2.2 pleckstrin homology domain containing, 
family Q member 1 
PLEKHQ1   GAACAAGGTCAGCGACATCAAATTC 
2.2 rho-associated, coiled-coil containing 
protein kinase 1 
ROCK1   AATTGGATGAAGAGGGAAATCAAAG 
2.2 calcitonin gene-related peptide-receptor 
component protein 
RCP9   GGAGATCCAGCTGATGGTGGAAGAG 
2.2 zinc finger, CCHC domain containing 4 ZCCHC4   GCACATCCAAGGATGGCAGGAAATG 
2.4 (28B08) Homo sapiens cDNA FLJ31066 
fis, clone HSYRA2001153 
ADAM12   CCACGGCACACTCAGGCTGGAGATC 
2.4 forkhead box l1 FOXL1   CTCGACCCGCATGTCCAGGGCGGCT 
2.4 cadherin 1, type 1, e-cadherin (epithelial) CDH1   CCCCATCAGGCCTCCGTTTCTGGAA 
2.4 cadherin 11, type 2, OB-cadherin 
(osteoblast) 
CDH11 ACCAACACCCTCACCATCAAA GGCCGGCGTTCAGAATG TGCGGGTGCGACGTGAACG 
2.4 frizzled-related protein FRZB CTGGACTAGCAAAGGAAAATTGCA GCCCCCAAACCATTACAAAGG AAGCAGAAACCAAAAGAG 
2.4 frizzled-related protein FRZB   GCAAGCAGTGAACGCTGTAAATGTA 
2.4 frizzled homolog 1 (drosophila) FZD1   CGGCGCCGGCGAGCTGTGCGTGGGC 
2.4 frizzled homolog 2 (drosophila) FZD2   CTCACAGGAGGAGACGCGTTTCGCG 
2.4 frizzled homolog 7 (drosophila) FZD7   CCCGTACTGCTTTCAGGTCTTGTAA 
2.4 syndecan 1 SDC1   CGGCCCTGCCGCAAATTGTGGCTAC 
2.4 secreted frizzled-related protein 2 SFRP2 CTTGAGTGCGACCGTTTCC CGTTTCCATTATGTCGTTGTCATCA ACCTTTGGAGCTTCCTCG 
2.4 adenomatosis polyposis coli APC   GAAAAACGAGCACAGCGAAGAATAG 
2.4 Rho guanine nucleotide exchange factor 
(gef) 10 
ARHGEF10   CATGCTGCCAGGGCACCAGCGGCTG 
2.4 Homo sapiens axin (axin) mrna, partial 
cds. 
AXIN1   CACGGACAGCAGCGTGGATGGGATC 
2.4 carcinoembryonic antigen-related cell 
adhesion molecule 1 (biliary glycoprotein) 
CEACAM1 CAGCCCCACTTCACAGAGT GGCGGGTTCCAGAAGGTT CTCACAGCCTCACTTCT 
2.4 casein kinase 1, delta CSNK1D CGACAAGATACCTCTCGCATGT GCCGTGGTGTTCGAAAGGA CACCTCACAGAATAGC 
2.4 casein kinase 1, epsilon CSNK1E   GGCTATCCCTCCGAATTCTCAACAT 
2.4 catenin (cadherin-associated protein), 
alpha 1, 102kDa 
CTNNA1   AGACAACAGGAATTGAAAGATGTTG 
2.4 catenin (cadherin-associated protein), 
beta 1, 88kda 
CTNNB1   TAGAAGCTGGTGGAATGCAAGCTTT 
2.4 dishevelled, dsh homolog 1 (drosophila) DVL1   ACGAGCAGGCTCAGCAGCTCCACGG 
2.4 glycogen synthase kinase 3 beta GSK3B   TAGAAATAATCAAGGTCCTGGGAAC 
2.4 Rho-associated, coiled-coil containing 
protein kinase 1 
ROCK1   AATTGGATGAAGAGGGAAATCAAAG 
2.4 vinculin VCL   GAGTCTGAGCAGGCCACAGAGATGC 
2.4 lymphoid enhancer-binding factor 1 LEF1   AGCAACGGACACGAGGTGGCCAGAC 
2.4 transcription factor 7 (T-cell specific, 
HMG-box) 
TCF7   ACTGTGAGCTGGTTCACCCACCCAT 
2.4 transcription factor 7-like 2 (T-cell specific, 
HMG-box) 
TCF7L2   GTGTCCAGGTTCCCTCCCCATATGG 
2.4 epithelial membrane protein 3 EMP3   GTCAGCGAGAATGGCTGGCTGAAGG 
2.4 interleukin 8 IL8 GGAATTGAATGGGTTTGCTAGAA TGTGGATCCTGGCTAGCAGAC TGGAAATCCTGGATTTTTTTCTGTTAAATCTG
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Section Gene Name or Primer Pair Gene 
Symbol 
Forward Primer Sequence 
5' to 3' 
Reverse Primer Sequence 
5' to 3' 
Probe Sequence/ Context 
sequence 
GCAA 
2.4 jun b proto-oncogene JUNB   GGTGGCGGCAGCTACTTTTCTGGTC 
2.4 transcription factor 4 TCF4   CTTCTTCATGCAAGATGGCCATCAC 
2.4 discs, large (Drosophila) homolog 5 DLG5 GGA GAA GCG GCC ATT TCG CTC AAT AGC GTG CGG AGC AA AAA GGA GAT CAC AGA AAA GAA CCG ACA 
CTG C 
2.4 cinculin VCL   GAGTCTGAGCAGGCCACAGAGATGC 
2.4 Rho guanine nucleotide exchange factor 
(gef) 10 
ARHGEF10   CATGCTGCCAGGGCACCAGCGGCTG 
2.4 claudin 1 CLDN1   TTTCTTCTTGCAGGTCTGGCTATTT 
2.4 claudin 2 CLDN2 GAAGGTGCTGCTGAGGATAGAC CCCATTTCTGCCTTTGCTCAAT CCAATGGCCAAAGTCA 
2.4 claudin 3 CLDN3   CGGCCACCAAGGTCGTCTACTCCGC 
2.4 claudin 4 CLDN4   CGGGTTTAGAGGGGAGGGGCGAAGG 
2.4 claudin 7 CLDN7   TGCTCGCCCTGTCCGCGGCCTTGCA 
2.4 occludin OCLN   CCACGCCGGTTCCTGAAGTGGTTCA 
2.4 tight junction protein 1 (zona occludens 1) TJP1   GCCGCCAAGAGCACAGCAATGGAGG 
2.4 tight junction protein 2 (zona occludens 2) TJP2   TTGGCTCCGCGCCCCAGGCATGGAA 
2.4 tight junction protein 3 (zona occludens 3) TJP3   AGATTCTGCAGGTGAATGACGTGCC 
2.4 cadherin 1, type 1, e-cadherin (epithelial) CDH1   CCCCATCAGGCCTCCGTTTCTGGAA 
2.4 cadherin 11, type 2, OB-cadherin 
(osteoblast) 
CDH11 ACCAACACCCTCACCATCAAA GGCCGGCGTTCAGAATG TGCGGGTGCGACGTGAACG 
2.4 catenin (cadherin-associated protein), 
alpha 1, 102kDa 
CTNNA1   AGACAACAGGAATTGAAAGATGTTG 
2.4 catenin (cadherin-associated protein), 
beta 1, 88kda 
CTNNB1   TAGAAGCTGGTGGAATGCAAGCTTT 
2.4 Erbb2 interacting protein ERBB2IP   CCCGCCGAAAGAATGTTGGCTCAAT 
2.4 clathrin, heavy polypeptide (Hc) CLTC   CATCTCCAGCTCCAGAACCTGGGTA 
2.4 filamin a, alpha (actin binding protein 280) FLNA   GAACAGCAGCGCAACCTCTGCTCCC 
2.4 integral membrane protein 3 (Interim) ITM2C GGGCCAAGAACTGCAATGC GAGCGTCTCCACCACGAA CCACTTCGAGAACACC 
2.4 mucin 1, transmembrane MUC1 GTGCCCCCTAGCAGTACCG GAAGTGGCTGCCACTGCTG TGAGAAGGTTTCTGCAGGTAATGGTGGCA 
2.4 neuregulin 1 NRG1   ACAAAAAAAGCCAGGGAAGTCAGAA 
2.4 vinexin beta (sh3-containing adaptor 
molecule-1) (interim) 
SORBS3   GATGGCTGGTTTGTGGGTGTCTCCC 
2.4 deleted in malignant brain tumors 1 DMBT1   AATCCGGAGTGGATGCGTGAGGGAT 
2.4 serine peptidase inhibitor, Kazal type 5 SPINK5   ATGCCCCCGTCTGACGAATGACAGG 
      
 
* AoD gene assays are provided with context sequence surrounding the assay location. 
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8.5 Abbreviations 
 
Table 8.4. List of abbreviations used in thesis text 
Abbreviation Description 
5-ASA 5-Aminosalicylate 
ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1 
AGR2 anterior gradient 2 homolog (Xenopus laevis) 
APC adenomatous polyposis coli 
ASCA anti-Saccharomyces cerevisiae antibody 
ASPN asporin (LRR class 1) 
ATP5F1 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit B1 
BLAST Basic Local Alignment Search Tool 
BST2 bone marrow stromal cell antigen 2 
C14orf43 chromosome 14 open reading frame 43 
C2 complement component 2 
C3 complement component 3 
C5 complement component 5 
CAI colitis activity index 
CARD15 caspase recruitment domain family, member 15 
CBP CREB-binding protein 
CD Crohn's disease 
CD_I inflamed Crohn's disease 
CD_IS inflamed Crohn's disease treated with immunosuppressive 
CD_NI non-inflamed Crohn's disease 
CD11 ITGAL; integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated 
antigen 1 
CD14 CD14 molecule 
CD19 CD19 molecule 
CD79A CD79a molecule, immunoglobulin-associated alpha 
CDAI Crohn’s disease activity index 
CDK2AP2 CDK2-associated protein 2 
cDNA complementary DNA 
CFB complement factor B 
CHST5 carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 5 
CKI casein kinase I 
CSF2 colony stimulating factor 2 (granulocyte-macrophage) 
CSNK1 casein kinase I gene family 
CSNK1D casein kinase 1, delta 
Ct number of cycles to reach threshold 
CTNNB1 beta-catenin 
DC disease control 
DEFA5 defensin, alpha 5, Paneth cell-specific 
DEFA6 defensin, alpha 6, Paneth cell-specific 
DKK dickkopf  
DLD dihydrolipoamide dehydrogenase 
DLG5 discs, large homolog 5 (Drosophila) 
DNA deoxyribonucleic acid 
DSH/DVL dishevelled 
DSS dextran sulfate sodium 
EDTA ethylenediaminetetraacetic acid 
EGFR epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) 
oncogene homolog, avian) 
EPHB2 EPH receptor B2 
EPHB3 EPH receptor B3 
F female 
F11R F11 receptor, CD321, JAM, JAM-1, JAM-A 
FAM 6-carboxyfluorescein 
FCGR3B Fc fragment of IgG, low affinity IIIb, receptor (CD16b) 
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Abbreviation Description 
FDR false discovery rate 
FGFR2 fibroblast growth factor receptor 2 (bacteria-expressed kinase, keratinocyte 
growth factor receptor, craniofacial dysostosis 1, Crouzon syndrome, Pfeiffer 
syndrome, Jackson-Weiss syndrome) 
FOS v-fos FBJ murine osteosarcoma viral oncogene homolog; c-fos 
FTH1 ferritin, heavy polypeptide 1 
FZ Frizzled  
g gram 
GNAI2 guanine nucleotide binding protein (G protein), alpha inhibiting activity 
polypeptide 2 
GO Gene Ontology 
GSK3 glycogen synthase-3 
GSN gelsolin (amyloidosis, Finnish type) 
HGF hepatocyte growth factor (hepapoietin A; scatter factor) 
HLA-A major histocompatibility complex, class I, A 
HLA-B major histocompatibility complex, class I, B 
HLA-DMB major histocompatibility complex, class II, DM beta 
HLA-DRA major histocompatibility complex, class II, DR alpha 
HLA-E major histocompatibility complex, class I, E 
HOXB13 homeobox B13 
HOXB6 homeobox B6 
HSPG heparan sulphate proteoglycans 
IBD inflammatory bowel disease 
ICAM1 intercellular adhesion molecule 1 (CD54), human rhinovirus receptor 
ICAM-1 intercellular adhesion molecule 1 (CD54),  
IFNG Interferon, gamma 
IgG immunoglobulin G 
IGH@ immunoglobulin heavy locus 
IGHA1 immunoglobulin heavy constant alpha 1 
IGHD immunoglobulin heavy constant delta 
IGHG1 immunoglobulin heavy constant gamma 1 (G1m marker) 
IGHM immunoglobulin heavy constant mu 
IGKC immunoglobulin kappa constant 
IGKV1-5 immunoglobulin kappa variable 1-5 
IGL@ immunoglobulin lambda locus 
IGLC2 immunoglobulin lambda variable 3-21 
IGLL1 immunoglobulin lambda-like polypeptide 1 
IL10 interleukin 10 
IL12 interleukin 12 
IL13 interleukin 13 
IL2 interleukin 2 
IL4 interleukin 4 
IL4R interleukin 4 receptor 
IL5 interleukin 5 (colony-stimulating factor, eosinophil) 
IQR interquartile range 
ITGAD integrin, alpha D 
ITGAL integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 
1; alpha polypeptide) 
ITGAM integrin, alpha M (complement component 3 receptor 3 subunit) 
ITGAX integrin, alpha X (complement component 3 receptor 4 subunit) 
JAK3 janus kinase 3 (a protein tyrosine kinase, leukocyte) 
JNK c-Jun N-terminal kinase 
JUN jun oncogene; c-Jun; AP1 
L liter 
LEF lymphoid enhancer-binding transcription factor 
LGALS2 lectin, galactoside-binding, soluble, 2 (galectin 2) 
LIMS laboratory information management system 
LRP5/6 lipoprotein-receptor-related proteins 5 and 6 
m milli; 10-3
µ micro; 10-6  
M molar (mol/L) 
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Abbreviation Description 
MAS microarray suite 
MHC major histocompatibility complex 
min minute 
MOPS 3-(4-morpholino)propane sulfonic acid 
mRNA  messenger RNA 
MUC3 mucin 3A, cell surface associated 
MYC v-myc myelocytomatosis viral oncogene homolog (avian); c-myc 
NC normal control 
NCBI National Center For Biotechnology Information 
NOD2 nucleotide-binding oligomerization domain 2; CARD15 
NOS nitric oxide synthase 
NSAID non-steroidal anti-inflammatory drug 
OCTN organic cation transporter 
pANCA anti-neutrophil cytoplasmic antibody 
PAPSS2 3'-phosphoadenosine 5'-phosphosulfate synthase 2 
PARP8 soly (ADP-ribose) polymerase family, member 8 
PCR polymerase chain reaction 
PKC protein kinase C 
PPARD peroxisome proliferative activated receptor, delta 
PRKCB1 srotein kinase C, beta 1 
PSMB10 proteasome (prosome, macropain) subunit, beta type, 10 
QSCN6 Quiescin Q6 
RAB13 RAB13, member RAS oncogene family 
RAB27A RAB27A, member RAS oncogene family 
RAB5C RAB5C, member RAS oncogene family 
RAB5C RAB5C, member RAS oncogene family 
RDH11 Retinol dehydrogenase 11 (all-trans/9-cis/11-cis) 
RNA ribonucleic acid 
ROK Rho kinase 
rpm revolutions per minute 
RRAS2 selated RAS viral (r-ras) oncogene homolog 2 
RZPD Deutsches Ressourcenzentrum fuer Genomforschung 
s second 
S100A10 S100 calcium binding protein A10 (annexin II ligand, calpactin I, light polypeptide 
(p11)) 
SCFA short chain fatty acids 
SEMFs subepithelial myoblasts 
sFRP secreted Frizzled-related protein 
SLC11A2 solute carrier family 11 (proton-coupled divalent metal ion transporters), member 
2 
SLC22A4 solute carrier family 22 (organic cation transporter), member 4 
SLC22A5 solute carrier family 22 (organic cation transporter), member 5 
SPN sialophorin (leukosialin, CD43) 
SPON1 spondin 1, extracellular matrix protein 
SRRM2 serine/arginine repetitive matrix 2 
TBXA2R thromboxane A2 receptor 
TCF T-cell-specific transcription factor 
TET 6-carboxytetramethylrhodamine 
Th1 type 1 helper T cell 
Th2 type 2 helper T cell 
Th3 suppressor T-cells 
TLR5 Toll-like receptor 5 
TNF tumor necrosis factor (TNF superfamily, member 2) 
TYK2 tyrosine kinase 2 
UC ulcerative colitis 
UC_I inflamed ulcerative colitis 
UC_NI non-inflamed ulcerative colitis 
WFDC2 WAP four-disulfide core domain 2 
WIF1 Wnt-inhibitory factor-1 
xg acceleration due to the force of gravity 
y year 
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